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The work presented in this thesis explores the encapsulation of human natural and induced regulatory T-cells 
(nTregs and iTregs), and the generation of phenotypically stable iTregs for application in 3D-bioprinting with 
pancreatic islets. 3D-bioprinting of Tregs with islets could serve as an alternative method of islet transplantation 
to tackle current challenges associated with intra-hepatic islet transplantation such as side-effects of 
immunosuppressive drugs and sub-optimal characteristics of liver as the site of islet implantation. Paper one 
explores in vitro evaluation of nTregs and iTregs encapsulated in alginate-gelatin methacryloyl (GelMA) 
hydrogel. While encapsulation of islets has been extensively investigated since the 1950s, encapsulation of 
Tregs has never been done, thus this paper aimed to examine whether Tregs can viably be encapsulated. In this 
study, the alginate-GelMA hydrogel was supplemented with Treg-specific bioactive factors IL-2 and CCL1, to 
evaluate the effect of IL-2 on encapsulated Tregs and to investigate the potential of CCL1 to recruit recipient 
Tregs upon transplantation. This study demonstrated that encapsulated nTregs and iTregs are viable, 
phenotypically stable and functional. Furthermore, encapsulation prevented migration of Tregs out of the 
hydrogel structure in the presence of potent chemotactic signals. Supplementation of the hydrogel with IL-2 and 
CCL1 improved encapsulated Treg viability, phenotype and function, and recruited Tregs to the hydrogel 
structure, respectively. Moreover, peripheral blood CD4+ T-cells expressing the chemokine receptor for CCL1, 
CCR8, were highly enriched with Tregs, and selective recruitment of these Tregs from peripheral blood 
mononuclear cells was demonstrated using CCL1. Paper two investigates the generation of stable human iTregs. 
Most trials of Treg-therapy have been focusing on nTregs, as iTregs are unstable and can differentiate into pro-
inflammatory Th17 cells. For applications in transplantation, iTregs could be an attractive alternative to nTregs 
given their TCR repertoire and the ease of generating enough iTregs for clinical dosage. In this study, an iTreg 
differentiation method was optimized and demonstrated to generate superior iTregs to a commercially available 
kit in terms of viability, and CD25 and FOXP3 expression. In-house generated iTregs were stable in the absence 
of IL-2 and in the presence of Th17-polarizing cytokines without upregulation of Th17 signature genes, even 
though demethylation of the Treg-specific demethylation region (TSDR) was not demonstrated. Moreover, they 
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Diabetes mellitus (DM), is a chronic disorder characterized by hyperglycaemia due to failing of glucose 
metabolism, which causes long-term complications in multiple organs including retinopathy, 
nephropathy, neuropathy, and vasculopathy[1]. DM is a serious public health problem, causing 
significant cost to both the health care system and the economy, with an estimation of 673 billion USD 
per annum worldwide. Globally, DM is the eighth leading cause of death causing over 5 million deaths. 
In 2015, there were an estimated 415 million adults with diabetes worldwide with the global prevalence 
of 8.8% and it is predicted to increase to 642 million by 2040[2]. 
 
Type 1 diabetes mellitus (T1DM), also known as juvenile diabetes, accounts for 5-10% of the population 
with diabetes[3]. Symptoms of T1DM include polyuria, polydipsia, polyphagia, weight loss, blurry 
vision and extreme fatigue. T1DM may occur at virtually any age but is most common in children and 
young adults and occurs as a consequence of an autoimmune destruction of the insulin-producing β cells 
of the islets of Langerhans in the pancreas, leading to absolute insulin deficiency[1,4]. The autoimmune 
destruction is caused by islet-specific T cell response[5] by various autoantibodies such as 
autoantibodies to insulin[1,3]. Recent studies suggest T1DM is triggered by environmental factors such 
as exposure to pathogens or environmental antigens in individuals who are genetically predisposed to 
diabetes by particular genes such as the HLA genes, which contribute to 50% of the genetic 
susceptibility to T1DM[3,4]. 
 
Currently, patients with T1DM are treated with daily exogenous insulin administration[6,7]. However, 
despite advances in medicine, there has not yet been a development of an insulin therapy that can mimic 
the physiological rhythms or a mechanical replacement for pancreatic β cells. An intensive monitoring 
of blood glucose level accompanied by exogenous insulin therapy via insulin injection or pump 
represents the current state of treatments for T1DM. Although these treatments are able to delay the 
progression of diabetic complications including neuropathy and retinopathy, it is not sufficient to 
prevent these complications[8]. The replacement of β-cell function through whole pancreas 
transplantation is presently the only permanent alternative for re-establishing endogenous insulin 
secretion in patients with T1DM[9]. 
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Current approaches for β-cell replacement 
 
Pancreas transplantation is reserved and performed in patients with T1DM and advanced or end-stage 
renal disease. As a result, over three quarters of the whole pancreas is transplanted in conjunction with 
kidney transplantation as either simultaneous kidney-pancreas transplantation or alternatively pancreas 
after kidney transplantation[10]. Furthermore, the surgical procedure is associated with significant 
mortality risk, accompanied with clinically significant complications such as pancreatitis, bleeding, re-
occurrence of autoimmunity, and rejection post-transplantation, which motivates the urgent need for the 
search of an alternative therapy[11]. 
 
A logical alternative to whole-organ transplantation is to transplant the cells that have been destroyed. 
Pancreatic islet transplantation is a minimally invasive approach where purified allogeneic donor islets, 
isolated from deceased organ donor pancreata are currently percutaneously infused into recipient liver 
through the portal vein (Figure 1)[12–14]. This procedure has lower risk compared to pancreas 
transplantation as major surgery is not required and a differing immunosuppression regimen is 
employed. A cellular approach was first tried unsuccessfully in man in 1894 using fragmented sheep 
pancreas in a subject with diabetes[13,15]. The successful application of islet transplantation as a 
treatment for diabetes was not realized for many decades until reversal of diabetes was initially observed 
in rodents and in a patient with chronic pancreatitis who underwent pancreatectomy followed by islet 
auto-transplantation[16–18]. Following these findings, intensive research has been conducted in the 
field of islet transplantation. In 2000, the Edmonton immunosuppression protocol, which utilized a 
corticosteroid-free immunosuppression regimen and multiple islet infusions from different donors was 
established[19]. An insulin independence rate of 100% was achieved in seven patients following one 
year of islet transplantation and partial graft function was observed in most of the seven patients after 
five years[19,20] which represented a significant improvement from the success rate of 10% prior to 
the protocol [13,21,22]. Critically long-term insulin independence has been difficult to achieve, and 
most patients require at least two infusions to achieve insulin independence[20]. Islet transplantation 
has been adopted as a treatment option for T1DM in a number of countries and has proved an attractive 




Figure 1. Current procedure of pancreatic islet transplantation. Islets are purified from the donor 
pancreas then infused into the recipient’s liver via hepatic portal vein. Image adapted from R. P. 
Robertson[13].   
 
Despite the significant progress in islet transplantation procedures, numerous obstacles remain that 
currently limit its clinical application[9,23]. The current clinical standard of care involves the infusion 
of islets into the patient liver via the portal vein where islets encounter a sub-optimal non-pancreatic 
environment: high glucose concentration, lower oxygen tension, and higher level of toxins[24]. 
Moreover, infusion of islets via hepatic portal vein triggers an innate immune reaction upon contact 
with blood, known as the instant blood mediated inflammatory reaction [25]. The hypoxic islets secrete 
chemokines and express tissue factors, which activates a thrombotic reaction[26]. Platelets are attracted 
to the islet surface, recruiting leukocytes and macrophages to infiltrate and destroy the islet cells[25,27]. 
Together these factors kill up to 70% of transplanted islets in the first 48 hours[28,29] and 
consequentially islets from up to three donor pancreata are required for clinical benefit, limiting the 
availability of the transplantation. Additionally, the obligatory use of immunosuppressive regimen is 
another major challenge of islet transplantation. Immunosuppressive drugs used for islet transplantation 
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are associated with many side effects including risks of infection, higher rate of malignancy, β-cell 




Upon transplantation, recipient T cells recognize alloantigens of the allograft, which activates recipient 
T cells to induce inflammation at the site of the allograft, as part of the alloresponse (Figure 2)[30]. 
Allogeneic major histocompatibility complex (MHC) molecules are the major drivers of this 
response[31].These molecules are presented to the recipient T cells through a number of pathways 
(Figure 3)[32]. In the direct pathway, donor antigen presenting cells (APCs) migrate from the allograft 
to the secondary lymphoid organ, in which they mature and present donor MHC molecules to naïve T 
cells[30,32]. In the indirect pathway, recipient APCs obtain donor MHC molecules from donor cells 
that have undergone necrosis and apoptosis, and present the processed peptides on self-MHC molecules 
to naïve T cells[33]. In the semi-direct pathway, recipient APCs acquire intact donor MHC molecules 
via direct contact with donor APCs or MHC-containing endosomes released from donor APCs, 
presenting donor MHC molecules on their surface to naïve T cells[33]. The direct pathway has been 
associated with acute graft rejection early on while the indirect and the semi-direct pathways have been 
tied to chronic graft rejection in later stages of the disease[30].  
 
Figure 2. Overview of allorecognition and alloresponse. Image is adapted from Golshayan et al.[30].  
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Figure 3. Different pathways of allorecognition. (A) The direct pathway involves interactions of donor 
APCs with recipient T-cells. (B) The indirect pathway involves presentation of processed donor MHC 
peptides on recipient APCs to recipient T-cells. (C) The semi-direct pathway involves transfer of intact 
donor MHC molecules via cell-to-cell contact or endosomes on recipient APCs and interactions with 
recipient T-cells. Image adapted from Afzali et al.[33]. 
 
In the 1950s it was discovered that antimetabolite 6-mercaptopurine possesses immunosuppressive 
properties that prolong survival of kidney transplants in dogs[34]. Since this discovery, many 
immunosuppressants with different properties and mechanisms of action have been developed[35–39]. 
The use of immunosuppressants has significantly improved the early rate of graft and patient survival 
by preventing allorecognition and consequent acute graft rejection[30]. However, long-term survival is 
still a major issue due to chronic graft dysfunction and the side effects of immunosuppression regimen 
being deleterious, causing high mortality and morbidity. In the case of pancreatic islet transplantation, 
sirolimus and tacrolimus are the immunosuppressants of choice. They are however associated with 
infections, selective organ toxicity and increased risk of cancer. The most common sites of infection are 
the upper respiratory, skin and urinary tract; most of which have mild symptoms and are entirely 
treatable. Multi-organ toxicity caused by sirolimus and tacrolimus ranges from minor acne to severe 
neurologic side effects such as tremor and higher risks of malignancy in various cell lines (notably 
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squamous cells of skin). Additionally, β-cells of the transplanted islets are directly affected by sirolimus 
and tacrolimus. Sirolimus diminishes β-cell proliferation and causes apoptosis of β-cells, while 
tacrolimus inhibits transcription of the insulin gene, decreasing insulin secretion and increasing insulin 
resistance[21]. Thus, in order to improve long-term outcomes of islet transplantation, there is a need for 
novel immunotherapies able to prevent allorecognition and alloresponse without the need for 
immunosuppressants.  
 
Alternative transplantation sites 
 
Many studies in recent years have explored alternative sites for islet transplantation with the following 
key characteristics (Figure 4): (a) sufficient space for islet engraftment; (b) close proximity to vascular 
network to provide optimal oxygen tension, sensing and release of insulin; (c) allow real time 
communication between cellular graft and the circulation; and (d) offer minimal inflammatory potential 
to support long term graft survival. A few sites with immunological privileges such as testis or thymus 
have been tested in small animals, however, to date they remained clinically irrelevant due to limited 
space for islet engraftment[40,41]. Among many sites explored, the skin site received attention as it 
offers a readily accessible site via a minimally invasive surgical procedure. The only drawback is that 
unlike the liver or kidney capsule, dermal poor vascularization limits the integration and functionality 
of engrafted islets[42]. The pancreas, the native home of islets, has also been explored as a site of islet 
transplantation. However, it is not considered for a transplantation site due to the metabolic 
complications such as pancreatitis (potentially induced after embolization) and limited vascular supply. 
At this point in time for clinical islet transplantation, intra-portal infusion remains the gold standard[43]. 
 
As no suitable alternative transplantation site in the human body has been found, one option to explore 
is the fabrication of an artificial transplantation site. The recent advancements in bio-engineering 
technology now enable constructing of such sites. Hydrogels are a multi-component system comprised 
of a tri-dimensional network of polymer chains with absorbed water filling the space between the 
macromolecules, within which various biomaterials may be incorporated to mimic tissue-like properties. 
The main approach of incorporating such technology in islet transplantation is via islet encapsulation 
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(Figure 5). Pancreatic islets are embedded within a hydrogel, and this “mini organ” hold pores which 
allow bidirectional diffusion of small molecules such as insulin (~6 kDa), nutrients and glucose, and at 
the same time, protects islets from immune attack by restricting the access of immune cells or antibodies 
(~150-900 kDa)[44].  
 
Figure 4. Candidates for alternative transplantation sites for pancreatic islets. Image adapted from 
Sakata et al.[45]  
 
The pivotal point in this field of research has been the search for a suitable hydrogel. To date, various 
types of naturally derived polymers such as alginate, collagen, gelatin, fibrin, and fibronectin and 
synthetic polymers such as poly(lactic-co-glycolic acid), polysulphone, poly(lactic acid), poly(vinyl 
alcohol) have been evaluated[46]. Amongst all, alginate-based hydrogels have been the most 
extensively investigated polymers for their utility with pancreatic islets to treat T1DM. Alginate is a 
naturally occurring anionic polymer typically obtained from brown seaweed. Due to its anionic 
properties, alginate readily cross-links to form a polymer upon exposure to divalent cations such as 
Ca2+[47]. Additionally, alginate is biocompatible and biosafe with non-toxic degradation products and 
a relatively low production cost[48]. Alginate has several limitations including an inability to 
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biodegrade, a lack of interaction with cells, and a tendency to induce foreign body reactions in recipients. 
These limitations can be easily overcome by partially oxidizing alginate to confer biodegradability, by 
copolymerizing alginate with gelatin or gelatin derivatives to which cells can adhere and by utilising 
high purity alginate.  
 
Figure 5. Encapsulation of pancreatic islets. Bidirectional diffusion of nutrients, oxygen, insulin and 
waste products is allowed while physical immune isolation is achieved. Image adapted from Sakata et 
al.[49] 
 
Another aspect that must be considered is the degree of cross-linking. Mechanical stability, the pore 
size and the rate of diffusion and degradation are directly linked to the degree of cross-linking and these 
must be finely balanced[47]. In the case of alginate, the degree of cross-linking can be altered by varying 
the exposure time and concentration of divalent cations. While this is straightforward in theory, several 
challenges were observed in numerous small animal models. Islet encapsulation was demonstrated to 
improve glucose homeostasis for a short term, but no permanent restoration of euglycemia was 
observed[50–54]. One challenge arises as physical irregularities from fabricating hydrogel result in an 
incomplete coverage of the islets within the capsules. This may trigger a pericapsular fibrotic 
overgrowth (PFO) which blocks the diffusion of nutrients and oxygen, resulting in islet necrosis[55,56]. 
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Even the successfully encapsulated islets suffer from hypoxia due to the restricting hydrogel 
permeability and increased distance from the surrounding blood vessels reduces the availability of 
oxygen by diffusion. This introduces a challenge in scaling up into a large animal model or clinically 
relevant dose of islets. Moreover, encapsulation prevents immediate re-vascularization post-
transplantation, subjecting the islets to further hypoxic stress. As hypoxia hampers the function and 




One approach to address hypoxia involves “seeding” of islets onto degradable 3D scaffold 
structures[57]. Scaffolds are made of similar biopolymers to mimic the pancreatic microenvironment. 
The construct provides increased surface area to volume ratio compared to the hydrogel capsules, and 
even allows for vascular ingrowth, thereby providing increased oxygen and nutrient supply[58]. Upon 
slow degradation of the scaffold, the extracellular matrix proteins are deposited by surrounding tissues 
and engrafted islets, gradually re-building the suitable environment required for islet survival[59]. Even 
though immune isolation is not achieved through this method, the scaffolds can prevent direct contact 
of embedded islets to circulating immune cells to reduce the inflammatory response until the scaffolds 
eventually degrades[25]. The efficacy of such device have been demonstrated in animal studies[60–62]. 
Moreover, utilization of 3D bioprinting technology with higher accuracy could provide highly 
controlled seeding of islets, thereby minimizing the onset of PFO arising with conventional techniques.    
 
The concept of 3D printing was first introduced in 1986 by Charles W. Hull, and has become 
increasingly prominent over the past decades[63]. 3D printing technology allows printing of a 3D 
structure, typically through stacking successive thin layers in a layer-by-layer fashion. Advances in 
engineering technology have now opened up the possibility of using 3D printing to “print” spatially 
controlled biomaterial structures with embedded bioactive factors and cells into a functional tissue 
construct[64]. Such automated printing allows for the precise control of architecture, pore 
interconnectivity, and a high degree of reproducibility necessary for commercial clinical application and 
regulation. Furthermore, bioprinting allows the deposition of a wide array of cell types and bioactive 
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factors in a precise order to simulate native tissue environment and support cell survival[65–67].  
 
The current varieties of 3D bioprinting techniques including inkjet bioprinting, extrusion bioprinting, 
laser-assisted and stereolithography bioprinting (Figure 6)[68,69]. Inkjet bioprinting was the first 
bioprinting technique to be developed. It often utilizes conventional inkjet printers which have been 
modified and customized to enable deposition of bioinks instead of inks. Inkjet bioprinting is driven by 
thermal or piezoelectric actuation which results in drop-by-drop deposition of the bioinks. Inkjet 
bioprinting allows rapid deposition of bioinks, however, only low viscosity bioinks with low cell 
densities can be used. Extrusion bioprinting has derived from inkjet bioprinting to enable printing of 
high viscosity bioinks with high cell densities. Extrusion bioprinting is driven by continuous pneumatic 
or manual force, depositing bioink filaments in a layer-by-layer fashion. One drawback of extrusion 
bioprinting is that cells are exposed to mechanical stresses such as shear forces, which could affect the 
viability of printed cells. Laser-assisted bioprinting employs laser-direct write and laser-induced transfer 
technologies. In laser-assisted bioprinting systems, a laser pulse is applied to the donor layer, often made 
of gold or titanium, which induces vaporization of the donor layer. Following vaporization, a bubble is 
generated between the donor layer and the underlining bioink layer, triggering deposition of the bioinks 
on to the receiving substrate. Laser-assisted bioprinting can print moderate viscosity bioinks with 
moderate cell densities with minimal mechanical stresses, however, is associated with high cost and 
complexity of operation. Finally, stereolithography bioprinting utilizes a light source to selectively 
crosslinks and deposit bioinks in a layer-by-layer fashion. Stereolithography bioprinting can rapidly 
generate high resolution structure with minimal mechanical stresses.  
 
Among these, extrusion bioprinting has been most extensively investigated for the generation of 
artificial tissue constructs such as cartilages[70,71], liver[72] and neural tissues[73], as most existing 
commercial bioprinters uses extrusion bioprinting[68,69]. Extrusion bioprinting has also been explored 
for the generation of artificial pancreata using various sources of islets. A rat β-cell line, mouse and 
human islets were printed into a predefined 3D scaffold using alginate-based bioinks and the subsequent 
cell viability and morphology were found to be unaffected[74]. Furthermore, rat islets were printed into 
macroporous 3D constructs using an alginate/methylcellulose bioink. These printed rat islets retained 
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their viability, morphology and function, for up to 7 days in culture[75].   
 
Figure 6. Different types of bioprinting techniques. (a) Inkjet bioprinting involves deposition of bioink 
droplets via thermal or piezoelectric actuation. (b) Extrusion bioprinting involves layer-by-layer 
deposition of pneumatically or manually extruded bioink filaments. (c) Laser-assisted bioprinting 
involves vaporization of the donor layer via a laser which causes formation of bubbles followed by 
deposition of bioinks. (d) Stereolithography bioprinting involves layer-by-layer deposition of 
selectively crosslinked bioinks using a digital light source. (e) Comparison of the different techniques. 
Adapted from Yue et al. [68]   
 
Beyond the modification of the bioinks to support islet cells, bioprinting also enables the co-
transplantation of islets with supporting cells that could enhance islet survival[76]. Recently, our group 
developed a extrusion bioprinter equipped with a co-axial extruder nozzle and two separate ink 
chambers (Figure 7)[77]. Different bioinks tailored with cell-type specific bioactive molecules can be 
utilized in each chamber, allowing co-printing of islets with supporting cells. These geometries have the 
advantage that more delicate components can be strategically placed within the core with a surrounding 
protective layer, referred to as the shell. The use of a co-axial structure has been shown to significantly 
improve islet encapsulation by minimizing material volume per islet and reducing the risk of PFO[55]. 
For co-axial printing of islets, alginate-gelatin methacryloyl (GelMA) bioink was formulated. 
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Modification of gelatin with methacryloyl moieties enabled photo-crosslinking of GelMA molecules 
using visible light. Alginate-GelMA bioink showed mechanical stability, optimal macroscopic and 
rheological properties, shear-thinning behavior, and capacity to support cell survival. Indeed, co-axially 
printed mouse islets and endothelial progenitor cells demonstrated high viability[77]. Together, co-axial 
3D bioprinting has the potential to enable the embedding of clinically relevant doses of islets with 
support for islet survival, including supporting cells and bioactive factors. Regulatory T-cells (Tregs) 
are a key candidate for this, given their natural ability to mediate immune regulation and suppression. 
Incorporation of Tregs, in conjunction with Treg-specific bioactive factors may provide local immune-
protection to co-printed islets, achieving graft tolerance without the use of systemic immunosuppression.   
 
Figure 7. 3D co-axial extrusion bioprinter. (A) Schematic of the 3D structure printed with the bioprinter. 
Pancreatic islets will be localized to the core while supporting cells surround islets in the shell. (B,C) 
Image of the bioprinter. (D) Co-axial nozzle for the bioprinter. (E) Microscope image of the co-axial 
nozzle. (F) Brightfield image of co-axially printed strands using lutrol bioink coloured with red (shell) 






Regulatory T-cells (Tregs) 
 
The immune system can respond to a broad range of pathogens while being unresponsive to specific 
antigens. This state of unresponsiveness is termed immunological tolerance and is crucial for one’s 
health. Immunological tolerance is tightly regulated by several mechanisms, breakdown of which can 
be deleterious and result in autoimmunity, allergy, and failure to clear tumour cells and pathogens. 
Mechanisms of immunological tolerance can be classified based on their site of establishment. Central 
tolerance is established in the primary lymphoid organs, such as bone marrow and the thymus during 
lymphocyte development, through clonal deletion of self-reactive lymphocytes as required for tolerance 
to self-antigen. Peripheral tolerance occurs in peripheral tissue, suppressing immune responses to 
environmental antigens and inhibiting activation of self-reactive lymphocytes that escaped central 
tolerance. Peripheral tolerance is achieved through several mechanisms including anergy, deletion, 
clonal ignorance and suppression (Figure 8)[78,79].  
 
Figure 8. Central and peripheral tolerance of T-cells. During thymic development, self-reactive T-
cells are negatively selected. In the periphery, self-reactive T-cells which have escaped central 
tolerance are neutralized via various mechanisms including anergy, clonal ignorance, deletion and 
suppression. Image adapted from Walker et al.[79] 
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Regulatory T cells (Tregs) are a sub-population of T cells that specialize in immune suppression. The 
idea of Tregs arose when, in 1970, Gershon and Kondo discovered that a subset of T cells diminish 
immune responses[80]. This T cell population was named suppressor T cells at the time and was 
intensely investigated[81,82]. CD4+ CD25hi T cells were defined as Tregs in mice[83] and humans in 
1995 and 2001[84–87], respectively. In later years, forkhead box p3 (FOXP3)[88–90] was identified as 
the master regulator of Tregs and the absence of CD127[91,92] found to be a complementary marker, 
eventually defining Tregs as CD4+ FOXP3+ CD25hi CD127- T cells. To date, two types of natural Tregs 
(nTregs) have been identified with the CD4+ FOXP3+ CD25hi CD127- profile. Thymic Tregs (tTregs) 
arise from highly self-reactive T cells in the thymus during T cell development and establishment of 
central tolerance[93]. tTregs are characterized by complete demethylation of the FOXP3 promoter 
region and Treg-specific demethylation region (TSDR) in conserved non-coding sequence 2 (CNS2), 
which results in stable expression of FOXP3 and a suppressive phenotype[94,95]. On the other hand, 
peripheral Tregs (pTregs) are generated from naïve CD4+ T cells in the periphery upon stimulation of 
the T cell receptor (TCR), transforming growth factor beta (TGF-β), retinoic acid (RA) and IL-2, which 
can be mimicked in vitro to generate induced Tregs (iTregs)[96,97]. The FOXP3 promoter region and 
TSDR of pTregs and iTregs are not demethylated leading to their functional instability[94,95]. Besides 
the canonical CD4+ FOXP3+ CD25hi CD127- Tregs, there are other types of Tregs found in the periphery, 
including Th3 Tregs, Tr1 Tregs and CD8+ FOXP3+ Tregs[98].                  
 
Treg-mediated suppression is the main mechanism of peripheral tolerance. Thus, Tregs are a vital 
component of the immune system[78,99]; loss of Tregs is lethal in humans, causing 
immunodysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX), a fatal multi-organ 
autoimmune disorder[100]. Tregs play many roles in the immune system including downregulation of 
immune responses once pathogens have been cleared, maintaining tolerance to self, gut microbiota, new 
chemicals, environmental and food antigens and the fetus in cases of pregnancy. Treg-mediated 
suppression targets a broad spectrum of immune cells such as other T cell subsets, B cells, APCs and 
natural killer (NK) cells[101]. Suppression is achieved via several circumstance dependent mechanisms, 
including inhibitory cytokines, cytolysis, metabolic disruption and modulation of dendritic cells (DCs) 
(Figure 9)[99]. Given such versatility, Tregs are a promising candidate for novel immunotherapies. 
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Downregulation and upregulation of Tregs could be utilized for the treatment of cancer and 
autoimmunity/allergy, respectively. Furthermore, Treg cell therapy could be used to establish graft 
tolerance in transplant recipients, potentially tackling the issues of organ scarcity and the long-term side 
effects of immunosuppression in transplantation.  
 
Figure 9. Suppression mechanisms of Tregs. (a) Inhibitory cytokines such as TGF-β, IL10 and IL35. 
(b)Cytolysis via perforin/granzyme pathway. (c) Metabolic disruption via CD25-mediated IL-2 
deprivation, transfer of cAMP and CD39/73-mediated generation of pericellular adenosine. (d) 
Targeting of dendritic cells via co-inhibitory molecules such as CTLA-4 and LAG3.  
 
Since the first organ transplantation clinical trials, spontaneous graft tolerance(the acceptance of 
allograft without immunosuppressive regimen) has been observed, mostly in liver transplant 
recipients[102–104]. The exact factors underlying this phenomenon have not yet been fully identified, 
however, it has been shown that Tregs play a major role in spontaneous graft tolerance in mice liver 
allograft models[105,106] and there is elevation of Treg proportion in spontaneously tolerant 
patients[107]. Additionally, it has been demonstrated that Tregs mediate infectious tolerance against 
allografts, a phenomenon in which tolerance in one population of lymphocytes is transferred to another 
population[108,109]. Together, these properties promise a Treg-based immunotherapy with the goal of 
long-term graft tolerance. To date, several different approaches have been attempted. In vivo 
augmentation/induction of Tregs has proven problematic as there was a lack of specificity towards Tregs 
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resulting in ineffective or adverse outcomes[110–112]. Alternatively, Treg cell therapy utilizing 
adoptive transfer of ex vivo expanded Tregs has a number of advantages compared with the in vivo 
approach, including greater control over the expansion/generation of Tregs, the possibility of functional 
and phenotypical analysis prior to delivery and finer control of dosage and delivery time[111,112]. 
Adoptive transfer of ex vivo expanded nTregs has been extensively investigated with most clinical trials 
utilizing this method[113]. It has proved promising in many animal transplantation models[114–118], 
including murine islet transplantation models[119,120] and clinical liver[121] and kidney[122] 
transplantation trials. One challenge of adoptive transfer is generation of sufficient numbers of Tregs 
for clinically significant results. As the frequency of nTregs in the human peripheral blood is low, the 
expansion protocols can be extremely time-consuming and costly[123,124]. Recent clinical trials have 
used up to 5 billion nTregs per patient, taking up to 36 days for expansion[124]. Thus, more targeted 
approaches and alternative ways to generate large number of Tregs in shorter amount of time could be 
beneficial[123]. These could be achieved by encapsulating Tregs through 3D-bioprinting to serve as a 
localised immunosuppression and utilizing iTregs which are induced from naïve CD4+ T-cells with 
significantly higher frequency in human peripheral blood than nTregs, respectively. Moreover, studies 
have shown that while TCR repertoire diversity of nTregs is similar to conventional T-cells, TCR 
repertoire of nTregs is distinct from conventional T-cells and is skewed towards self-antigens[125–130]. 
Thus, given that iTregs are generated from conventional T-cells, TCR repertoire of iTregs would be 
skewed towards non-self-antigens which could be advantageous in allogeneic transplantation[131]. As 
mentioned above, iTregs exhibit phenotypic instability and can transit into Th17 cells in pro-
inflammatory environments[132]. Thus, the key to utilization of iTregs for adoptive transfer is 
stabilisation of their phenotype.   
    
Treg-specific bioactive factors 
 
Interleukin-2 (IL-2) is a T cell stimulatory cytokine, largely produced by CD4+ T helper cells. IL-2 
signalling is crucial for activation and clonal expansion T cells[133]. While CD4+ T helper cells can 
produce IL-2 for autocrine signalling upon T-cell receptor stimulation, Treg cells cannot and thus are 
reliant on IL-2 produced by other cells[81,134]. IL-2 is crucial for Treg function as well as their survival. 
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Tregs highly express CD25, the α-chain of the high affinity IL-2 receptor complex [135] and the 
interaction of IL-2 and CD25 induces high expression of FOXP3 and inhibits Th17 polarization thereby 
reinforcing Treg phenotype and function[131,136–138]. Moreover, with high expression of CD25, 
Tregs can respond to low concentrations of IL-2 and bind to IL-2 with high affinity[139], which can 
lead to sequestration of IL-2 from effector T cells, depriving them of survival signal[99]. Administration 
of exogenous IL-2 in autoimmunity and organ transplantation has been investigated to augment Treg 
numbers and function[140]. Particularly, low-dose IL-2 therapy has shown promising results in 
hematopoietic stem cell transplantation graft-versus-host disease, selectively increasing Treg 
numbers[141–144]. Thus, incorporation of IL-2 in the bioink may enhance survival and function of 
printed Tregs and create a Treg-rich microenvironment around the 3D bioprinted scaffold.  
 
Chemokine ligand 1 (CCL1) is a chemotactic protein which only binds to chemokine receptor 8 (CCR8). 
CCR8 is pre-dominantly expressed on Tregs and Th2 cells in the peripheral blood with the main function 
of CCL1-CCR8 interactions being trafficking of Tregs and Th2 cells[145,146]. Pathologically, CCL1 is 
produced in various human tumour tissues to exploit the CCL1-CCR8 axis by recruiting Tregs to the 
tumour sites to create immunosuppressive microenvironments and inhibit anti-tumour responses 
mediated by effector CD4+ and CD8+ T-cells, natural killer T-cells and natural killer cells[147–149]. 
Indeed, blockade of CCL1 was shown to augment anti-tumour responses by specifically inhibiting Treg 
function in tumour sites[147]. Thus, mimicking of CCL1-induced immune evasion of tumour cells via 
incorporation of CCL1 in the bioink may be beneficial as it could recruit recipient Tregs and create 
Treg-enriched microenvironment to establish a long-lasting recipient-driven tolerance to the islets. 
Furthermore, the CCL1-CCR8 axis has been shown to upregulate expression Treg-suppression 
molecules and augment suppressive activities of Tregs, suggesting that Tregs recruited to the 
transplantation site via CCL1-mediated chemotaxis would have augmented suppressive activities[150]. 
One drawback of CCL1 incorporation may be the unintended recruitment of Th2 cells, however, Th2 
cells could be beneficial with their ability to inhibit Th1 responses, which are implicated in acute 
rejection[151]. 
 
Transforming growth factor-β (TGF-β) is a highly pleiotropic cytokine involved in many biological 
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processes. In the context of adaptive immunity, TGF-β is an immunosuppressive cytokine secreted by 
Tregs. It also plays an essential role for differentiation and development of Tregs[152]. It was the first 
factor to be used for generation of iTregs from murine naïve CD4+ T-cells[153]. Furthermore, the gut 
environment has particularly large population of pTregs due to TGF-β secreted by CD103+ intestinal 
dendritic cells (DCs). TGF-β induces binding of transcription factors, Smad2 and Smad3, to conserved 
non-coding DNA sequence 1 (CNS1) region of fopx3 locus[97,131], which is required for FOXP3 
induction in pTregs and iTregs[154]. In addition, similar to TGF-β, all trans retinoic acid (ATRA), a 
vitamin A derivative, is highly versatile with the ability to inhibit cytokine production of memory T-
cells[155]. ATRA is also secreted by CD103+ intestinal DCs and works in conjunction with TGF-β to 
enhance TGF-β-mediated binding of Smad3 to CNS1 region through histone acetylation of the Smad3 
binding region. This prevents Th17 polarization, which also requires TGF-β signalling[97,131,156]. 
Moreover, TGF-β and ATRA are important for the maintenance of the Treg phenotype in iTregs post-
differentiation, as well as the stability of nTregs under pro-inflammatory conditions[155,157,158].  
Thus, incorporation of TGF-β and ATRA into the bioink may stabilise the phenotype of printed nTregs 
and iTregs, induce differentiation of circulating naïve CD4+ T-cells into pTregs via infectious tolerance 
to further augment the immunosuppressive milieu around the printed structure[152,159], and directly 
suppress effector T-cells in the vicinity.  
 
Rapamycin is a macrocyclic lactone product of Streptomyces hygroscopicus, which was originally 
isolated as an antifungal antibiotic[160]. In humans, rapamycin binds to immunophilin FKBP-12 and 
inhibits the mTOR (mammalian target of rapamycin) pathway[161]. The mTOR pathway is involved in 
cell growth and proliferation,[162] thus, inhibition of the mTOR pathway results in cell cycle arrest at 
G1 and S phase[163]. In particular, inhibition of the mTOR pathway in T-cells disrupts IL-2 signalling, 
which is required for T-cell activation and proliferation[164]. Due to this property, rapamycin is a 
common immunosuppressive drug used in allogeneic transplantation to prevent allograft rejection[165]. 
Interestingly, it has been shown that rapamycin promotes preferential expansion of Tregs over 
conventional T-cells[166], as Tregs utilize IL-2R-depedent STAT5 pathway for IL-2 signalling instead 
of mTOR pathway[167,168]. As such, rapamycin enhances the purity of iTreg differentiation and 
expansion through selective inhibition of effector T-cell differentiation[96]. Furthermore, rapamycin 
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has been shown to stabilise FOXP3 expression to reinforce Treg phenotype and Treg-lineage 
commitment, in both nTregs and iTregs[169,170]. Thus, incorporation of rapamycin into the bioink may 
serve as a local immunosuppressant by selectively inhibiting conventional T-cells and promoting growth 




Pancreatic islet transplantation is a promising curative cell therapy for T1DM. The field is limited by 
human cadaveric islet cell sources at present. The current procedure of islet infusion into liver may not 
be optimal, and so alternative transplant strategies such as 3D bioprinting may provide new strategies. 
Modifications of the bioinks with local immunosuppression and bioactive factors to support the cells, 
are new directions for the field. The recent 3D bioprinting technology, especially with the development 
of the co-axial bioprinter, thus has potential to change the current pancreatic islet transplantation 
paradigm. The possibility of co-printing islets with supporting cells and bioactive factors potentiates 
direct improvement of engraftment condition, and thus survival and function of transplanted islets. 
Incorporation of Tregs via 3D-bioprinting could provide localized immune protection to islets. 
Bioactive factors such IL-2, CCL1, TGF-β, ATRA and rapamycin could enhance the survival, stability 
and function of printed cells to maximize the efficacy of the graft and augment the local 
immunosuppressive milieu through the recruitment of recipients Tregs, induction of pTregs, and 
promotion of Treg expansion. Furthermore, generation of phenotypically stable iTregs have an 
important clinical potential as it could significantly reduce the duration of ex vivo expansion required 
to generate enough Tregs for clinically relevant doses. Together, extra-hepatic islet transplantation 
without the use of immunosuppression might be clinically achieved by utilizing 3D bioprinting 










This thesis aims to develop and evaluate the encapsulation of two types of human regulatory T-cells, 
natural and induced regulatory T-cells (nTregs and iTregs), in alginate-GelMA hydrogel supplemented 
with IL-2 and CCL1, and the generation of stable iTregs for application in 3D-bioprinting with 
pancreatic islets as an alternative to the immunosuppressive regimens necessitated by current pancreatic 
islet transplantation methods. In order to achieve these, several hypotheses need to be addressed.  
 
1. Encapsulation will not compromise Treg viability, phenotype and function. 
 
2. Encapsulated Tregs will be spatially restricted to the hydrogel structure. 
 
3. Supplementation of the alginate-GelMA hydrogel with IL2 will improve Treg viability, 
phenotype and function. 
4. Supplementation of the alginate-GelMA hydrogel with CCL1 will recruit Tregs to the 
hydrogel structure. 
5. iTregs generated with the optimised protocol will exhibit stability. 
 
 
This thesis explores four main aims – which are covered by manuscript 1 & 2: 
 
 
1. To evaluate the effect of encapsulation on the viability, phenotype and function of Tregs 
using IL-2-supplemented alginate-GelMA bioink  
 
2. To assess migration capacity of encapsulated Tregs and recruit Tregs to the hydrogel 
structure using CCL1-supplemented alginate-GelMA bioink  
 
3. To compare encapsulation of natural Tregs and induced Tregs to determine more suitable 
cell-type for 3D-bioprinting and maximise the efficacy of Treg incorporation.  
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Regulatory T-cells (Tregs) are important modulators of the immune system through their intrinsic suppressive 
functions. Systemic adoptive transfer of ex vivo expanded Tregs has been extensively investigated for 
allogeneic transplantation. Due to the time-consuming and costly expansion protocols of Tregs, more targeted 
approaches could be beneficial. Here, we describe for the first time the encapsulation of human natural and 
induced Tregs for localized immunosuppression. Tregs encapsulated in alginate-GelMA hydrogel remained 
viable, phenotypically stable, and functional. Furthermore, encapsulation was sufficient to prevent migration 
of Tregs. Supplementation of the hydrogel with the Treg-specific bioactive factors IL-2 and CCL1 improved 
Treg viability, suppressive phenotype and function, and attracted to the structure CCR8+ T-cells enriched with 
anti-inflammatory subpopulations, including Tregs, from human peripheral blood. This work establishes the 
co-encapsulation of Tregs by co-axial 3D-bioprinting as a valid option for providing local immune protection 





Regulatory T-cells (Tregs) constitute a vital CD4+ T-cell sub-population specialized in immune 
suppression and regulation[1]. Tregs were initially reported in 1970 as suppressor T-cells, a subset of 
T-cells with the ability to abrogate the pro-inflammatory immune responses[2]. Since then, intensive 
investigations led to the discoveries of Treg-defining surface markers, CD4+, CD25hi and CD127-, 
and the master transcriptional regulator of Treg-lineage, FOXP3[3–8]. To date, two main subgroups 
of natural Tregs (nTregs) exhibit the CD4+ CD25hi CD127- FOXP3+ profile: thymic-derived Tregs 
(tTregs), which stably express FOXP3, and CD4+ T cells that acquire FOXP3 expression in the 
periphery, called pTregs. pTregs generated in vitro are named induced Tregs (iTregs)[9,10].   
 
Tregs are a crucial component of immunological tolerance and homeostasis, playing many roles in 
the immune system, including establishing tolerance to self and selected foreign antigens, and 
regulating the duration of immune responses to minimize self-damage[1]. Tregs mediate suppression 
via the secretion of anti-inflammatory cytokines, cytolysis of target cells, metabolic disruption, and 
modulation of dendritic cells[11]. Treg-mediated suppression, thus, targets a broad range of immune 
cells including other T-cell subsets, B cells, antigen presenting cells, and natural killer cells[12]. 
With such versatility in modes and targets of action, immunotherapies utilizing Tregs have been 
extensively investigated for the treatment of autoimmunity and allogeneic transplantation[13].  
 
In particular, Treg-therapy could establish allograft tolerance in transplant recipients, overcoming 
challenges associated with the requirement for life-long systemic immunosuppression to prevent 
allograft rejection, such as an increased risk of infection, malignancy, and organ toxicity[14]. 
Furthermore, spontaneous allogeneic organ tolerance, a phenomenon in which transplant recipients 
accept the allografts without the use of immunosuppressive regimen, has been observed in liver 
transplant recipients with elevated Treg levels[15]. Currently, most clinical trials of Treg-therapies 
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utilize systemic adoptive transfer of ex vivo expanded Tregs[16]. While this method has shown 
promising results in clinical trials[17,18], ex vivo expansion of Tregs requires extremely time-
consuming and costly protocols to generate appropriate numbers of cells for clinically significant 
results, due to the low frequency of Tregs in human peripheral blood[19,20]. Thus, it would be 
advantageous to employ more targeted approaches, such as hydrogel encapsulation to provide 
localized immunosuppression.  
 
Pancreatic islet transplantation is currently the only curative cell therapy for type 1 diabetes mellitus. 
Islet transplantation is unique, compared to solid organ transplantation, as it involves the isolation 
and purification of islets from a donor pancreas, which are then infused into the recipient liver via the 
hepatic portal vein[21]. Due to such characteristics, it is possible to co-transplant islets with other 
cell types beneficial to their survival[22,23]. As rejection by the immune system remains a major 
hurdle, co-encapsulation of islets with Tregs could be of great benefit. This could be achieved via 
3D-bioprinting using a recently developed customized co-axial bioprinter, equipped with dual bioink 
chambers, to generate a scaffold containing a core of islets surrounded by a shell of Tregs, providing 
localized immune-protection[24–26].  
 
Here, we encapsulated human nTregs and iTregs in an alginate-GelMA (gelatin methacryloyl) 
hydrogel, a bioink that we recently developed for co-axial bioprinting of islets with supporting 
cells[25]. While islets have been routinely encapsulated since 1980[27], Tregs have never previously 
been encapsulated. Therefore, this study investigated the impact of encapsulation on human nTregs 
and iTregs. Furthermore, the hydrogel was supplemented with Treg-specific bioactive factors, 
interleukin-2 (IL-2) and chemokine ligand 1 (CCL1), to enhance the encapsulation of Tregs. IL-2 is a 
T-cell stimulatory cytokine which is crucial for Treg survival and function[28] The effect of IL-2 on 
the encapsulated Tregs was evaluated. CCL1 is a ligand for chemokine receptor 8 (CCR8) which is 
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preferentially expressed on Tregs[29]. The capability of CCL1 to recruit additional Tregs to the 
hydrogel structure was examined, as well as the composition of the lymphocyte population that 
would actively be recruited from human peripheral blood.    
 
2.  Materials and Methods 
2.1. Preparation of alginate-GelMA hydrogel precursor 
Gelatin (porcine skin, type A, gel strength ~175 g Bloom, Sigma-Aldrich) was dissolved in 
phosphate buffered saline (PBS; 10% w/v) for one hour at 50 °C. Methacrylic anhydride (Sigma-
Aldrich) was added to the 10% w/v gelatin solution in a drop-wise manner with stirring (final 
concentration of 7.4% v/v). The reaction continued for 3 hours and then terminated by diluting the 
solution four times with PBS. 1% v/v of Chloroform was added, and the mixture was dialyzed 
against distilled water for seven days at 40 °C (cellulose membrane, molecular weight cut off 
(MWCO): ~12 kDa). The dialyzed GelMA solution was lyophilized to white porous foam (stored at -
20 °C until further use). The above process was undertaken under sterile conditions. The degree of 
functionalization (DoF) of GelMA was measured by a ninhydrin assay as described by Loessner et 
al[30]. Alginate (medium viscosity, Sigma-Aldrich) was sterilized by UV for 20 minutes then 
dissolved in PBS (2% w/v) for two days at 37 °C. GelMA was added to the alginate solution at a 
concentration of 7.5% w/v, resulting in 2%|7.5% w/v alginate-GelMa. The alginate-GelMA hydrogel 
precursor was incubated at 37 °C with occasional shaking until a homogenous formulation was 
formed.  
 
2.2. Cell isolation and in vitro expansion 
Human buffy coat (Australian Red Cross) was treated with a RossetteSep Human CD4+ T cell 
enrichment cocktail (STEMCELL Technologies) for 20 minutes on a platform mixer at 80 rpm. 
Treated buffy coat was diluted with PBS (+2% foetal calf serum (FCS), Bovogen) prior to isolation 
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of CD4+ T cells by density-gradient centrifugation over Lymphoprep (STEMCELL Technologies). 
Enriched CD4+ T cells were surface-stained for CD4, CD25, CD127 and CD45RA. CD4+ CD25+ 
CD127- T cells (natural regulatory T cells or nTregs) and CD4+ CD25- CD127+ CD45RA+ T cells 
(naïve CD4+ T-cells) were sorted by fluorescence-activated cell sorting (FACS; BD FACSAria 
Fusion, BD Biosciences; Fig. S1A). Sorted nTregs and naïve CD4+ T-cells were rested overnight in a 
complete X-vivo medium (cX-vivo: serum-free with gentamycin and phenol red, Lonza, 
supplemented with 2% HEPES, 1% L-glutamine and 5% human serum (Gibco, HyClone and Sigma-
Aldrich, respectively) with 500 U/mL of IL-2 (Novartis Vaccines and Diagnostics). After overnight 
resting, these cells were checked for purity by staining for CD4, CD25 and FOXP3 (Foxp3/ 
Transcription factor staining buffer set, eBioscience; Fig. S1B). nTregs were cultured in an 
expansion medium consisting of cX-vivo and a 1:1 ratio of Human T-expander CD3/CD28 
Dynabeads™ (Thermo Fisher Scientific). Naïve CD4+ T-cells were cultured in an induction medium 
composed of the expansion medium supplemented with 5 ng/mL of human TGF-β (eBioscience), 10 
nM/mL of all-trans retinoic acid (Sigma-Aldrich) and 2 nM/mL rapamycin (LC Laboratories) for the 
generation of induced regulatory T cells (iTregs). nTreg expansion and iTreg generation were 
verified by expression of CD4, CD25 and FOXP3 (Fig. S1C). Following expansion, the expander 
beads were removed and Tregs were rested in cX-vivo (+500 U/mL of IL-2) for two days prior to 
use.    
 
2.3. Encapsulation of Tregs 
Rested Tregs were mixed well with 2%|7.5% w/v alginate-GelMa hydrogel precursor at 2 × 106 
cells/mL, and then lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP, Tocris Bioscience; a 
final concentration of 0.06% w/v) was added. For some experiments, IL-2 (500 U/mL) or CCL1 (10 
µg/mL) was directly added to the above cell suspension. The hydrogel precursor-cell suspension was 
injected into a disc-mold (8 mm diameter with 1 mm height; approximately 50 μL in volume per 
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disc) using a drawing-up needle (BD Biosciences), which was then photo-crosslinked at 400 nm 
(Omnicure LX505, Excelitas) for 1 minute and then further crosslinked in 2% w/v CaCl2 (BDH) 
solution for 10 minutes. The cell-laden discs were cultured in cX-vivo medium (no IL-2) for 24 or 72 
hours at 37 ˚C with 5% CO2 prior to downstream assays. Non-encapsulated Tregs were prepared by 
suspending Tregs at 2 ×106 cells/mL in cX-vivo medium (+ 500U/mL of IL-2). Some discs made 
with IL-2-free 2%|7.5% w/v alginate-GelMa were cultured in cX-vivo medium (+ 500U/mL of IL-2); 
these were dubbed “Encapsulated (+IL-2 in media)”. For viability, phenotype, functionality and 
CD154 suppression assay, the encapsulated Tregs were recovered by digesting the hydrogel 
constructs in TrypLE Express (Thermo Fisher Scientific) for 10 minutes at 37˚C and then washed 
twice with PBS (non-encapsulated Tregs were treated the same way). 
 
2.4. Viability, Treg phenotype and Treg functionality assay  
Unstained control and compensation controls were used when required. For assessment of viability, a 
positive dead control was prepared by three cycles of rapid freeze-thaw (at -80 °C and 37 °C, 
respectively). For viability, propidium iodide (PI; 50 μg/mL) was added to the samples to a final 
concentration of 2.5 μg/mL. For Treg phenotype and functionality, recovered cells were stained for 
viability (fixable viability stain; supplementary table 1) then surface-stained for CD4 and CD25 
before being fixed, permeabilized and intracellularly stained for FOXP3. Stained cells were divided 
into four groups: the first group was stained for CD69, the second for TGF-β, the third for CD39, and 
the fourth for CTLA-4. All samples were analyzed on a BD FACS Canto II flow cytometer (BD 
Biosciences), and the data analyzed with FCS Express 6 (De Novo Software). 
 
2.5. CD154 suppression assay 
Human peripheral blood mononuclear cells (PBMCs) cells were isolated from a fresh buffy coat by 
density gradient centrifugation as described above. Naïve CD4+ T-cells were isolated using 
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EasySep™ Human Naïve CD4+ T Cell Isolation kit (STEMCELL Technologies). Naïve CD4+ T-
cells were labelled with 3,30-dioctadecyloxacarbocyanine perchlorate (DiOC18(3) (Thermo Fisher 
Scientific; a final concentration of 2 μg/mL) by incubation at 37 ˚C with 5% CO2 for 45 minutes. 96-
well round bottom plates were seeded with DiOC18(3)-labelled naïve CD4
+ T-cells (5 × 104 cells per 
well; “Teffector”) and Tregs were added to the wells at various ratios of Treg:Teffector (1:1, 1:2, 1:4 
and 1:8). Human T-expander CD3/CD28 Dynabeads™ (bead:Teffector ratio of 1:4) and anti-CD154 
antibody were added to each well. DiOC18(3)-labelled naïve CD4+ T-cells with and without Tregs 
were used as positive and negative controls, respectively. The plate was incubated at 37 ˚C with 5% 
CO2 for 7 hours then analyzed for expression of CD154 by flow cytometry (FACS Canto II). 
Percentage suppression was calculated as follows: 100 × [1 - (%CD154+ in the experiment sample 
divided by %CD154+ in the positive control)].           
 
2.6. Transmission electron microscopy (TEM) 
Encapsulated Tregs and non-encapsulated controls were fixed overnight in electron microscopy 
fixative (4% paraformaldehyde/1.25% glutaraldehyde in PBS, + 4% sucrose, pH 7.2). Fixed samples 
were washed in washing buffer (PBS + 4% sucrose) for 5 minutes then stained with 2% OsO4 
solution for 1 hour. Stained samples were dehydrated through a series of washes (two washes in 70% 
ethanol for 15 minutes each, two washes in 90% ethanol for 15 minutes each, three washes in 100% 
ethanol for 15 minutes each then one wash in propylene oxide for 15 minutes). Dehydrated samples 
underwent resin infiltration (50% propylene oxide 50% epoxy resin for 1 hour, two washes in 100% 
resin for 1 hour each then 100% resin overnight). After overnight incubation, samples were 
embedded in fresh 100% resin then polymerized at 70 °C for at least 24 hours. Sections were cut 




2.7. Whole blood chemokine receptor phenotyping  
Human peripheral blood mononuclear cells (PBMCs) were isolated from a fresh whole blood by 
density gradient centrifugation, as above. PBMCs were stained for CD3, CD4, CD45RA, CD25, 
CD127, CXCR3, CCR4, CCR6, CCR8 and CCR10 then analyzed on BD FACSymphony (BD 
Biosciences). Additionally, PBMCs were stained for CD4, CD45RA, CD25, CD127, CCR8 and 
FOXP3 for assessment of FOXP3 expression by CCR8+ and CCR8- Tregs.  
 
2.8. Chemotaxis assay 
Chemotaxis assays were performed with either 96-well or 24-well transwell plates with 5 μm 
polycarbonate membranes (Corning). All chemokines and cells were resuspended in a chemotaxis 
buffer composed of RPMI 1640 medium (Gibco) with 0.5% w/v bovine serum albumin (Sigma-
Aldrich) and 2.5% HEPES. 96-well plates employed 150 μL in the lower chamber and 50 μL in the 
upper chamber. 24-well plates employed 600 μL in the lower chamber and 100 μL in the upper 
chamber. To generate a migration response profile for CCL1 (96-well), various concentrations of 
CCL1 ranging from 100 ng/mL to 10 μg/mL (3-fold increments) were placed in the lower chambers, 
and Tregs (2 × 106 cells/mL) were placed in the upper chambers. CXCL12 (30 ng/mL) was utilized 
as a positive control. For assessment of encapsulated Treg migration (24-well), 10 μg/mL of CCL1 
was placed in the lower chamber and encapsulated (2 × 106 cells/mL) and non-encapsulated (1 × 106 
cells/mL) Tregs were placed in the upper chamber. For assessment of CCL1 addition to the hydrogel 
(24-well), CCL-1-added hydrogel disc (no cells) and 10 μg/mL of CCL1 were placed in the lower 
chamber and Tregs (2 × 106 cells/mL) were placed in the upper chamber. For all transwell migration 
assays, a spontaneous migration control with no chemokine in the lower chamber was included. The 
plates were incubated for 3 hours at 37 ˚C with 5% CO2, and then migrated cells in the lower 
chamber were analyzed by flow cytometry (BD LSRFortessa for the 96 well set up and BD FACS 
Canto II for the 24 well set up; BD Biosciences) using counting beads (CountBright Absolute 
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Counting Beads; Thermo Fisher Scientific). Migration index was calculated as follows: number of 
cells in the experimental sample per 1000 beads divided by number of cells in the spontaneous 
migration control per 1000 beads. For immune phenotyping post-chemotaxis with CCL1, human 
PBMCs (2 × 106 cells/mL) were placed in the upper chambers with 10 μg/mL of CCL1 in the lower 
chamber (24-well). After 3-hour incubation, cells in the lower chamber were stained as described in 
whole blood chemokine receptor phenotyping.   
 
2.9. Statistics  
Statistical significance (p<0.05) was analyzed using the GraphPad Prism 7. One-way ANOVA with 
Tukey’s multiple comparisons test, Two-way ANOVA with Tukey’s multiple comparisons test and 
paired two-tailed T-test were used to identify statistical significance. All replicates are biological 
replicates. All experiments utilized triplicates as technical replicates except for whole blood 
chemokine receptor phenotyping which used no technical replicates.   
 
2.10. Antibodies  
Antibody details are listed in the supplementary table 1.  
 
2.11. 3D-bioprinting of Tregs and viability staining  
Human nTregs and iTregs were 3D-bioprinted as described previously at 2 × 106 cells/mL.[25] 3D-
bioprinted nTregs and iTregs were cultured in cX-vivo medium (+ 500U/mL of IL-2) overnight at 37 
˚C with 5% CO2. 3D-bioprinted nTregs and iTregs were stained with Calcein AM (final 
concentration 1 μM; Thermo Fisher Scientific) and DAPI (300 ng/mL; Thermo Fisher Scientific) for 
30 minutes at 37 ˚C with 5% CO2 in dark. 3D-bioprinted cells were washed in PBS then imaged with 




3.1. Preparation of alginate-GelMA hydrogel precursor and Treg encapsulation 
Alginate-GelMA hydrogel precursor was generated by the addition of GelMA to an alginate solution. 
GelMA was prepared from porcine gelatin by the addition of methacrylic anhydride (Fig. 1A). The 
degree of functionalization (DoF) was measured by a ninhydrin assay quantifying absorbance at 570 
nm. The concentration of unfunctionalized gelatin remaining in the GelMA was interpolated from 
gelatin standards ranging from 0 mg/mL to 100 mg/mL, confirming successful methacryloyl 
functionalization with a DoF of 82 ± 5%. The hydrogel precursor was then used to encapsulate Tregs 
via photo- and chemical- crosslinking (Fig. 1B). Successful encapsulation was demonstrated by 
transmission electron microscopy (Fig. 2). In some experiments, Tregs were recovered via enzymatic 
dissolution of the hydrogel discs using TrypLE, which targets peptide bonds on the C-termini of 




Fig. 1. (A) Schematics for preparation of alginate-GelMA hydrogel precursor and (B) Treg encapsulation. 
  
 
Fig. 2. Treg encapsulation in alginate-gelMA hydrogel.TEM images of non-
encapsulated and encapsulated nTregs and iTregs. Scale bar represents 2 




3.2. Viability of encapsulated Tregs 
The viability of encapsulated or control non-encapsulated Tregs at days 1 and 3 was evaluated by 
measuring dye exclusion, based on % Propidium Iodide+ (100% - %PI+; Fig. 3A). On Day 1, 
encapsulated Treg viability was significantly reduced in both nTregs and iTregs (8% and 10%; 
p=0.0034 and p=0.0038, respectively) in the absence of IL-2, while there was no significant decrease 
in viability upon encapsulation in the presence of IL-2. Non-encapsulated and encapsulated Tregs 
without IL-2 displayed significantly lower viability than those with IL-2, a 9% (p=0.0012) and 12% 
(p<0.0001) decrease in nTregs and 16% (p<0.0001) and 23% (p<0.0001) decrease in iTregs, 
respectively. At day 3, viability of non-encapsulated and encapsulated Tregs without IL-2 decreased 
by 23% and 41% in nTregs and 29% and 40% in iTregs (p<0.0001), compared with those IL-2. The 
viability of encapsulated Tregs with IL-2 was significantly lower than non-encapsulated Tregs with 
IL-2 (18% decreases in both nTregs and iTregs, p=0.0001 and 0.0042 respectively; Fig. 3B and Fig. 
S2A, B). These decreases were reversed by supplementing the media with IL-2 (‘encapsulated with 
IL-2 in media’) instead of the hydrogel. The viability of encapsulated Tregs with IL-2 in the media 








3.3. Phenotype of encapsulated Tregs 
Tregs are classically defined as CD4+ CD25+ FOXP3+ cells. Expression of CD25 and FOXP3 was 
measured as mean fluorescence intensity (MFI) in viable CD4+ populations (Fig. 4A). Analysis 
showed no significant differences in the MFI of CD25 expression between non-encapsulated and 
encapsulated Tregs. CD25 MFI of non-encapsulated and Tregs encapsulated with IL-2 were higher 
Fig. 3. Viability of Tregs encapsulated in alginate-GelMA hydrogel at day 1 and 3. (A) Gating strategy to determine the 
percentage of dead cells. Propidium iodide (PI) was used to stain dead cells (black line: unstained control; Indigo line: 
positive dead control). (B) Viability at day 1 and 3 for both nTregs and iTregs. Non-encapsulated Tregs were cultured in 
either IL-2-supplemented media “non-encapsulated (+IL-2) or IL-2-free media “non-encapsulated (-IL-2). Encapsulated 
Tregs were made with either IL-2-supplemented hydrogel “encapsulated (+IL-2) or IL-2-free hydrogel “encapsulated (-IL-2) 
then cultured in IL-2-free media. (C) Day 3 viability of encapsulated Tregs upon supplementation of the media with IL-2 
instead of the hydrogel “encapsulated (+IL2 in media)”. Data represented as mean ± SEM, n=3, statistical significance 




than Tregs without IL-2 for nTregs (non-encapsulated: p=0.0305) and iTregs (p<0.0001). Tregs 
encapsulated with IL-2 showed significantly lower FOXP3 MFI than non-encapsulated Tregs 
cultured with IL-2 (p=0.0006 for nTregs and p<0.0001 for iTregs). This was in contrast to Tregs 
encapsulated without IL-2 which showed no significant decrease in FOXP3 MFI compared with non-
encapsulated Tregs cultured without IL-2. Moreover, FOXP3 MFI of non-encapsulated and 
encapsulated Tregs without IL-2 were significantly reduced compared with those with IL-2 in both 
nTregs (p<0.0001 and p=0.0069) and iTregs (p<0.0001 and p=0.0001; Fig. 4B and Fig. S3A). Treg 
functional markers CD69, transforming growth factor beta (TGF-β), CD39 and cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4), which are surrogates for activation status and 
suppressive functionality (inhibitory cytokines, metabolic disruption and dendritic cell (DC) 
targeting)[11,31], were also assessed (Fig. 5A). There were no significant differences in CD69, 
CD39 and CLTA-4 MFI between non-encapsulated and encapsulated Tregs. Non-encapsulated Tregs 
without IL-2 showed significantly lower CD69 (p=0.0472) and CD39 (p=0.0062) MFI in iTregs and 
CTLA-4 (p=0.0062) MFI in nTregs while there were significant differences between encapsulated 
Tregs with and without IL-2. TGF-β expression mimicked that of FOXP3, showing significant 
differences between non-encapsulated and encapsulated Tregs with IL-2 (p=0.0001 in nTregs and 
p=0.0011 in iTregs) and between non-encapsulated and encapsulated Tregs with and without IL-2 
(p<0.0001 and p=0.0023 in nTregs and p<0.0001 in iTregs; encapsulated Tregs showed n.s in iTregs; 
Fig. 5B and Fig. S3A). Again, upon supplementation of the media with IL-2, FOXP3 and TGF-β 
MFI expression was equivalent to non-encapsulated Tregs, showing significantly higher MFI 
(FOXP3: p<0.0001 in both nTregs and iTregs. TGF-β: p=0.0044 in nTregs and p=0.0003 in iTregs) 
than encapsulated Tregs with IL-2 (Fig. 5C and Fig. S3B). Percentage positive of each markers 






Fig. 4. Expression of Treg phenotype markers upon encapsulation in alginate-GelMA hydrogel. (A) Gating strategy for CD4
+ 
cells using an 
unstained population. Mean fluorescence intensity (MFI) for CD25 and FOXP3 were measured from this CD4
+
 population. MFI was 
normalized to the maximum raw value in each marker and experiment. (B) CD25 and FOXP3 MFI in non-encapsulated and encapsulated 
nTregs and iTregs (±IL-2). Data represented as mean ± SEM, n=3, statistical significance identified by One-way ANOVA with Tukey’s 







3.4. Suppressor function of encapsulated Treg 
Suppressive activities of non-encapsulated and encapsulated Tregs were assessed using CD154 
suppression assays. CD154 is an activation marker transiently expressed during T-cell activation and 
can be measured in naïve CD4+ T-cells (Teffectors) in the presence of Tregs to assess the suppressor 






cells using an unstained population. Mean fluorescence intensity (MFI) for CD69, TGF-β, CD39 and CTLA-4 were 






 population. MFI was normalized to the maximum raw value in each marker and 
experiment. (B) CD69, TGF-β, CD39 and CTLA-4 MFI in non-encapsulated and encapsulated nTregs and iTregs (±IL-2). (C) 
FOXP3 and TGF-β MFI of encapsulated nTregs and iTregs (+IL-2 in media). Data represented as mean ± SEM, n=3, statistical 
significance identified by One-way ANOVA with Tukey’s multiple comparisons test *P<0.05, **0.01, ***0.001, ****0.0001. 
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function of Tregs[32]. Tregs to Teffectors ratios of 1:1 to 1:8 were utilized. DiOC18(3) (3,30-
dioctadecyloxacarbocyanine perchlorate) was used to differentiate Teffectors from Tregs in the flow 
cytometric analysis. Negative control (DiOC18(3) labelled and CD154 stained) Teffectors provided 
baseline unstimulated % CD154+ to gate CD154+ cells. Positive control (DiOC18(3) labelled, CD154 
stained Teffectors stimulated with anti-CD3/CD28 beads) served as baseline stimulated %CD154+ to 
calculate % suppression (Fig. 6A). No significant differences in % suppression was shown between 
non-encapsulated and encapsulated Tregs at all ratios. In the absence of IL-2, Tregs displayed 
significant losses in their suppressor function compared with those in the presence of IL-2. At 1:1 
ratio, both non-encapsulated and encapsulated groups displayed 10% (p=0.0115 and 0.0132) 
decreases in nTregs and 13% (p=0.0048 and 0.0038) decreases in iTregs. At 1:2 ratio, 8% (n.s; 
p=0.0771) and 10% (p=0.0324) decreases were shown in nTregs and 13% (p<0.0001) and 18% 
(p=0.0034) decreases were observed in iTregs (Fig. 6B). 
 
 
Fig. 6. Function of Tregs encapsulated in alginate-GelMA hydrogel. (A) Gating strategy to determine %CD154+ from DiOC18(3)
+ 
cells. DiOC18(3) was used differentiate naïve T-cells (Teffectors) from Tregs. Unstained control was used to gate for DiOC18(3)
+. 
Negative control (black; DiOC18(3)-labelled and CD154-stained with no anti-CD3/CD28 beads) set baseline non-activated %CD154
+. 
Positive control (indigo; DiOC18(3) and CD154 stained with anti-CD3/CD28 beads) provided baseline activated %CD154+ to 
calculate %suppression. Control wells contained no Tregs. (B) %suppression of non-encapsulated and encapsulated nTregs and 
iTregs (±IL-2) at various Treg:Teffector ratios (1:1 to 1:8). Data represented as mean ± SEM, n=3, statistical significance identified 
by Two-way ANOVA with Tukey’s multiple comparisons test *P<0.05, **0.01, ***0.001, ****0.0001. 
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3.5. Migration capacity of encapsulated Tregs and CCL supplementation of the hydrogel  
For successful localized immunosuppression, it is important that Tregs stay confined within the 
hydrogel structure, which can be facilitated by strong chemotactic signals. The chemotactic response 
profile of nTregs and iTregs to CCL1 was measured from 100 ng/mL to 10 μg/mL with 3-fold 
increments, to determine concentration dose response. Spontaneous migration with no chemokine 
was utilized to calculate migration index (MI). Maximal responses were observed at 10 μg/mL with 
migration index of 30 and 9 in nTregs and iTregs, respectively (Fig. 7A). 10 μg/mL of CCL1 was 
used to assess the migration capacity of non-encapsulated and encapsulated Tregs. Migration 
capacity of encapsulated Tregs was significantly reduced compared with non-encapsulated Tregs 
with 400-fold reduction (p=0.0003) for nTregs and 220-fold (p<0.0001) reduction for iTregs (Fig. 
7B). In parallel, the Treg-recruitment capability of hydrogel discs supplemented with CCL1 was 
evaluated. CCL1-supplemented hydrogel demonstrated recruitment of Tregs with an MI of 5 in 
nTregs and 3 in iTregs. This was significantly lower than the 10 μg/mL of CCL1 in chemotaxis 
buffer which showed a MI of 43 with nTregs (p<0.0001) and 19 with iTregs (p<0.0001) (Fig. 7C). 
Moreover, CCL1 has been shown to enhance Treg function[33]. Therefore, CCL1-supplimented 
hydrogel was used to encapsulate Tregs and suppressive activities of encapsulated Tregs with and 
without CCL1 were measured. Interestingly, nTregs and iTregs showed completely opposite results. 
Suppressive activity of encapsulated nTregs was significantly higher in the presence of CCL1 with 
12% (p=0.0211), 13% (p=0.0125) and 15% (p=0.0365) differences at 1:1, 1:2 and 1:8 ratios (1:4 
ratio n.s with 12% difference; p=0.1129) while suppressive activity of iTregs was significantly lower 
in the presence of CCL1 with 8% (p=0.0355), 12% (p=0.0385), 16% (p=0.0277) and 18% 






To investigate which types of lymphocytes would be recruited from the human peripheral blood 
through CCL1-mediated chemotaxis, peripheral blood mononuclear cells (PBMCs) were isolated 
from whole blood for immunophenotyping. Particular interests were in CD4+ T-cell subsets as most 
of CCR8+ cells in the peripheral blood are CD4+ memory T-cells[29]. PBMCs were stained for CD3, 
CD4, CD45RA, CD25, CD127, and CXCR3, CCR4, CCR6, CCR8 and CCR10 to compare 
proportions of CD4+ T-cell subsets in the whole memory (inclusive of CCR8+ and CCR8-) CD4+ T-
cells with CCR8+ memory CD4+ T-cells. Within these two populations, memory Tregs (mTregs) and 
memory conventional T-cells (mTconvs) were gated based on their CD25 and CD127 expression. 
Fig. 7. Migration capacity of encapsulated Tregs and assessment of CCL-1-supplemented alginate-GelMA hydrogel. (A) 
Chemotactic response profile of nTregs and iTregs to CCL1 (100 ng/mL to 10 µg/mL). 10 μg/mL of CCL1 was used for subsequent 
experiments, either supplementing chemotaxis buffer or the hydrogel. (B) Migration capacity of non-encapsulated and encapsulated 
Tregs. (C) Treg recruitment capability of CCL-1-supplemented hydrogel and CCL-1-supplemeted buffer. (D) %suppression of 
encapsulated nTregs and iTregs (±CCL1). Data represented as mean ± SEM, n=3, statistical significance identified by paired two-
tailed T-test *P<0.05, **0.01, ***0.001, ****0.0001. 
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mTconvs were then further divided into T-helper subsets using chemokine receptors (Fig. 8A). 
CCR8+ memory CD4+ T-cells showed significant enrichments of mTregs (p=0.0006), Th2 
(p=0.0036) and Th22 cells (p=0.0001) compared to whole memory CD4+ T-cells. Proportions of 
mTconvs (p=0.0004), Th1 (p=0.0126), Th1/17 (p=0.0097), Th17 (p=0.0035) and Th9 (p<0.0001) 
cells showed significant reduction (Fig. 8B). PBMCs were then utilized for the chemotaxis assay 
with CCL1. The proportions of mTregs and mTconvs migrated in response to CCL1 were 
comparable to CCR8+ memory CD4+ T-cells, with significant enrichment of mTregs (p<0.0001) and 
reduction of mTconvs (p<0.0001) compared to the whole memory CD4+ T-cells (Fig. 8C). 
Percentages of CCR8+ cells in each memory CD4+ T-cell subsets were also measured (Fig. S4). Th22 
cells had the highest expression of CCR8 followed by mTregs and Th2 cells at (53%, 28% and 28% 
respectively). Other subsets exhibited %CCR8+ below 10% (mTconvs at 10% and Th1, Th1/17 and 
Th17 at 7%) with Th9 cells being the least positive (2%) (Fig. 8D). Moreover, FOXP3 MFI of 
CCR8+ mTregs and CCR8- mTregs was assessed (Fig. S5). CCR8+ mTregs showed 1.5-fold higher 







Fig. 8. Immunophenotyping of human peripheral blood CD4
+ 
memory T-cells. (A) Gating strategy for proportions of various CD4+ 
T-cell subsets within whole memory (CD3+ CD4+ CD45RA-) inclusive of both CCR8+ and CCR8- and CCR8+ memory T-cells from 
human whole blood PBMCs. CCR8+ was gated using naïve CD4+ T-cells (CD45RA+) as a negative control. Memory Tregs 
(mTregs) and memory conventional T-cells (mTconvs) were defined as CD25+ CD127- and CD25- CD127+, respectively. 
mTconvs were divided into T-helper subsets using chemokine receptors: CXCR3+ CCR6- Th1, CXCR3+ CCR6+ Th1/17, CXCR3-, 
CXCR3- CCR6+ CCR4+ CCR10- Th17, CXCR3- CCR6+ CCR4- CCR10- Th9, CCR6- CCR4+ CCR10- Th2 and CXCR3- CCR6+ 
CCR4+ CCR10+ Th22. (B) Proportions of T-cell subsets in whole memory and CCR8+ memory populations. (C) Proportions of 
mTregs and mTconvs in PBMCs migrated in response to CCL1. (D) %CCR8+ of T-cell subsets. (E) FOXP3 MFI of CCR8+ and 
CCR8- mTregs.
 
Data represented as mean ± SEM, n=6 for b-d and n=5 for e, statistical significance identified by paired two-




This is the first study to investigate encapsulation of human Tregs. Tregs are a crucial part of the 
human immune system, with their key role in the maintenance of immune tolerance and homeostasis. 
Through encapsulation, these intrinsic properties could be co-opted in a localized manner. In this 
study, we used 2%|7.5% w/v alginate-GelMA hydrogel to successfully encapsulate human nTregs 
and iTregs. The primary aim of this study was to demonstrate that Treg encapsulation caused no 
detrimental effects and thus have the capacity to provide local immune-protection to co-encapsulated 
cells. This hydrogel was recently formulated as a bioink for 3D-bioprinting of islets with supporting 
cells for its optimal macroscopic and rheological properties, its shear-thinning behavior, and its 
capacity to support cell survival. Tregs were “pseudo-printed” using encapsulation parameters that 
mimicked recently published islet 3D-bioprinting[25]. Our findings presented in this paper are 
applicable to the 3D-bioprinting setting, as demonstrated by highly viable 3D-bioprinted nTregs and 
iTregs (Fig. S6).   
 
Encapsulated Tregs were shown to be viable, phenotypically stable and functional. Addition of IL-2 
directly into the hydrogel protected Tregs from the encapsulation process, sustained viability during 
incubation, increased expression of CD25 and enhanced suppressive activity. The hydrogel was 
designed with high porosity to facilitate adequate nutrient and oxygen diffusion into the discs. 
Therefore, bioactive factors have the potential to diffuse out of the structure. As a result of this, Tregs 
encapsulated in IL-2-supplemented hydrogel displayed decreased viability at day 3 and reduced 
expression of FOXP3 and TGF-β compared with non-encapsulated Tregs cultured with IL-2, which 
was reversible upon addition of IL-2 directly to the media, instead of the hydrogel (Fig. 3-6). Given 
that the hydrogel discs (approx. 50 μL in volume) are cultured in 1 mL of IL-2-free media, the final 
concentration of IL-2, once equilibrium had been reached, would be 25 U/mL, which is much lower 
than the desired concentration of 500 U/mL. Moreover, as interaction of IL-2 with its receptor leads 
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to internalization of the complex[34], 25 U/mL of IL-2 may be rapidly sequestered by Tregs, as IL-2 
induces high expression of CD25, the α chain of the high affinity IL-2 receptor[35]. IL-2 signaling 
also supports strong expression of FOXP3, reinforcing the Treg phenotype and lineage 
commitment[36,37]. This is important because Tregs are not able to produce IL-2 for autocrine 
signaling[1,38]. Thus, incorporation of an IL-2-eluting sustained-release system will be required to 
maintain IL-2 concentrations within the hydrogel. Additionally, given that IL-2 has extremely short 
half-life in serum and low-dose IL-2 therapy has demonstrated preferential expansion of Tregs, 
sustained-release of low-dose IL-2 may be more beneficial than sustained-release of high-dose IL-
2[39,40]. 
 
The primary goal of Treg encapsulation is to serve as a localized cellular immunosuppression for co-
encapsulated cell types such as islets. To achieve this, Tregs need to be able to remain in the vicinity 
of the co-encapsulated cells. To this end, encapsulation was shown to halt migration of Tregs out of 
the hydrogel structure in the presence of a potent chemotactic signal (Fig. 7B). Acute rejection 
episodes could be prevented by these Tregs, yet, they may not provide a long-term solution as ex vivo 
expanded Tregs are short-lived.[41,42] Utilization of a chemokine to recruit recipient Tregs could aid 
in the establishment of long-lasting recipient-driven tolerance. This is a common strategy employed 
by tumor cells. It has been shown that CCL1 is expressed in certain tumor cells, locally recruiting 
Tregs to generate an immunosuppressive milieu that abrogates the anti-tumor response mediated by 
effector CD4+ and CD8+ T-cells[43–45]. Indeed, CCL1-supplmented hydrogel demonstrated 
recruitment of Tregs. Treg-recruitment capability of CCL1-supplemented hydrogel was significantly 
lower than CCL1 in the chemotaxis buffer, again, due to the porous nature of the hydrogel. The final 
concentration of CCL-1 in the chemotaxis buffer (600 μL) would have been approximately 800 
ng/mL once equilibrated, instead of 10 mg/mL. The migration indices shown in CCL-1-suplimented 
hydrogel discs were comparable with the 1 mg/mL of CCL1 in the buffer (Fig. 7A and 7C). In the 
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case of CCL1, the high porosity of the hydrogel facilitates the formation of chemokine gradients, and 
maintenance of this gradient through utilization of a CCL1-eluting sustained release system will 
maximize the recruitment capability. Furthermore, Tregs preferentially expressed CCR8 and were 
enriched in CCR8+ and CCL1-recruited peripheral blood T-cells. Together, this suggests that the use 
of CCL1-supplemented hydrogel could provide a microenvironment enriched with recipient Tregs in 
vivo. Although, it is possible that the same chemokines may actively recruit other T helper cells to 
the site. Th2 and Th22 cells showed preferential expression of CCR8 and enrichment in CCR8+ 
peripheral blood T-cells (Figure 8b-d). Despite previous studies regarding expression of CCR8 on 
Th2 cells[46], the use of CCL1 was justified as Th2 cells could assist with tolerization given their 
ability to inhibit rejection-causing Th1 responses[47]. Expression of CCR8 on Th22 cells had not 
been described to date. Moreover, the role of Th22 cells in transplantation is currently unknown[48]. 
It has been shown that CCR8+ conventional skin T-cells are less effector-like, with decreased 
functionality compared with their CCR8- counterparts[49]. Thus, recruitment of CCR8+ Th22 cells 
may not equate to a pro-inflammatory response, especially in an environment enriched with CCR8+ 
Tregs which have greater FOXP3 expression than CCR8- Tregs (Fig. 8E), hence a greater 
suppressive capacity[33,50]. In addition, similar approaches have been demonstrated using 
CCL22[51] and CXCL12[52] with promising results, illustrating the potential of chemokine 
incorporation.  
 
Two types of human Tregs, nTregs and iTregs, were compared in this study to determine which 
would be more suitable for encapsulation. While both types are defined as CD4+ CD25+ FOXP+ T-
cells, there are fundamental differences between them. Natural Tregs are generated during thymic 
development and pTregs are generated in the periphery in vivo or can be induced in vitro from 
conventional T-cells (iTregs). Induced Tregs were shown to be more sensitive to IL-2 than nTregs in 
terms of viability, CD25 expression and suppressive activity, which could be disadvantageous in an 
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IL-2-limited environment. iTregs displayed greater suppressive activity than nTregs, indicating that 
iTregs could suppress the recipient immune system more effectively[53]. Moreover, migration 
indices of nTregs in response to CCL1 was higher than iTregs. The migration index of nTregs in 
response to CXCL12, a ligand for pan-leukocyte chemokine receptor CXCR4[54], was also higher 
and there were no significant differences in CCR8 expression between nTregs and iTregs. This 
indicates that the differences in CCL1 migration index is due to iTregs being more motile in nature, 
rather than nTregs being more responsive to CCL1 (Fig. S7). CCL1 also had different effects on 
encapsulated nTregs and iTregs, enhancing nTreg suppressive activity while dampening iTreg 
suppressive activity. This may be due to CCR8 signaling causing iTregs to be less suppressive due to 
their origin of being differentiated from the conventional T-cell lineage[49]. Ultimately, while iTregs 
were found to be more suppressive than nTregs and possess a more relevant repertoire of antigen 
specificities for allogeneic transplantation[55], nTregs may be more suitable than iTregs due to their 
phenotypic stability. The methylation status of the FOXP3 promotor region and Treg-specific 
demethylation region (TSDR) determine the stability of the Treg phenotype. These regions in iTregs 
are incompletely demethylated, allowing iTregs to convert to a proinflammatory Th17 phenotype in a 
pro-inflammatory settings[56]. Thus, the utilization of iTregs for co-encapsulation with other cells 
may act as an immunological Trojan horse.  
 
5. Conclusion 
In this study, we demonstrated the potential of encapsulating human Tregs in alginate-GelMA 
hydrogel as a means to provide localized cellular immunosuppression to transplanted islets. IL-2 and 
CCL1, as Treg-specific bioactive factors, were investigated as supplements to the hydrogel. 
Encapsulated Tregs were viable, and phenotypically and functionally stable. Furthermore, 
encapsulation prevented migration of Tregs out of hydrogel structure. Addition of IL-2 and CCL1 to 
the hydrogel showed several benefits including the improvement of Treg viability, suppressive 
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phenotype and function, and the capacity to recruit additional Tregs. Due to the highly porous nature 
of the hydrogel, adding these factors directly into the hydrogel produced sup-optimal concentrations 
once the factors diffused into the surrounding media. Therefore, incorporation of a sustained-release 
system via recently developed polylactic-co-glycolic acid (PLGA)-based microspheres will be 
implemented for further improvement[57]. To further enhance Treg numbers, low-dose rapamycin 
could be added as an additional bioactive factor[58], utilizing recently developed rapamycin loaded 
porous silicon nanoparticles[59,60]. Moreover, peripheral blood CCR8+ T-cells were highly enriched 
with Tregs, and CCL1 was shown to specifically induce chemotaxis of these cells, providing an 
insight into the cellular microenvironment in humans upon utilization of CCL-1-supplemented 
hydrogel. Lastly, while this study focused on the encapsulation of Tregs for future applications in 
islet transplantation through 3D-bioprinting, the findings could be applied to other types of cell 
therapies such as adrenocortical, thyroid and parathyroid cell transplantation[61–63].   
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Summary: Induced regulatory T-cells are an attractive alternative for adoptive transfer in an allogeneic 
transplant setting. Here, Kim et al. reports the generation of stable human induced regulatory T-cells with a 
differentiation method utilizing TGF-β, all-trans retinoic acid and low-dose rapamycin.  
Regulatory T-cells are a vital sub-population of CD4+ T-cells with major roles in immune tolerance and 
homeostasis. Treg-based immunotherapies have been extensively investigated, with a focus on adoptive transfer 
of ex vivo-expanded natural Tregs (nTregs). Induced Tregs (iTregs) provide an attractive alternative due to their 
diverse T-cell receptor repertoire and ease of generating ample cell numbers for clinical dosage. The challenge 
for therapeutic iTreg generation has been their instability. Here, we aim to optimize an iTreg-differentiation 
method for the generation of stable human iTregs. iTregs engineered with our optimized method are superior to 
iTregs generated with a commercial kit, with increased CD25 and FOXP3 expression, viability and rate of 
expansion. Furthermore, these iTregs show stability in the absence of IL-2, in the presence of Th17-polarizing 
cytokines, and upon re-stimulation without differentiation components. These iTregs are highly functional upon 
re-stimulation, displaying superior suppressive activities compared with nTregs. This work establishes a method 
to generate stable iTregs suitable for adoptive cell transfer. 
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Introduction 
Regulatory T-cells (Tregs) are a sup-population of CD4+ T-cells with immune-suppressive and immune-
modulatory properties. With such properties, Tregs form a vital part of immune homeostasis, providing tolerance 
to self and non-pathogenic foreign antigens, and down-regulating immune responses once pathogens are cleared 
in order to minimize tissue-damage (Sakaguchi et al., 2008). Currently, Tregs are defined by the surface 
phenotype CD4+, CD25hi and CD127lo, and expression of the master regulator of Treg-lineage, FOXP3 
(Sakaguchi et al., 1995; Baecher-Allan et al., 2001; Hori et al., 2003; Fontenot et al., 2003; Liu et al., 2006; 
Seddiki et al., 2006). Within the CD4+ CD25hi CD127- FOXP3+ population, however, there are two main 
subgroups of Tregs: thymic-derived natural Tregs (nTregs) and periphery-induced peripheral Tregs (pTregs). 
nTreg generation occurs during thymic development from self-reactive CD4+ T-cells, and accounts for 5-10% 
of circulating CD4+ T-cells (Singer et al., 2014). Most self-reactive CD4+ T-cells are negatively selected and 
deleted by apoptosis to establish central tolerance, however, some self-reactive CD4+ T-cells with high affinity 
for self-antigens receive signals to differentiate into nTregs by the induction of FOXP3 expression (Bettini and 
Vignali, 2010). nTregs express a T-cell receptor (TCR) repertoire towards self-antigens and establish peripheral 
tolerance, suppressing self-reactive conventional T-cells that have escaped central tolerance and thus preventing 
autoimmunity (Pohar et al., 2018; Yadav et al., 2013). In contrast, peripheral naïve CD4+ T cells, which account 
for 40-50% of circulating CD4+ T cells in adults, can acquire FOXP3 expression upon activation, becoming 
pTregs. As pTregs are differentiated from conventional T-cells they express a TCR repertoire towards foreign 
antigens and play major roles establishing tolerance against microbiota, environmental and food allergens, and 
fetal alloantigens during pregnancy (Kanamori et al., 2016; Yadav et al., 2013). The induction of pTregs can be 
mimicked in vitro to generate induced Tregs (iTregs; Kanamori et al., 2016; Schmitt and Williams, 2013).  
 
iTregs provide an attractive alternative for Treg-based immunotherapies in allogeneic transplantation. Currently, 
most Treg-based immunotherapies employ adoptive transfer of ex vivo expanded nTregs (Fuchs et al., 2018). 
To generate the required number of cells for clinical dosage, which requires up to 5 billion Tregs per patient, 
nTregs need to be ex vivo expanded for a prolonged period of time due their low frequency in peripheral blood 
(Romano et al., 2019; Safinia and Lombardi, 2015). Extended expansion could result in T-cell exhaustion, 
altering the functional/migratory ability of nTregs (Wherry, 2011). Thus, it would be beneficial to generate large 
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number of Tregs in a shorter time frame, by differentiating iTregs from naïve CD4+ T-cells, which are at a 
significantly higher frequency in peripheral blood. The TCR repertoire of iTregs is potentially more relevant for 
allogeneic transplantation, as rejection of the donor tissue occurs in response to foreign antigens (Schmitt and 
Williams, 2013). In addition, the broader TCR repertoire of iTregs compared with nTregs has advantages in the 
generation of antigen-specific Tregs, potentially providing a more targeted therapy (Kanamori et al., 2016; 
Relland et al., 2012).  
 
The pivotal point in the generation of iTregs has been the discovery of differentiation induction molecules 
converting naïve CD4+ T-cells into pTregs. One particular environment in which pTregs are present in 
significant numbers is the gut (Russler-Germain et al., 2017; Luu et al., 2017). The gut mucosal environment 
contains TGF-β, all-trans retinoic acid (ATRA), and short chain fatty acids, such as butyrate, which have been 
shown to promote pTreg differentiation (Furusawa et al., 2013; Coombes et al., 2007). Additionally, 
manipulation of ex vivo iTreg generation has validated various molecules such as IL-2, rapamycin and 
progesterone as enhancer of pTreg differentiation (Schmitt and Williams, 2013). To date, different approaches 
using combinations of these molecules have been explored to generate human iTregs (Hippen et al., 2011; 
Schmidt et al., 2016, 2018; Zanin-Zhorov et al., 2017; Riquelme et al., 2018). While these approaches work, the 
issue of phenotypic instability of iTregs presents a major challenge upon re-stimulation, significantly limiting 
the use of iTregs for therapeutic applications. 
 
Here, we optimized an iTreg differentiation method for the robust and reproducible production of iTregs with 
phenotypic and functional stability. Characteristics of iTregs, including expression of CD25 and FOXP3, 
viability, and growth were evaluated over time throughout expansion and after resting. The phenotypic stability 
of iTregs was assessed by resting in the absence of IL-2, measuring TSDR methylation status, challenging with 
Th17-polarizing cytokines, and re-stimulating without iTreg differentiation components. Furthermore, the in 
vitro suppressive function of iTregs was evaluated, and the functional stability of the iTregs was assessed upon 





Characteristics of induced Tregs 
Naïve CD4+ T-cells were differentiated into iTregs over a 7-day culture period, followed by a 7-day rest in the 
presence of IL-2. During this time course, cells were periodically assessed for expression of Treg markers CD25 
and FOXP3, as well as for viability and fold-expansion. iTregs were generated by an in-house optimized method 
(iTreg) or using a commercial kit (cTregs), and donor matched nTregs were expanded as Treg phenotype 
controls (Fig. 1 A). CD25 and FOXP3 expression was measured via flow cytometry and expressed as a 
percentage (%CD25+FOXP3+; gating was based on nTreg at ~85% CD25+FOXP3+) of the viable CD4+ 
population, and as protein expression levels by MFI (MFI was normalized to the maximum value in each 
experiment as %; nMFI). Viability was evaluated concurrently using a dead cell discriminating dye (Fig. 1 B). 
On day 0, prior to induction and expansion, an nTreg baseline %CD25+FOXP3+ of 89% and a naïve CD4+ T-
cell baseline %CD25+FOXP3+ of 1.5% was shown with significant differences in MFI of CD25 and FOXP3 
(p<0.0001 for all). After 1 day of culture, iTreg %CD25+FOXP3+ increased to 50% from the naïve CD4+ T-cell 
baseline, compared with 25% for cTregs (p=0.0018). By day 3, iTreg %CD25+FOXP3+ increased to 60% while 
cTregs reached 38% (p=0.0041). At day 5 and 7, iTregs were >85% CD25+FOXP3+ and cTregs were >75% 
CD25+FOXP3+. Upon resting, both iTregs and cTregs became >90% CD25+FOXP3+. The nTreg control culture 
maintained >85% CD25+FOXP3+ from day 1 to 14 (Fig. 1 C and Fig. S1 A). CD25 MFI of iTregs became equal 
to nTregs by day 5 (p<0.0001 on day 1 and 3), while CD25 MFI of cTregs became equal to nTregs by day 7 
(p<0.0001 on day 1, 3 and 5). CD25 MFI of iTregs was significantly higher than cTregs on day 1, 3 and 5 
(p<0.0001 for all). On day 10, CD25 MFI of iTregs and cTregs exceeded nTregs (p<0.0001 and p=0.0012, 
respectively). iTregs showed significantly higher CD25 MFI than cTregs (p<0.0001). Day 14, CD25 MFI of 
iTregs and cTregs remained higher than nTregs (p<0.0001 and p=0.0013, respectively), with no significant 
differences between iTregs and cTregs (Fig. 1 D and Fig. S1 B). FOXP3 MFI of both iTregs and cTregs equaled 
nTregs by day 5 (p<0.0001 for both day 1 and 3). On day 7, FOXP3 MFI of iTregs exceeded both nTregs and 
cTregs (p=0.0027 and p<0.0001, respectively). FOXP3 MFI of cTregs was lower than nTregs (p<0.0091). On 
day 10, FOXP3 MFI of iTregs was higher than nTregs (p=0.0092). Day 14 FOXP3 MFI of iTregs and nTregs 
were higher than cTregs (p=0.0004 and 0.0018, respectively; Fig, 1 E and Fig. S1 C). iTregs retained above 95% 
viability from day 0 to 14. cTreg and nTreg viability gradually decrease below 95% viability over days 1 to 14. 
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On day 7, cTregs showed 88% viability, significantly lower than iTregs with 98% viability (p=0.0007). Viability 
of cTregs decreased to 32% (p<0.0001 compared with iTregs and nTregs) on day 10. nTregs also displayed 
significantly lower viability (86%) than iTregs (p=0.0018). On day 14, the viability of cTregs further decreased 
to 22% (p<0.0001 compared with iTregs and nTregs). The viability of nTregs further reduced to 83% (p<0.0001 
compared with iTregs; Fig. 1 F and Fig S1 D). All three types of Tregs showed similar cell growth rates 
throughout the induction/expansion. By day 7, iTregs, cTregs and nTregs showed 13, 11 and 12-fold cell growth, 
respectively. Upon resting at day 10, iTregs and nTregs continued to proliferate while cTregs showed no 
additional growth. iTregs and nTregs increased to 39 and 35-fold growth, significantly higher than cTregs which 
increased 11-fold (p=0.0001 and p=0.0007, respectively). On day 14, iTreg cell growth was at 43-fold, while 
nTregs displayed a decreased rate at 33-fold. cTregs also showing a decrease, at 8-fold. (p<0.0001 and p=0.0005 
compared to iTregs and nTregs; Fig. 1 G and Fig S1 E).  
 
In vitro stability of induced Tregs 
Stability of iTregs was evaluated initially by resting without IL-2 (Fig. 2 A), which plays a crucial role for 
maintenance of Treg phenotype (Sakaguchi et al., 2008). In the absence of IL-2, nTreg and iTreg remained >85% 
CD25+FOXP3+ with no significant differences compared with cells rested in the presence of IL-2. On the other 
hand, cTregs showed a significant reduction in %CD25+FOXP3+ in the absence of IL-2 (p=0.0196). While all 
three Tregs showed no significant decreases in FOXP3 MFI in the absence of IL-2, CD25 MFI of all three Treg 
subtypes was significantly reduced in the absence of IL-2. iTregs displayed a 12% decrease (p=0.0009), nTregs 
a 11% decrease (p=0.0149), and cTregs a 46% decrease (p<0.0001; Fig. 2 A-C). Moreover, all three subtypes 
showed significant reductions in their viability in the absence of IL-2. The viability of iTregs decreased from 
93% to 33%, nTregs decreased from 83% to 29%, and cTregs decreased from 37% to 2% (p<0.0001 for all; Fig. 
2 E). The demethylation status of Treg-specific demethylation region (TSDR) is an important assay for stability 
of FOXP3 expression (Floess et al., 2007; Baron et al., 2007). Methylation levels of 11 CpG motifs in the TSDR 
were measured via targeted bisulfite pyrosequencing. DNA from iTregs and cTregs was collected at each 
timepoint throughout induction/expansion and resting, while DNA of nTregs was collected pre-expansion (day 
0), at the end of expansion (day 7), and post-expansion (day 10; Fig. 3 A). iTreg and cTreg methylation was 
above 90% at each timepoint, while nTregs showed 42%, 57% and 62% methylation on days 0, 7 and 10, with 
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each CpG motifs showing various levels of methylation (Fig. 3, B and C and Table S1). cTregs were excluded 
from further investigations due to poor long-term viability. 
 
It has previously been shown that iTregs can convert to pathogenic Th17 cells in a pro-inflammatory 
environment (Beres et al., 2011; Ghali et al., 2017). Therefore, the stability of iTregs was investigated by 
challenging them with Th17-polarizing cytokines IL-1β, IL-6, IL-21, IL-23 and TGF-β (Muranski and Restifo, 
2013; Martinez et al., 2008). Due to the dual role of TGF-β for differentiation of both iTregs and Th17 cells 
(Tran, 2012), it was unclear whether inclusion of TGF-β would prevent or augment the effects of other Th17-
polarizing cytokines on iTregs. Thus, two types of challenge media either excluding TGF-beta (1) or including 
TGF-beta (2) were used (Fig. 4 A). iTregs and nTregs remained >70% CD25+FOXP3+ in the presence of Th17-
polarizing cytokines, with no significant differences compared with non-challenged Tregs. No significant 
differences were shown between with and without TGF-β (Fig. 4 B). CD25 MFI of challenged iTregs and nTregs 
was significantly reduced compared with non-challenged Tregs (iTregs: p=0.0008 w/o TGF-β and p<0.0001 
with TGF-β. nTregs: p=0.0146 w/o TGF-β and p<0.0001 with TGF-β). Inclusion of TGF-β was shown to further 
reduce CD25 MFI (p=0.0075 in iTregs, p=n/s in nTregs; Fig. 4 C). FOXP3 MFI of challenged iTregs and nTregs 
was also significantly decreased compared with non-challenged Tregs (iTregs: p=0.0316 w/o TGF-β and 
p=0.0118 with TGF-β. nTregs: p=0.0029 w/o TGF-β and p=0.0041 with TGF-β), with no significant differences 
with or without TGF-β (Fig. 4 D). Additionally, challenged iTregs and nTregs showed significantly lower 
viability compared with non-challenged Tregs (p<0.0001 for all). Although non-significant, inclusion of TGF-
β reduced the viability of iTregs and nTregs by an additional 10%. Furthermore, expression of Th17 signature 
genes in challenged Tregs was evaluated via RT-qPCR (Fig. 5 A). RORC, STAT3, IL17A and CCR6 were chosen 
to represent a Th17 transcriptional program, Th17-differentiation STAT pathway, Th17 signature cytokines, 
and Th17 signature chemokine receptor (Egwuagu, 2009; Castro et al., 2017). Expression of RORC, STAT3 and 
CCR6 was not upregulated in challenged iTregs and nTregs, with no significant differences compared with non-
challenged Tregs. In the case of IL17A, nTregs showed significant upregulation upon challenge while iTregs 
did not (p=0.0273 w/o TGF-β and p=0.0006 with TGF-β; Fig. 5, B-E). Baseline expression of RORC and IL17A 
were significantly higher in nTregs compared with iTregs (p=0.0176 and p=0.0233, respectively), while there 
were no differences in baseline expression of STAT3 and CCR6 (Fig. S2). 
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Lastly, reduction of FOXP3 expression and suppressive activities has been observed in human iTregs upon re-
stimulation without iTreg differentiation components (Rossetti et al., 2015). Thus, the stability of iTregs was 
assessed upon re-stimulation. Initially, the expression of CD25 and FOXP3 in iTregs re-stimulated without the 
components (referred to as “ss-iTregs”; single stimulated) was compared with iTregs re-stimulated with the 
components (referred to as “ds-iTregs”; double stimulated) and re-stimulated nTregs (Fig. 6 A). ss-iTregs 
remained >77% CD25+FOXP3+ with no significant difference compared with ds-iTregs and nTregs (Fig. 6 B). 
CD25 MFI of ss-iTregs was not significantly different between ds-iTregs and nTregs. ds-iTregs showed 
significantly higher CD25 MFI than nTreg (p=0.0027; Fig. 6 C). FOXP3 MFI of ss-iTregs was significantly 
lower than both ds-iTregs and nTregs (p<0.0001 for both; Fig. 6 D). Baseline in vitro suppressive activities of 
iTregs and nTregs prior to re-stimulation was evaluated, then the suppressive activities of ss-iTregs, ds-iTregs 
and nTregs were measured (Fig. 7 A). T-cell suppression can be measured by using the expression of transient 
T-cell activation marker, CD154, in naïve CD4+ T-cells (Teffectors) as a surrogate for T-cell proliferation (Hill 
et al., 2012; Fig. 7 B). Prior to re-stimulation, iTregs displayed significantly higher suppressive activities than 
nTregs at all ratios of Treg to Teffector (p=0.0003 at 1:1, p=0.0356 at 1:2, p=0.0249 at 1:4 and p<0.0001 at 1:8; 
Fig. 7 C). Upon re-stimulation, ss-iTregs retained their suppressive activity. The suppressive activity of ss-
iTregs was higher than nTregs (p=0.0310 at 1:1, n.s at 1:2, p=0.0275 at 1:4 and n.s at 1:8) and lower than ds-
iTregs (n.s at 1:1, p<0.0001 at 1:2, p<0.0246 at 1:4 and n.s at 1:8). ds-iTregs were significantly more suppressive 
than nTregs at all ratios (p<0.0001 for all; Fig. 7 D).           
 
Discussion 
In this study, we optimized an iTreg differentiation method utilizing TGF-β, ATRA, rapamycin, IL-2, and α-
CD3/CD28 beads to differentiate and expand human iTregs from naïve CD4+ T-cells. These molecules have 
previously been shown to induce or enhance iTreg generation. TGF-β secreted by CD103+ intestinal dendritic 
cells (DCs) plays an essential role in the generation of pTregs in the gut by inducing binding of the transcription 
factors Smad2 and Smad3 to conserved non-coding DNA sequence 1 (CNS1) region of FOXP3 locus (Kanamori 
et al., 2016; Schmitt and Williams, 2013), which is crucial for FOXP3 induction in pTregs but not in nTregs 
(Samstein et al., 2012). Additionally, ATRA secreted by CD103+ intestinal DCs enhances binding of Smad3 to 
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CNS1 region through histone acetylation of Smad3 binding region, preventing Th17 polarization, also requiring 
TGF-β signaling (Kanamori et al., 2016; Schmitt and Williams, 2013; Oh and Li, 2013). Furthermore, the mTOR 
(mammalian target of rapamycin)-targeting drug, rapamycin, has been shown to stabilize FOXP3 expression 
(Zhang et al., 2013). Rapamycin also enhances purity of generated iTregs by selectively inhibiting the activation 
of conventional T-cells (Singer et al., 2014), as Tregs utilize an IL-2R-dependent STAT5 pathway for activation 
while conventional T-cells require the mTOR pathway for activation (Burchill et al., 2007; Delgoffe et al., 2009). 
Lastly, IL-2 promotes FOXP3 expression, Treg expansion, and inhibits Th17 polarization (Kryczek et al., 2007; 
Schmitt and Williams, 2013). The combination of TGF-β, ATRA, rapamycin, and IL-2 has previously been 
used to successfully generate iTregs with superior in vitro suppressive activities. However, these iTregs lost 
FOXP3 expression when rested in the absence of IL-2 and re-stimulation. The iTregs were then not able to 
prevent the onset of xenogeneic graft-versus-host-disease in a humanized mice model (Schmidt et al., 2016). 
Notably, inhibition of mTORC1, one of two distinct mTOR complexes, induces FOXP3 expression and 
promotes expansion (Chapman and Chi, 2014). Only 0.45 ng/mL of rapamycin is required to inhibit mTORC1 
(Foster and Toschi, 2009), thus, we utilized low-dose rapamycin of 1 ng/mL, compared with 100 ng/mL 
traditionally seen in the literature (Schmidt et al., 2016, 2018), to minimize unwanted downstream signals 
induced by rapamycin at higher doses, such as the inhibition of glycolysis (Li et al., 2014), as glycolysis has 
been shown to be important for iTreg differentiation and function (De Rosa et al., 2015). It has been 
demonstrated that strong TCR stimulation stabilizes FOXP3 expression (Wakamatsu et al., 2018), and that 
superior stability is achieved with α-CD3/CD28 beads compared with plate-bound α-CD3 and soluble α-CD28 
in murine iTregs (Gu et al., 2014). Hence, α-CD3/CD28 beads were used instead of plate-bound α-CD3 and 
soluble α-CD28 (Schmidt et al., 2016, 2018). 
iTregs generated by the in-house optimized method (“iTregs”) demonstrated superior expression of CD25 and 
FOXP3, viability, and fold expansion, compared with both nTregs and iTregs generated with a commercial kit 
(“cTregs”). iTregs became dual positive for CD25 and FOXP3 earlier than cTregs, and the expression level of 
CD25 in iTregs matched nTreg earlier than cTregs. Although the rate of increase in expression of FOXP3 was 
similar among iTregs and cTregs, this suggested higher stimulatory capacity of the in-house method compared 
with the commercial kit. Expression levels of CD25 in iTregs exceeded nTreg-levels. This high expression of 
 78 
CD25 and FOXP3 was maintained throughout the 7-day resting period, while expression levels of CD25 and 
FOXP3 in nTregs and cTregs fluctuated, demonstrating phenotypic stability over long duration of resting. iTregs 
remained highly viable during expansion and resting while reduction in viability was observed in nTregs and 
cTregs. In particular, the viability of cTregs was significantly reduced upon resting. It was initially thought that 
cTregs were dying from exhaustion after extended expansion, as the commercial kit protocol specified 5-day 
expansion, however, cTregs rested after 5 days showed even lower viability (Fig. S3). This reduction in viability 
was due to significantly high percentages of apoptotic cells in cTregs (Fig. S4), however, it is unclear why these 
cells became apoptotic, as the contents of the commercial kit are not specified beyond the use of plate-bound α-
CD3. The reduction in viability also affected the rate of expansion of the cTregs. iTregs, nTregs and cTregs 
showed similar initial expansion rates, while iTregs and nTregs continued to expand upon resting. As a result, 
the total cTreg cell number was not increased significantly, due to significant cell death. iTregs demonstrated 
the highest overall fold expansion, as they continued to proliferate after three days of resting, unlike nTregs. 
Together, these results suggested that the in-house optimized method for iTreg generation can produce 
significantly larger numbers of highly viable iTregs compared with conventional nTreg expansion methods, 
which is important given that the starting population for manufacturing iTregs, naïve CD4+ T-cells, is 6-fold 
more frequent in human peripheral blood than nTregs (Fig. S5). 
 
To provide a clinical benefit in the context of organ transplant it is important that iTregs remain stable in 
unfavorable conditions, such as the absence of IL-2. Given that Tregs cannot produce IL-2 for autocrine 
signaling, unlike conventional T-cells (Chinen et al., 2016), and IL-2 is crucial for survival of Tregs, 
maintenance of FOXP3 expression and reinforcement of Treg phenotype (Sadlon et al., 2010; Beyer et al., 2011), 
iTregs could lose FOXP3 expression (Schmidt et al., 2016) or convert back to conventional T-cells to produce 
autocrine IL-2 to survive. iTregs and nTregs remained dual positive for CD25 and FOXP3 upon resting without 
IL-2 while cTregs displayed a significant reduction. Expression levels of FOXP3 were not reduced, while 
expression of CD25 significantly decreased in all three Treg subtypes. This was expected as CD25 is the α chain 
of the high affinity IL-2 receptor complex (Létourneau et al., 2009). Expression of CD25 was more drastically 
reduced on cTregs compared with iTregs and nTregs, indicating that cTregs are more sensitive to IL-2. 
Moreover, significant cell death was observed in the absence of IL-2 in all three Treg subtypes. Currently, 
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demethylation of Treg-specific demethylation region (TSDR), the CpG-rich CNS2 region of FOXP3 locus, is 
thought to be the hallmark of stable FOXP3 expression, thus stable Treg phenotype (Kanamori et al., 2016; 
Schreiber et al., 2014; Polansky et al., 2008). In humans, it has been shown that nTregs exhibit full 
demethylation of TSDR, while conventional T-cells and iTregs present partial methylation of TSDR (Baron et 
al., 2007). Even though iTregs demonstrated phenotype stability over extended periods of resting and in the 
absence of IL-2, demethylation of TSDR in iTregs was not observed throughout expansion and resting. cTregs 
also showed no demethylation of TSDR, and no differences were observed between iTregs and cTregs. 
Interestingly, pooled nTregs analyzed for methylation status only displayed partial demethylation, which 
suggested possible contamination by cells with non-demethylated TSDR, such as pTregs. As nTregs in this 
study were sorted based on their CD4, CD25 and CD127 expression, they contained both CD45RA+ naïve Treg 
population and CD45RA- effector Treg population. Currently, there are no surface markers for distinguishing 
human nTregs and pTregs, and the exact proportions of circulating nTregs and pTregs in human peripheral 
blood are unknown (Szurek et al., 2015; Mohr et al., 2018). As such, the CD45RA- effector Treg population is 
heterogenous with both nTregs and pTregs, while CD45RA+ naïve Treg population is thought to be 
predominantly nTregs (Mohr et al., 2018). Indeed, similar level of demethylation were observed in nTregs sorted 
with only CD25 expression (Schmidt et al., 2016). Thus, more complex gating strategies may need to be utilized 
to enhance the purity of nTreg expansion. Notably, it has been observed that CD45RA+ Tregs show a higher 
degree of demethylation of the TSDR than CD45RA- Tregs (Baron et al., 2007). A sup-population of CD45RA- 
Tregs with intermediate expression of CD25, termed Fraction (Fr).III, display decreased demethylation 
(Cuadrado et al., 2018), supporting this notion. Furthermore, the degree of demethylation in nTregs decreased 
over the duration of expansion and resting, possibly indicating preferential expansion of pTregs or Fr.III Tregs 
over nTregs.  
 
The tendency of iTregs to switch to a pro-inflammatory phenotype, such as Th17, in a pro-inflammatory 
microenvironment, needed to be assessed. This is because conversion of iTregs into pathogenic pro-
inflammatory T cells in vivo is the major challenge to the use of iTregs for therapeutic purposes (Ghali et al., 
2017; Dons et al., 2011; Beres et al., 2011). Despite their fully methylated TSDR, iTregs remained dual positive 
for CD25 and FOXP3 upon challenge with Th17-polarizing cytokines. Expression levels of CD25 and FOXP3 
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were significantly reduced, but these decreases were also observed in nTregs. Moreover, the viability of iTregs 
and nTregs was significantly reduced when challenged. While the decreases in expression level of CD25 and 
viability were most likely caused by the lack of IL-2 in the challenge media, the decreases in expression level 
of FOXP3 may have been due to IL-1β and IL-21, which have been shown to reduce FOXP3 expression (Li et 
al., 2010; Jandl et al., 2017). IL-2 was excluded from the challenge media due to its ability to limit Th17 
polarization (Laurence et al., 2007), and IL-23 in the challenge media would have promoted survival and 
proliferation of Th17-converted iTregs (Fitch et al., 2007). Thus, these results demonstrated phenotypically 
stable iTregs in a pro-inflammatory environment. Interestingly, inclusion of TGF-β in the challenge media 
further decreased expression levels of CD25, especially in iTregs, and viability in both iTregs and nTregs. It has 
been shown that TGF-β without IL-2 signaling can promote cell death in T-cells (Travis and Sheppard, 2014), 
and IL-2 is essential for TGF-β-mediated induction of CD25 expression (Zheng et al., 2007). Moreover, 
upregulation of Th17 signature genes was not observed in iTregs, with relative expression of these genes being 
extremely low. Interestingly, although still extremely low compared to RPL13A, expression of IL17A was 
upregulated upon challenge in nTregs, which could have been due to higher baseline expression of RORC and 
IL17A in nTregs compared with iTregs. It has previously been shown that Tregs are divided into various subsets 
reflecting counterpart T-helper subsets (Duhen et al., 2012), and Tregs can be polarized to Th17-like Tregs, 
which express Th17 signature markers while retaining regulatory phenotype and function, under pro-
inflammatory conditions (Jung et al., 2017; Kim et al., 2017). Thus, these results suggest that iTregs were not 
polarized into Th17-like Tregs in a Th17 differentiating environment, which could be a double-edged sword 
due to their expression of RORγt and Th17 cytokines (Jung et al., 2017), with perhaps more resistance to Th17-
polarization than nTregs.    
 
The efficacy of iTreg-based immunotherapies would rely on their ability to retain a regulatory phenotype and 
function upon reactivation within an in vivo environment. iTregs remained dual positive for CD25 and FOXP3 
upon re-stimulation without iTreg differentiation components, which simulated in vivo reactivation. While the 
expression level of CD25 in these iTregs was lower than iTregs re-stimulated with differentiation components, 
it remained higher than nTregs. On the other hand, expression level of FOXP3 in these iTregs was significantly 
lower than both nTregs and iTregs re-stimulated with differentiation components. Furthermore, iTregs displayed 
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higher baseline suppressor function than nTregs prior to re-stimulation, and iTregs re-stimulated without 
differentiation components were still more suppressive than nTregs, despite having lower expression level of 
FOXP3. In contrast, iTregs re-stimulated with differentiation components were more suppressive than iTregs 
re-stimulated without differentiation components. It has been previously shown that expression levels of FOXP3 
can be directly correlated with suppressive activity (Chauhan et al., 2009; Barsheshet et al., 2017), however, 
this indicated that FOXP3 cannot be a direct surrogate for suppressor function, particularly when comparing 
nTregs and iTregs. In this case, the suppressive activities of nTregs or iTregs re-stimulated with and without 
differentiation components, correlated with their expression levels of CD25 instead of FOXP3. This could, of 
course, be an over-simplified interpretation, as distinctive suppressive mechanisms are observed in nTregs and 
iTregs (Schmitt and Williams, 2013). Indeed, recent transcriptomic and proteomic profiling of iTregs generated 
by multiple differentiation protocols revealed iTreg-specific molecular pathways and molecules (Schmidt et al., 
2018), even though these protocols were not able to generate stable iTregs. Thus, in-depth analysis of 
transcriptomes and proteomes may be required to see which factors and genes are attributing to discrepancies 
in the suppressor function of these Tregs. Nonetheless, these results corroborated functional stability as well as 
phenotypic stability of iTregs, even in an environment(s) which has previously resulted in loss of FOXP3 
expression and loss of suppressive activities (Schmidt et al., 2016; Rossetti et al., 2015).   
 
In summary, we demonstrated the generation of in vitro stable human iTregs with an in-house optimized method 
which utilized TGF-β, ATRA and low-dose rapamycin, providing an attractive alternative for manufacturing 
Treg-based immunotherapies. The in-house optimized method resulted in rapid generation of large number of 
iTregs that are superior to commercially generated iTregs. These iTregs were highly viable with strong CD25 
and FOXP3 expression over resting periods. Their phenotypic stability was demonstrated in the absence of IL-
2, in the presence of Th17-polarizing cytokines, and upon re-stimulation without TGF-β, ATRA and rapamycin. 
Furthermore, in the presence of Th17-polarizing cytokines, upregulation of Th17 signature genes was not 
observed in iTregs, while IL17A was upregulated in nTregs, further emphasizing the stability of iTregs. iTregs 
were also functionally stable upon re-stimulation without the components, and with higher suppressive activities 
than nTregs. Despite their phenotypic and functional stability, demethylation of TSDR was not shown for iTregs. 
While, TSDR demethylation has been thought to be a surrogate for Treg stability, there might be further factors 
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involved in stabilization of Treg phenotype. Indeed, it has been shown that demethylation of other Treg signature 
genes such as TNFRSF18, CTLA-4, IKZF4 and IL2RA, dubbed as Treg-specific demethylation patterns 
(“TSDP”), is crucial for Treg development and stable FOXP3 expression, as well as TSDR demethylation 
(Ohkura et al., 2012). Moreover, the iTreg differentiation method could be modified to induce TSDR 
demethylation. Notably, in mice, hypoxia (Ma et al., 2018) and vitamin C (Sasidharan Nair et al., 2016; Someya 
et al., 2017) were shown to enhance expression and activity of TET (ten eleven translocation) enzymes, which 
facilitate demethylation of the TSDR. This differentiation protocol not only has the potential to generate robust 
suppressor cells, but it can be achieved with shorter culture times, which has a dramatic impact on the cost of 
manufacturing. While this work serves a proof of principle for generation of stable human iTregs, the stability, 
safety and effectiveness of this improved iTreg differentiation protocol requires validation in a preclinical 
transplant model such as pancreatic islet transplant model or graft-versus-host-disease (GVHD) model. 
 
Materials and Methods 
Cell isolation, induction and expansion 
Human buffy coat (Australian Red Cross) was treated with a RossetteSep Human CD4+ T-cell enrichment 
cocktail (STEMCELL Technologies) for 20 minutes on a platform mixer at 80 rpm. Treated buffy coat was 
diluted with PBS (+2% foetal calf serum (FCS), Bovogen) prior to isolation of CD4+ T-cells by density-gradient 
centrifugation over Lymphoprep (STEMCELL Technologies). Enriched CD4+ T-cells were surface-stained for 
CD4, CD25, CD127 and CD45RA. CD4+ CD25+ CD127- T cells (natural regulatory T-cells or nTregs) and CD4+ 
CD25- CD127+ CD45RA+ T cells (naïve CD4+ T-cells) were sorted by fluorescence-activated cell sorting 
(FACS; BD FACSAria Fusion, BD Biosciences). Sorted nTregs and naïve CD4+ T-cells were rested overnight 
in a complete X-vivo medium at 1 × 106 cells/mL (cX-vivo: serum-free with gentamycin and phenol red, Lonza, 
supplemented with 2% HEPES, 1% L-glutamine and 5% human serum (Gibco, HyClone and Sigma-Aldrich, 
respectively) with 500 U/mL of IL-2 (Novartis Vaccines and Diagnostics). After overnight resting, nTregs were 
resuspended in an expansion medium consisting of cX-vivo and a 1:1 ratio of Human T-expander CD3/CD28 
Dynabeads™ (Thermo Fisher Scientific) at 1 × 106 cells/mL. Naïve CD4+ T-cells were resuspended in either 
(1) an optimized iTreg differentiation medium composed of the expansion medium supplemented with 5 ng/mL 
of human TGF-β (eBioscience), 10 nM/mL of all-trans retinoic acid (Sigma-Aldrich) and 2 ng/mL rapamycin 
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(LC Laboratories) at 1 × 106 cells/mL (iTregs) or (2) a commercial iTreg differentiation kit medium at 1-2 × 105 
cells/mL (“cTregs”). For the commercial kit (R&D Systems), manufacturer’s protocol was followed with an 
exception regarding the culture time which was specified as 5 days. Expansion for nTregs, iTregs and cTregs 
were carried out for 7 days. For nTregs and iTregs, media was replenished on day 3 and 5 to keep the cell density 
at 1 × 106 cells/mL. For cTregs, media was not replenished as their starting densities were lower. On day 7, 
Tregs were washed three times with PBS (+2% FCS). After washing, expander beads were magnetically 
removed from nTregs and iTregs. Tregs were re-suspended in cX-Vivo with 500 U/mL of IL-2 at 2 × 106 
cells/mL and rested up to 7 days. On day 10 (3 days of resting), media was replenished to keep the cell densities 
at 2 × 106 cells/mL.  
 
iTreg Stability Evaluation  
For evaluation of iTreg stability, iTregs were (1) rested in the absence of IL-2, (2) challenged with Th17-
polarizing cytokines and (3) re-stimulated without iTreg differentiation components. For (1), Tregs were rested 
for 3 days with or without IL-2 in the media at 2 × 106 cells/mL after 7-day expansion. For (2), Tregs were 
challenged for 3 days with Th17-polarizing cytokines, IL-1β (10 ng/mL; Biolegend), IL-6 (10 ng/mL; 
Biolegend), IL-21 (10 ng/mL; Biolegend), IL-23 (10 ng/mL; Biolegend) and TGF-β (5 ng/mL; eBioscience), at 
2 × 106 cells/mL. Two different media were prepared which contained (i) IL-1β, IL-6, IL-21 and IL-23 and (ii) 
IL-1β, IL-6, IL-21, IL-23 and TGF-β, respectively, after 7-day expansion. Tregs were rested with IL-2 as a 
control. For (3), Tregs were re-stimulated for 7 days at 1 × 106 cells/mL then rested with IL-2 for 3 days at 2 × 
106 cells/mL, after initial 7-day expansion and 3-day resting. nTregs were re-stimulated using the same 
expansion media. iTregs were re-stimulated with or without iTreg differentiation components. For (2) and (3), 
cTregs were excluded.     
    
Flow Cytometric Analysis for CD25, FOXP3 and viability 
1 x 105 cells were stained for viability and CD4 and CD25. Cells were fixed and permeabilized (Foxp3/ 
Transcription factor staining buffer set, eBioscience) then intracellularly stained for FOXP3. All samples were 
analyzed on a BD FACS Canto II flow cytometer (BD Biosciences), and the data analyzed with FCS Express 6 
(De Novo Software). 
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TSDR methylation assay 
Expander beads were magnetically removed from 2-3 × 105 cells. Cells were spun down and all supernatants 
were discarded, leaving cell pellets. Cell pellets were stored at -80 ˚C until assay. Assay was conducted by 
EpigenDx using the assay ADS783-FS1 and ADS783-FS2 (Ensembl Transcript ID: ENST00000376207) which 
assessed the methylation status of 11 CpG sites in the TSDR region of FOXP3 CNS2 by targeted bisulfite-
pyrosequencing of genomic DNA isolated from the cell pellets. This region covered CpG sites -2376 (CpG#44), 
-2371 (CpG#43), -2330 (CpG#42), -2322 (CpG#41), -2312 (CpG#40), -2309 (CpG#39), -2303 (CpG#38), -
2299 (CpG#37), -2291 (CpG#36), -2282 (CpG#35) and -2263 (CpG#34) relative to the FOXP3 ATG start codon. 
Internal low, medium, and high methylation controls were utilized.   
 
Reverse Transcription Quantitative Polymerase Chain Reaction 
5 × 105 cells were pelleted, and supernatants removed. Cell pellets were lysed, and RNA was isolated using 
RNAqueous™ Total RNA Isolation Kit (ThermoFisher Scientific) as per manufacturer’s protocol. Purified 
RNA was converted to cDNA using iScript Reverse Transcription Supermix (Bio-Rad) as per manufacturer’s 
protocol. cDNA was then used for measurement of gene expression via quantitative polymerase chain reaction 
on a CFX Connect Real-Time PCR Detection System (Bio-Rad) using TaqMan™ Gene Expression Master Mix 
(ThermoFisher Scientific) and Taqman primers for RORC (Hs01076112_m1), STAT3 (Hs00374280_m1), 
IL17A (Hs00174383_m1), CCR6 (Hs01890706_s1) and rpl13a (Hs04194366_g1; Housekeeping gene; 
ThermoFisher Scientific for all), as per manufacture’s protocol.  
 
CD154 suppression assay  
Human peripheral blood mononuclear cells (PBMCs) cells were isolated from a fresh buffy coat by density 
gradient centrifugation as described above. Naïve CD4+ T-cells were isolated using EasySep™ Human Naïve 
CD4+ T Cell Isolation kit (STEMCELL Technologies). Naïve CD4+ T-cells were labelled with 3,30-
dioctadecyloxacarbocyanine perchlorate (DiOC18(3) (Thermo Fisher Scientific; a final concentration of 2 
μg/mL) by incubation at 37 ˚C with 5% CO2 for 45 minutes. 96-well round bottom plates were seeded with 
DiOC18(3)-labelled naïve CD4+ T-cells (5 × 104 cells per well; “Teffector”) and Tregs were added to the wells 
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at various ratios of Treg:Teffector (1:1, 1:2, 1:4 and 1:8). Human T-expander CD3/CD28 Dynabeads™ 
(bead:Teffector ratio of 1:4) and anti-CD154 antibody were added to each well. DiOC18(3)-labelled naïve CD4+ 
T-cells with and without Tregs were used as positive and negative controls, respectively. The plate was 
incubated at 37 ˚C in 5% CO2 for 7 hours then analyzed for expression of CD154 by flow cytometry (FACS 
Canto II). Percentage suppression was calculated as follows: 100 × [1 - (%CD154+ in the experiment sample 
divided by %CD154+ in the positive control)].           
 
Statistics  
Statistical significance (p<0.05) was analyzed using the GraphPad Prism 8. One-way ANOVA with Tukey’s 
multiple comparisons test, Two-way ANOVA with Tukey’s multiple comparisons test and paired two-tailed T-
test were used to identify statistical significance. All replicates are biological replicates. All experiments utilized 
triplicates as technical replicates.  
 
Antibodies 
Antibody details are listed in the supplementary table 2.  
 
Flow Cytometric Analysis for Apoptosis  
1 × 105 cells were stained for Annexin V. All samples were analyzed on a BD FACS Canto II flow cytometer 
and the data analyzed with FCS Express 6. 
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Figure 1. Time-course analysis of iTreg characteristics. (A) Schematic for experimental design. nTregs were expanded 
with αCD3/CD28 beads and IL-2. iTregs were differentiated from naïve CD4+ T-cells using the in-house optimized method 
and a commercial kit. iTregs (In-house) was expanded with αCD3/CD28 beads and IL-2. The commercial kit included 
components for expansion. Following 7-day expansion, cells were rested up to 7 days with IL-2. Cells were analyzed on 
daypecified with asterisks. Expression of CD25 and FOXP3, viability and fold expansion were analyzed. MFI of CD25 and 
FOXP3 normalized to the maximum raw value in each experiment. (B) Gating strategy to determine 
viability, %CD25+FOXP3+ and MFI of CD25 and FOXP3 (unstained nTreg: black; stained nTreg: indigo). Viability was 
measured from lymphocyte population while %CD25+FOXP3+ and MFI of CD25 and FOXP3 were measured from viable 
CD4+ population. MFI was normalized to the maximum raw value in each marker and experiment. Fold expansion was 
calculated by tracking cell counts at each timepoints. Time-course analysis for (C) %CD25+FOXP3+, (D) CD25 MFI, (E) 






 Figure 2. Stability of iTregs in the absence of IL-2. (A) Schematic for experimental design. Following 7-day expansion, cells 
were rested for 3 days with or without IL-2. Cells were analyzed at the end-point of the experiment (day 10) specific by an 
asterisk. Expression of CD25 and FOXP3 and viability were analyzed. MFI of CD25 and FOXP3 normalized to the maximum 
raw value in each experiment.  (B) %CD25+FOXP3+, (C) CD25 MFI, (D) FOXP3 MFI and (E) Viability of nTregs, iTregs (In-
house) and iTregs (Commercial) rested with or without IL-2. Data represented as mean ± SEM, n=3. Statistical significance 





 Figure 3. TSDR methylation status of iTregs. (A) Schematic representing experimental design. DNA of cells were 
harvested at timepoints specified by asterisks. Two asterisks indicate timepoints where DNA of Tregs was also harvested. 
Methylation levels of 11 CpG locations from TSDR in FOXP3 CNS2 were measured by bisulfite pyrosequencing. (B) Time-
course analysis of TSDR methylation status in nTregs, iTregs (In-house) and iTregs (Commercial). Methylation level of 11 
CpG locations was averaged. Blue-shaded area indicates expansion. (C) Methylation levels of individual CpG locations in 









Figure 4. Stability of iTregs in the presence of Th17-polarizing cytokines. (A) Schematic for 
experimental design. Following 7-day expansion, cells were rested with (I) IL-2 or challenged with (II) IL-1β, 
IL-6, IL-21, IL-23 or (III) IL-1β, IL-6, IL-21, IL-23, TGF-β, for 3 days. Cells were analyzed at the end-point of 
the experiment (day 10) specified by an asterisk. Expression of CD25 and FOXP3 was analyzed. MFI of 
CD25 and FOXP3 normalized to the maximum raw value in each experiment. (B) %CD25+FOXP3+, (C) 
CD25 MFI, (D) FOXP3 MFI and (E) Viability of nTregs and iTregs (In-house) rested with (I) IL-2 or challenged 
with (II) IL1β, IL-6, IL-21, IL-23 or (III) IL1β, IL-6, IL-21, IL-23, TGF-β. Data represented as mean ± SEM, 
n=3. Statistical significance identified by One-way ANOVA with Tukey’s multiple comparisons test *P<0.05, 









Figure 5. Expression of Th17 signature genes in iTregs challenged with Th17-polarizing cytokines. (A) 
Schematic for experimental design. Following 7-day expansion, cells were rested with (I) IL-2 or challenged with 
(II) IL-1β, IL-6, IL-21, IL-23 or (III) IL-1β, IL-6, IL-21, IL-23, TGF-β, for 3 days. RNA was harvested at the end-point 
of the experiment (day 10) specified by an asterisk. Expression of RORC, STAT3, IL17A, CCR6 was measured 
via RT-qPCR. rpl13a was utilized as a housekeeping gene to calculate fold change in expression. Expression of 
(B) RORC, (C) STAT3, (D) IL17A and (E) CCR6 in nTregs and iTregs (In-house) rested with (I) IL-2 or challenged 
with (II) IL1β, IL-6, IL-21, IL-23 or (III) IL1β, IL-6, IL-21, IL-23, TGF-β. Data represented as mean ± SEM, n=4. 






Figure 6. Stability of iTregs upon re-stimulation without iTreg differentiation components. (A) Schematic for 
experimental design. Following 7-day expansion and 3-day resting, cells were re-stimulated for 7 days then rested 
with IL-2 for 3 days. nTregs were re-stimulated with αCD3/CD28 beads and IL-2. iTregs (In-house) were re-
stimulated either with iTreg differentiation components (double stimulated; “Double”) or without iTreg differentiation 
components (single stimulated; “Single”). Cells were analyzed at the end-point of the experiment (day 20) specified 
by an asterisk. Expression of CD25 and FOXP3 was analyzed. MFI of CD25 and FOXP3 normalized to the maximum 
raw value in each experiment. (B) %CD25+FOXP3+, (C) CD25 MFI and (D) FOXP3 MFI of re-stimulated nTregs and 
iTregs (In-house) re-stimulated with or without iTreg differentiation components. Data represented as mean ± SEM, 








Figure 7. Suppressive function of iTregs upon 
re-stimulation without iTreg differentiation 
components. (A) Schematic for experimental 
design. Following 7-day expansion and 3-day 
resting, cells were re-stimulated for 7 days then 
rested with IL-2 for 3 days. nTregs were re-
stimulated with αCD3/CD28 beads and IL-2. iTregs 
(In-house) were re-stimulated either with iTreg 
differentiation components (double stimulated; 
“Double”) or without iTreg differentiation 
components (single stimulated; “Single”). Base-line 
suppressive activities of nTregs and iTregs were 
analyzed after initial expansion and resting (day 10) 
then suppressive activities of re-stimulated cells 
were analyzed at the end-point of the experiment 
(day 20). These timepoints are specified with 
asterisks. CD154 suppression assay was utilized to 
measure suppressive activities. (B) Gating strategy 
to determine %CD154+ from DiOC18(3)
+
 cells. 
DiOC18(3) was used differentiate naïve T-cells 
(Teffectors) from Tregs. Unstained control was 
used to gate for DiOC18(3)
+. Negative control (black; 
DiOC18(3)-labelled and CD154-stained with no anti-
CD3/CD28 beads) set baseline non-
activated %CD154+. Positive control (blue; 
DiOC18(3) and CD154 stained with anti-CD3/CD28 
beads) provided baseline activated %CD154+ to 
calculate %suppression. Control wells contained no 
Tregs. (C) Base-line %suppression of nTregs and 
iTregs. (D) %suppression of re-stimulated nTregs 
and iTregs (In-house) re-stimulated with or without 
iTreg differentiation components. Data represented 
as mean ± SEM, n=3. Statistical significance 
identified by unpaired two-tailed T-test (C) and Two-
way ANOVA with Tukey’s multiple comparisons test 








In conclusion, we have been the first to show successful encapsulated of human Tregs, using parameters that 
mimicked 3D-bioprinting. We demonstrated the minimal impact encapsulation has on Treg viability, phenotype 
and function while also confining Tregs in the hydrogel structure, preventing cell migration. We further 
demonstrated the positive impacts of hydrogel supplementation with IL-2 and CCL1. IL-2 improved 
encapsulated Treg viability, phenotype and function while CCL1 showed the capability of recruiting Treg-rich 
populations from peripheral blood, further augmenting the immunosuppressive milieu of the transplantation site. 
In this study, we encapsulated human Tregs subtypes, nTregs and iTregs, to evaluate the suitability of each type 
for encapsulation therapies. iTregs proved to be more suppressive than nTregs, indicating they may provide 
increased transplanted islet protection. Previously, phenotype instability and tendencies to convert into 
pathologic Th17 cells under pro-inflammatory environments, such as the site of allogeneic transplantation, have 
limited the use of iTregs for therapeutic applications. Thus, we optimized an iTreg differentiation protocol for 
the generation of stable human iTregs, utilizing TGF-β, ATRA and low-dose rapamycin. Our optimized method 
resulted in rapid generation of large number of iTregs with superior viability and phenotype compared to a 
commercially available kit. The stability of iTregs were demonstrated in environments previously shown to 
cause loss of FOXP3 expression, such as the absence of IL-2, the presence of Th17-polarising cytokines and 
upon re-stimulation without the differentiation components. Although our Tregs maintained methylated TSDR, 
iTregs displayed higher resistance to Th17-polarising cytokines than nTregs, with no upregulation of Th17 
signature genes. iTregs remained highly suppressive upon re-stimulation, demonstrating their superiority to 
nTregs. The studies performed here provide a promising alternative utilizing 3D-bioprinting technology and 
human iTregs, tackling inherent challenges of conventional islet transplantation. Future experiments should 
evaluate the in vitro and in vivo immunomodulatory function of Tregs co-printed with islets. Furthermore, in 
vivo assessment of iTregs should be carried out to further confirm their stability, which may potentially shift the 
current paradigm of Treg stability by demonstrating that demethylation of TSDR is not required for stable 
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SUPPLEMENTARY INFORMATION 1 
 
Encapsulation of Human Natural and Induced Regulatory T-cells in 

































Fig. S1. (A) Percentage of nTregs, CD45RA+ nTregs and CD45RA+ Tconv in total CD4+ T-cells, mean ± SEM, n=33. (B) CD25 and 
FOXP3 staining of nTregs and CD45RA+ Tconv post-sorting. (C) CD25 and FOXP3 staining of nTregs and iTregs after .  
Fig. S2. Representative flow cytometry plots for viability assessment (A) day 1, (B) day 3 and (C) day 3 with additional condition of 
encapsulated with IL-2 in media. For (A) and (B), black: non-encapsulated with IL-2, red: encapsulated with IL-2, blue: non-
encapsulated without IL-2 and purple: encapsulated without IL-2. For (C), black: non-encapsulated with IL-2, red: encapsulated with 




Fig. S3. (A, B) Representative flow cytometry plots for phenotype and functionality assessment. For (A) black: non-encapsulated 
with IL-2, red: encapsulated with IL-2, blue: non-encapsulated without IL-2 and green: encapsulated without IL-2. For (B), black: 
non-encapsulated with IL-2, red: encapsulated with IL-2 and blue: encapsulated with IL-2 in media. (C, D) Percentage positive of 




















Fig. S4. Gating strategy for Figure 8D. %CCR8+ was gated using naïve CD4+ T-cells (CD45RA+) as a negative control then %CCR8+ 
of various T-cell subsets were measured.     












































Fig. S6. Viability of 3D-bioprinted nTregs and iTregs. Confocal laser scanning microscope images of 3D-Bioprinted nTregs and 
iTregs. Calcein AM was used to stain live cells (green) and DAPI was used to stain dead cells (light blue). Scale bars represent 100 
µm at 10× magnification.   
  
Fig. S7. Migration indices of nTregs and iTregs for CXCL12 and CCR8 expression of nTregs and iTregs. (A) Migration indices of nTregs 
and iTregs for CXCL12. CXCL12 was used as a positive control for CCL1 chemotactic response experiment. (B) Gating strategy for %CCR8+ 
and CCR8 MFI in nTreg and iTreg. (C) %CCR+ and CCR8 MFI of nTregs and iTregs. Data represented as mean ± SEM, n=3, statistical 
significance identified by paired two-tailed T-test *P<0.05, **0.01, ***0.001, ****0.0001 
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Antibody Clone Flurochrome Company 
Treg sorting/purity check    
CD4 SK3 APC-H7 BD 
CD25 M-A251 PE-Cy7 BD 
CD127 HIL-7R-M21 FITC BD 
CD45RA HI100 PE BD 
FOXP3 259D/C7 AF647 BD 
Treg phenotype/functionality    
CD4 OKT4 FITC eBioscience 
CD25 BC96 BV421 Biolegend 
FOXP3 259D/C7 AF647 BD 
CD69 L78 PE-Cy7 BD 
TGF-β FNLAP PE-Cy7 eBioscience 
CD39 eBioA1 PE-Cy7 eBioscience 
CTLA-4 L3D10 PE-Cy7 Biolegend 
LIVE/DEAD Stain - V500 ThermoFisher Scientific 
CD154 suppression assay    
CD154 89-76 APC BD 
Immunophenotyping panel    
CD3 UCTH1 BUV737 BD 
CD4 SK3 BUV395 BD 
CD25 M-A251 PE-Cy7 BD 
CD45RA HI100 APC-H7 BD 
CD127 HIL-7R-M21 PE-CF594 BD 
CXCR3 1C6 APC BD 
CCR4 1G1 BB700 BD 
CCR6 11A9 BV786 BD 
CCR8 433H BV421 BD 
CCR10 1B5 BB515 BD 
CCR8 FOXP3 panel    
CD4 SK3 BUV395 BD 
CD45RA HI100 APC-H7 BD 
CD127 HIL-7R-M21 PE-CF594 BD 
FOXP3 236A/E7 BB700 BD 
CD25 M-A251 BV421 BD 




































Table S1. Antibody panels 
Abbreviations: CD, cluster of differentiation; FOXP3, forkhead box P3; TGF-β, transforming growth factor beta; 
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Figure S1. Induvial timepoints from Figure 1. A) %CD25+FOXP3+, B) CD25 MFI, C) FOXP3 MFI, D) Viability and E) Fold expansion 
of nTregs, iTregs (In-house) and iTregs (Commercial) at individual timepoints. Data represented as mean ± SEM, n=3. Statistical 
significance identified by One-way ANOVA with Tukey’s multiple comparisons test *P<0.05, **0.01, ***0.001, ****0.0001. 
 
Figure S2. Baseline expression of Th17 signature genes, RORC, STAT3, IL17A and CCR6 in nTregs and iTregs.  
Data represented as mean ± SEM, n=4. Statistical significance identified by unpaired two-tailed T-test *P<0.05, 























Figure S3. Viability of day 5 rested iTregs (Commercial) and day 7 rested iTregs (Commercial). Data 
represented as mean ± SEM, n=3. Statistical significance identified by unpaired two-tailed T-test 






Figure S4. Percentage of apoptotic iTregs (In-house) and iTregs (Commercial). Annexin V was used 
to stain for apoptotic cells A) Gating strategy to determine %Annexin V+ from lymphocyte population. 
B) Percentage of apoptotic iTregs (In-house) and iTregs (Commercial) on day 5 and day 7 of 
expansion. Data represented as mean ± SEM, n=3. Statistical significance identified by unpaired two-








































Figure S5. Percentage of nTregs and naïve CD4+ T-cells in total peripheral CD4+ T-cells. Data 





  #44 #43 #42 #41 #40 #39 #38 #37 #36 #35 #34 
nTregs D0 Mean 39.23 37.77 60.77 43.23 43.47 39.03 42.07 43.87 40.7 35.3 36.67 
SEM 6.04 7.49 10.09 8.92 7.95 7.75 8.91 8.02 7.82 7.23 7.74 
iTregs (In-house) D0 Mean 97.10 94.30 100.00 100.00 100.00 92.77 99.23 96.83 85.87 78.10 95.10 
SEM 1.70 0.95 0.00 0.00 0.00 0.22 0.43 1.24 0.75 0.89 1.02 
iTregs (Commercial) D0 Mean 97.10 94.30 100.00 100.00 100.00 92.77 99.23 96.83 85.87 78.10 95.10 
SEM 1.70 0.95 0.00 0.00 0.00 0.22 0.43 1.24 0.75 0.89 1.02 
iTregs (In-house) D1 Mean 100.00 94.10 100.00 100.00 100.00 90.60 97.00 92.40 87.20 79.10 92.35 
SEM 0.00 0.00 0.00 0.00 0.00 0.50 1.80 0.10 2.00 4.10 3.65 
iTregs (Commercial) D1 Mean 98.00 93.00 100.00 100.00 100.00 91.15 95.35 95.05 85.40 79.90 95.95 
SEM 2.00 0.90 0.00 0.00 0.00 0.15 2.95 3.35 0.70 0.30 4.05 
iTregs (In-house) D3 Mean 100.00 92.87 100.00 98.40 100.00 90.67 96.83 96.60 86.73 80.43 95.03 
SEM 0.00 1.32 0.00 1.60 0.00 0.15 2.27 1.00 0.57 0.22 1.67 
iTregs (Commercial) D3 Mean 97.70 94.37 100.00 98.47 100.00 91.43 99.27 98.70 89.00 81.73 93.37 
SEM 0.97 1.07 0.00 0.93 0.00 0.55 0.73 0.85 1.04 0.82 2.42 
iTregs (In-house) D5 Mean 94.40 92.27 100.00 100.00 99.23 91.47 94.93 90.80 84.87 79.60 87.53 
SEM 2.82 1.10 0.00 0.00 0.77 0.58 1.48 0.32 0.52 0.15 1.39 
iTregs (Commercial) D5 Mean 95.87 91.80 100.00 98.00 97.70 91.50 97.73 93.97 85.27 80.23 86.73 
SEM 0.32 1.48 0.00 1.29 1.46 0.31 0.38 0.52 0.94 0.67 0.49 
nTregs D7 Mean 70.73 53.57 80.93 56.17 61.43 49.60 57.23 57.00 52.40 46.60 48.57 
SEM 9.66 4.14 8.17 7.25 6.64 4.07 5.45 4.26 5.24 4.84 6.07 
iTregs (In-house) D7 Mean 98.77 91.60 100.00 95.83 97.97 91.90 99.03 98.13 85.87 79.60 89.17 
SEM 0.62 1.65 0.00 1.71 1.05 1.01 0.61 0.80 0.77 0.90 0.79 
iTregs (Commercial) D7 Mean 100.00 92.30 100.00 99.10 100.00 90.73 94.53 94.77 84.67 78.70 87.53 
SEM 0.00 2.15 0.00 0.90 0.00 0.58 1.18 1.44 0.67 0.55 1.34 
nTregs D7 Mean 64.70 63.30 79.15 67.00 66.05 57.75 59.45 62.45 55.50 52.40 57.00 
SEM 10.50 11.80 15.95 15.90 15.15 13.35 12.75 11.65 11.80 12.00 13.00 
iTregs (In-house) D10 Mean 100.00 93.87 100.00 100.00 97.90 91.83 99.30 98.40 88.20 81.90 90.70 
SEM 0.00 0.95 0.00 0.00 1.31 0.68 0.36 1.10 2.07 0.95 1.04 
iTregs (Commercial) D10 Mean 96.13 93.17 100.00 95.67 100.00 91.93 93.87 93.03 86.50 80.33 88.70 




Antibody Clone Flurochrome Company 
Treg sorting    
CD4 SK3 APC-H7 BD 
CD25 M-A251 PE-Cy7 BD 
CD127 HIL-7R-M21 FITC BD 
CD45RA HI100 PE BD 
Treg phenotype    
CD4 OKT4 FITC BD 
CD25 M-A251 PE-Cy7 BD 
FOXP3 259D/C7 AF647 BD 
Fixable Viability Stain - 780 BD 
CD154 suppression assay    
CD154 89-76 APC BD 
Apoptosis staining    























Table S2. Antibody panels 
Abbreviations: CD, cluster of differentiation; FOXP3, forkhead box P3 
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Abstract
Purpose of Review Pancreatic islet cell transplantation is currently the only curative cell therapy for type 1 diabetes mellitus.
However, its potential to treat many more patients is limited by several challenges. The emergence of 3D bioprinting technology
from recent advances in 3D printing, biomaterials, and cell biology has provided the means to overcome these challenges.
Recent Findings 3D bioprinting allows for the precise fabrication of complex 3D architectures containing spatially distributed
cells, biomaterials (bioink), and bioactive factors. Different strategies to capitalize on this ability have been investigated for the
3D bioprinting of pancreatic islets. In particular, with co-axial bioprinting technology, the co-printability of islets with supporting
cells such as endothelial progenitor cells and regulatory T cells, which have been shown to accelerate revascularization of islets
and improve the outcome of various transplantations, respectively, has been achieved.
Summary 3D bioprinting of islets for generation of an artificial pancreas is a newly emerging field of study with a vast potential
to improve islet transplantation.
Keywords 3Dbioprinting .Pancreatic islet transplantation .RegulatoryTcell therapy .Endothelialprogenitorcell therapy .Type1
diabetes
Introduction
Diabetes mellitus (DM) is a chronic disorder characterized by
hyperglycemia due to failing of glucose metabolism, which
causes long-term complications in multiple organs including
retinopathy, nephropathy, neuropathy, and vasculopathy [1].
DM is a serious global public health problem, causing signif-
icant cost to both the health care system and the global econ-
omy. Globally, DM is the eighth leading cause of death caus-
ing over 1.5 million deaths directly, and 1.5 million indirectly
through hyperglycemia-associated illness such as cardiovas-
cular diseases. In 2014, there were an estimated 422 million
adults with diabetes worldwide with the global prevalence of
8.5% and it is predicted to increase to 592 million within
20 years [2].
Type 1 diabetes mellitus (T1DM), also known as juvenile
diabetes, accounts for 5–10% of the population with diabetes
[3]. Symptoms of T1DM include polyuria, polydipsia, poly-
phagia, weight loss, blurry vision, and extreme fatigue. T1DM
may occur at virtually any age but is most common in children
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and young adults and occurs as a consequence of an autoim-
mune destruction of the insulin-producing β cells of the islets
of Langerhans in the pancreas, leading to absolute insulin
deficiency [1, 2]. The autoimmune destruction is caused by
islet-specific T cell response [4] by various autoantibodies
such as autoantibodies to insulin [1, 3]. Recent studies suggest
T1DM is triggered by environmental factors such as exposure
to pathogens or environmental antigens in individuals who are
genetically predisposed to diabetes by particular genes such as
the HLA genes, which contribute to 50% of the genetic sus-
ceptibility to T1DM [2, 3].
Currently, patients with T1DM are treated with daily exog-
enous insulin administration [5, 6]. However, despite ad-
vances in medicine, there has not yet been a development of
an insulin therapy that can mimic the physiological rhythms or
a mechanical replacement for pancreatic β cells. An intensive
monitoring of blood glucose level accompanied by exogenous
insulin therapy via insulin injection or pump represents the
current state of treatments for T1DM. Although these treat-
ments are able to delay the progression of diabetic complica-
tions including neuropathy and retinopathy, it is not sufficient
to prevent these complications [7]. The replacement of β cell
function through whole pancreas transplantation is presently
the only permanent alternative for re-establishing endogenous
insulin secretion in patients with T1DM [8].
Current Approaches for β Cell Replacement
Pancreas transplantation is reserved and performed in patients
with T1DM and advanced or end-stage renal disease. As a
result, over three-quarters of the whole pancreas is
transplanted in conjunction with kidney transplantation as ei-
ther simultaneous kidney-pancreas transplantation or alterna-
tively pancreas after kidney transplantation [9]. Furthermore,
the surgical procedure is associated with significant mortality
risk, accompanied with clinically significant complications
such as pancreatitis, bleeding, re-occurrence of autoimmunity,
and rejection post-transplantation, which motivates the urgent
need for the search of an alternative therapy [10].
A logical alternative to whole organ transplantation is to
transplant the cells that have been destroyed. Pancreatic islet
transplantation is a minimally invasive approach where puri-
fied allogeneic donor islets, isolated from deceased organ do-
nor pancreata, are currently percutaneously infused into recip-
ient liver through the portal vein [11–13]. This procedure has
lower risk compared with pancreas transplantation, as major
surgery is not required and a differing immunosuppression
regimen is employed. A cellular approach was first tried un-
successfully in man in 1894 using fragmented sheep pancreas
in a subject with diabetes [12, 14]. The successful application
of islet transplantation as a treatment for diabetes was not
realized for many decades until reversal of diabetes was
initially observed in rodents and in a patient with chronic
pancreatitis who underwent pancreatectomy followed by islet
autotransplantation [15–17]. Following these findings, inten-
sive research has been conducted in the field of islet transplan-
tation. In 2000, the Edmonton immunosuppression protocol,
which utilized a corticosteroid-free immunosuppression regi-
men and multiple islet infusions from different donors, was
established [18]. An insulin independence rate of 100% was
achieved in seven patients following 1 year of islet transplan-
tation and partial graft function was observed in most of the
seven patients after 5 years [18, 19] which represented a sig-
nificant improvement from the success rate of 10% prior to the
protocol [12, 20, 21]. Critically long-term insulin indepen-
dence has been difficult to achieve, and most patients require
at least two infusions to achieve insulin independence [19].
Islet transplantation has been adopted as a treatment option for
T1DM in a number of countries and has proved an attractive
method of β cell replacement [21].
Despite the significant progress in islet transplantation pro-
cedures, numerous obstacles remain that currently limit its
clinical application [8, 22]. The current clinical standard of
care involves the infusion of islets into the patient liver via
the portal vein where islets encounter a sub-optimal non-pan-
creatic environment: high glucose concentration, lower oxy-
gen tension, and higher level of toxins [23]. Moreover, infu-
sion of islets via the hepatic portal vein triggers an innate
immune reaction upon contact with blood, known as the in-
stant blood-mediated inflammatory reaction [24]. The hypox-
ic islets secrete chemokines and express tissue factors, which
activates a thrombotic reaction [25]. Platelets are attracted to
the islet surface, recruiting leukocytes and macrophages to
infiltrate and destroy the islet cells [24, 26]. Together, these
factors kill up to 70% of transplanted islets in the first 48 h [27,
28] and consequentially islets from up to three donor
pancreata are required for clinical benefit, limiting the avail-
ability of the transplantation. Additionally, the obligatory use
of immunosuppressive regimen is another major challenge of
islet transplantation. Immunosuppressive drugs used for islet
transplantation are associatedwithmany side effects including
risks of infection, higher rate of malignancy, β cell toxicity,
and organ toxicity, significantly decreasing the individual’s
quality of life [20].
Alternative Transplantation Site
Many studies in recent years have explored alternative sites
for islet transplantation with the following key characteristics:
(a) sufficient space for islet engraftment; (b) close proximity to
vascular network to provide optimal oxygen tension, sensing,
and release of insulin; (c) allow real-time communication be-
tween cellular graft and the circulation; and (d) offer minimal
inflammatory potential to support long-term graft survival. A
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few sites with immunological privileges such as the testis or
thymus have been tested in small animals; however, to date,
they remained clinically irrelevant due to limited space for
islet engraftment [29, 30]. Among many sites explored, the
skin site received attention as it offers a readily accessible site
via a minimally invasive surgical procedure. The only draw-
back is that unlike the liver or kidney capsule, dermal poor
vascularization limits the integration and functionality of
engrafted islets [31]. The pancreas, the native home of islets,
has also been explored as a site of islet transplantation.
However, it is not considered for a transplantation site due to
the metabolic complications such as pancreatitis (potentially
induced after embolization) and limited vascular supply. At
this point in time, for clinical islet transplantation, intra-portal
infusion remains the gold standard [32].
As no suitable alternative transplantation site in the human
body has been found, one option to explore is the fabrication
of an artificial transplantation site. The recent advancements
in bio-engineering technology now enable constructing of
such sites. Hydrogels are a multi-component system com-
prised of a tri-dimensional network of polymer chains with
absorbed water filling the space between the macromolecules,
within which various biomaterials may be incorporated to
mimic tissue-like properties. To date, various types of natural-
ly derived polymers (e.g., alginate, collagen, gelatin, fibrin,
and fibronectin) and synthetic polymers (e.g., poly (lactic-
co-glycolic acid), polysulfone, poly (lactic acid), poly (vinyl
alcohol)) have been evaluated [33]. Among all, alginate-based
hydrogels have been the most extensively investigated poly-
mers for their utility with pancreatic islets to treat T1DM.
Alginate is a naturally occurring anionic polymer typically
obtained from brown seaweed. It is bio-inert, and naturally
hydrophilic, thus allowing covalent functionalization via in-
teraction with extracellular matrix proteins, peptides, and
growth factors [34, 35].
The main approach of incorporating such technology in
islet transplantation is via islet encapsulation. Pancreatic islets
are embedded within a hydrogel, and this “mini organ” holds
pores which allow bidirectional diffusion of small molecules
such as insulin (~ 6 kDa), nutrients, and glucose, and at the
same time, protects islets from immune attack by restricting
the access of immune cells or antibodies (~ 150–900 kDa)
[36]. Numerous small animal models have demonstrated that
islet encapsulation is able to improve glucose homeostasis for
a short term, but no permanent restoration of euglycemia was
observed [37–41]. Several challenges are suggested to limit
this biomedical approach to advance into clinical settings. One
challenge arises as physical irregularities from fabricating hy-
drogel result in an incomplete coverage of the islets within the
capsules. This may trigger a pericapsular fibrotic overgrowth
(PFO) which blocks the diffusion of nutrients and oxygen,
resulting in islet necrosis [42, 43]. Even the successfully en-
capsulated islets suffer from hypoxia due to the restricting
hydrogel permeability and increased distance from the sur-
rounding blood vessels reduces the availability of oxygen by
diffusion. This introduces a challenge in scaling up into a large
animal model or clinically relevant dose of islets. Moreover,
encapsulation prevents immediate revascularization post-
transplantation, subjecting the islets to further hypoxic stress.
As hypoxia hampers the function and responsiveness of islets
to glucose, even a larger number of islets are needed to restore
normoglycemia.
3D Bioprinting
One approach to address hypoxia involves “seeding” of islets
onto degradable 3D scaffold structures [44]. Scaffolds are
made of similar biopolymers to mimic the pancreatic micro-
environment. The construct provides increased surface area to
volume ratio compared with the hydrogel capsules, and even
allows for vascular ingrowth, thereby providing increased ox-
ygen and nutrient supply [45]. Upon slow degradation of the
scaffold, the extracellular matrix proteins are deposited by
surrounding tissues and engrafted islets, gradually re-
building the suitable environment required for islet survival
[46]. Even though immune isolation is not achieved through
this method, the scaffolds can prevent direct contact of em-
bedded islets to circulating immune cells to reduce the inflam-
matory response until the scaffolds eventually degrades [24].
The efficacy of such device has been demonstrated in animal
studies [47–49]. Moreover, utilization of 3D bioprinting tech-
nology with higher accuracy could provide highly controlled
seeding of islets, thereby minimizing the onset of PFO arising
with conventional techniques.
The concept of 3D printing was first introduced in 1986 by
Charles W. Hull and has become increasingly prominent over
the past decades [50]. 3D printing technology allows printing
of a 3D structure, typically through stacking successive thin
layers in a layer-by-layer fashion. Advances in engineering
technology have now opened up the possibility of using 3D
printing to “print” spatially controlled biomaterial structures
with embedded bioactive factors and cells into a functional
tissue construct [51]. Such automated printing allows for the
precise control of architecture, pore interconnectivity, and a
high degree of reproducibility necessary for commercial clin-
ical application and regulation. Furthermore, bioprinting al-
lows the deposition of a wide array of cell types and bioactive
factors in a precise order to simulate native tissue environment
and support cell survival [52–54].
The current varieties of 3D bioprinting techniques include
extrusion printing, inkjet printing, laser-assisted bioprinting,
and stereolithography bioprinting [55]. Among these, extru-
sion bioprinting has beenmost extensively investigated for the
generation of artificial tissue constructs such as cartilages [56,
57], liver [58], and neural tissues [59], with its ability to print
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various biomaterials at high cell density [60]. Extrusion
bioprinting has been utilized for the generation of artificial
pancreata. A rat β cell line, mouse and human islets were
successfully printed into a predefined 3D scaffold using
alginate-based bioinks and the subsequent cell viability and
morphology were found to be unaffected [61••]. Furthermore,
rat islets were printed into macroporous 3D constructs using
an alginate/methylcellulose bioink. These printed rat islets
retained their viability, morphology, and function, for up to
7 days in culture [62••].
Beyond the modification of the bioinks to support islet
cells, bioprinting also enables the co-transplantation of islets
with supporting cells that could enhance islet survival [63].
Recently, our group developed a 3D bioprinter equipped with
a co-axial extruder nozzle and two separate ink chambers
[64••]. Different bioinks tailored with cell type–specific bio-
active molecules can be utilized in each chamber, allowing co-
printing of islets with supporting cells. These geometries have
the advantage that more delicate components can be strategi-
cally placed within the core with a surrounding protective
layer, referred to as the shell. The use of a co-axial structure
has been shown to significantly improve islet encapsulation
by minimizing material volume per islet and reducing the risk
of PFO [42]. Co-axially printed mouse islets and endothelial
progenitor cells (EPCs) demonstrated high viability using re-
cently formulated alginate-gelatin methacryloyl bioink [64••].
Together, co-axial 3D bioprinting has the potential to enable
the embedding of clinically relevant doses of islets with sup-




The islet of Langerhans is densely vascularized with fenestrated
endothelium, and this feature is crucial forβ cells to readily sense
the blood glucose and secrete insulin into the systemic circulation
[65]. Endothelial cells are also crucial for promoting islet func-
tion through upregulating insulin transcription via either cell-to-
cell contact mechanism or secretion of humoral factors [66].
However, islets are removed from the vasculature during isola-
tion and remain avascular for up to several days post-
transplantation [67]. As native islets are physiologically adapted
to receiving a rich supply of oxygen (the islet mass in the pan-
creas comprises 1% of the cells but receives 10% of the blood
supply), prolonged hypoxia is detrimental to islet viability and
function. The hypoxia induced by isolation triggers activation of
NF-kB and inducible nitric oxide synthase, leading to the pro-
duction of cytotoxic nitric oxide [68, 69]. The consequence of
free radical production is decreased insulin production, macro-
phage cell infiltration, and islet apoptosis. Moreover, islets
exposed to hypoxia pre-transplantation display dysregulated glu-
cose responsiveness and elevated basal insulin secretion, due to
the upregulation of hypoxic response genes which can continue
post-transplantation, resulting in poor glycemic control [70].
Normally, the revascularization occurs 2–4 days post-
transplantation and takes over 2 weeks to complete [71]. The
eventual vascular density and oxygen tension in transplanted
engraftments are less than 50% as compared with the native
pancreatic islets [72]. This highlights the crucial need for amech-
anism to improve revascularization to restore full function of
engrafted islets.
One approach to achieving such acceleration is to directly
use pro-angiogenic cells such as EPCs. EPCs are a heteroge-
neous group of stem cells derived from the bone marrow that
are recruited to the site of hypoxia. EPCs promote vasculari-
zation by recruiting and differentiating other cell types, or by
differentiating themselves into endothelial cells, the building
blocks of the endothelial lining of blood vessels [73, 74].
Furthermore, the crosstalk between intra-islet endothelial cells
and islets enhances expression and secretion of insulin and
islet survival [75]. These properties of EPCs were shown to
be beneficial when EPCs were co-transplanted with islets in
several studies. Co-transplantation of human umbilical cord–
derived EPCs with porcine islets in diabetic nude mice signif-
icantly accelerated the revascularization in the first 2 weeks,
compared with islet transplantation alone, and increased ex-
pression of pro-angiogenic factor, vascular endothelial growth
factor-A (VEGF-A), in islets [76]. Co-transplantation of rat
bone marrow–derived EPCs with rat islets in diabetic rats
demonstrated long-lasting normoglycemia [77]. Moreover,
co-transplantation of mouse bone marrow–derived EPCs with
mouse islets in diabetic mice improved the cure rate and glu-
cose control with higher final β cell mass [78•].
Regulatory T Cells
Upon transplantation, recipient T cells recognize alloantigens
of the allograft, which activate recipient T cells to induce in-
flammation at the site of the allograft, as part of the
alloresponse [79]. Alloresponse results in acute graft rejection
as well as chronic graft dysfunction, and as such the use of
immunosuppressive drugs is necessitated to prevent the com-
mencement of alloresponse. However, as aforementioned, im-
munosuppressants are associated with deleterious side effects;
there is a need for novel immunotherapies to achieve
immunosuppression-free transplantation. Regulatory T cells
(Tregs) are a promising candidate for this.
Tregs are a sub-population of T cells that specialize in im-
mune regulation and suppression. Tregs are defined as CD4+
FOXP3+ CD25hi CD127− T cells with two main types of
Tregs. Natural Tregs (nTregs) arise from highly self-reactive
T cells in the thymus during T cell development and establish-
ment of central tolerance [80]. nTregs are characterized by
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complete demethylation of the FOXP3 promoter, which re-
sults in stable expression of FOXP3 and a suppressive pheno-
type [81]. On the other hand, peripheral or induced Tregs are
generated from naïve CD4+ Tcells in the periphery or in vitro
upon stimulation with transforming growth factor beta
(TGF-β) and retinoic acid. The FOXP3 promoter of induced
Tregs is only partially demethylated leading to their functional
instability. Treg-mediated suppression is the main mechanism
of peripheral tolerance. Tregs play many roles in the immune
system including downregulation of immune responses once
pathogens have been cleared, maintaining tolerance to self,
gut microbiota, new chemicals, environmental and food anti-
gens, and the fetus in cases of pregnancy. Treg-mediated sup-
pression targets a broad spectrum of immune cells such as
other T cell subsets, B cells, antigen-presenting cells, and nat-
ural killer cells [82]. Suppression is achieved via several
circumstance-dependent mechanisms, including inhibitory
cytokines, cytolysis, metabolic disruption, and modulation of
dendritic cells [83].
Since the first organ transplantation clinical trials, sponta-
neous graft tolerance (the acceptance of allograft without im-
munosuppressive regimen) has been observed, mostly in liver
transplant recipients [84–86]. The exact factors underlying
this phenomenon have not yet been fully identified; however,
it has been shown that Tregs play a major role in spontaneous
graft tolerance in mice liver allograft models [87, 88] and there
is elevation of Treg proportion in spontaneously tolerant pa-
tients [89]. Thus, various approaches to utilize their natural
abilities have been extensively investigated. In particular,
adoptive transfer of ex vivo expanded Tregs has a number of
advantages including greater control over the expansion/
generation of Tregs, the possibility of functional and pheno-
typical analysis prior to delivery, and finer control of dosage
and delivery time [90, 91]. This has proved promising in mu-
rine islet transplantation models [92, 93] and in clinical trials
for kidney [94•] and liver [95•] transplantation.
Bioactive Factors
Insulin-Like Growth Factor-2
Insulin-like growth factor-2 is a potent growth factor highly
expressed in islets during fetal development with much less
activity in post-natal life [96, 97]. The fetal overexpression of
IGF-II can enlarge individual organs, and the whole body size
of a new born murine, in a dose-dependent manner [98].
Notably, the expression pattern of IGF-II in pre-natal period
coincides with the pancreatic mass growth, suggesting its role
in proliferation or survival ofβ cells [99, 100]. In vitro, IGF-II
showed increased DNA replication in β cell lines, and IGF-II
survival effect on transplanted islets has been observed in
animal models [101–103]. Together, it is suggested that IGF-
II plays a dual beneficial role on β cells as a survival and
mitogenic factor. In addition, IGF-II pre-incubation or viral
transfection-induced overexpression of IGF-II can effectively
improve islet survival against cytokine exposure and islet en-
graftment [104]. As such, incorporation of IGF-II could pro-
tect islets from hypoxia and cytokine-driven cell deaths until
revascularization is established.
Vascular Endothelial Growth Factor
VEGF is a family of pro-angiogenic proteins which includes
VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F,
and PIGF (placental growth factor) in human. Among these,
VEGF-A plays a crucial role in vasculogenesis during em-
bryogenesis as well as angiogenesis in post-natal life [105].
Furthermore, VEGF-A is required for formation of a dense
network of fenestrated blood vessels around islets [106].
These properties give VEGF-A the therapeutic potential to
induce neovascularization in islet transplantation. VEGF-A
containing alginate scaffolds were demonstrated to pre-
vascularize murine intramuscular space prior to islet trans-
plantation and to improve islet survival after transplantation
[107]. In addition, 3D ring-shaped polycaprolactone scaffolds
functionalized with VEGF-Awere able to induce vasculariza-
tion and improve function of encapsulated islets embedded in
the polycaprolactone scaffolds, compared with free-floating
islets [108•]. Thus, incorporation of VEGF-A in conjunction
with EPCs could accelerate revascularization of the islets.
Interleukin-2
IL-2 is a Tcell stimulatory cytokine, largely produced byCD4+T
helper cells. IL-2 signaling is crucial for activation and clonal
expansion T cells [109]. While CD4+ T helper cells can produce
IL-2 for autocrine signaling upon T cell receptor stimulation,
Treg cells cannot and thus are reliant on IL-2 produced by other
cells [110, 111]. IL-2 is crucial for Treg function as well as their
survival. Tregs highly express CD25, the α-chain of the high-
affinity IL-2 receptor complex [112] and the interaction of IL-2
and CD25 induces high expression of FOXP3 thereby reinforc-
ing Treg phenotype and function [113, 114].Moreover, with high
expression of CD25, Tregs can respond to low concentrations of
IL-2 and bind to IL-2 with high affinity [115], which can lead to
sequestration of IL-2 from effector T cells, depriving them of
survival signal [83]. Administration of exogenous IL-2 in auto-
immunity and organ transplantation has been investigated to
augment Treg numbers and function [116]. Particularly, low-
dose IL-2 therapy has shown promising results in hematopoietic
stem cell transplantation graft-versus-host disease, selectively in-
creasing Treg numbers [117–120]. Thus, incorporation of IL-2
may enhance survival and function of printed Tregs and create a
Treg-rich microenvironment around the 3D bioprinted scaffold.
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Conclusion
Pancreatic islet transplantation is a promising curative cell
therapy for T1DM. The field is limited by human cadaveric
islet cell sources at present, but newer cell sources such as
embryonic stem cell or xenogeneic cell sources are in the
pipeline. The current procedure of islet infusion into liver
may not be optimal for these newer cell sources, and so alter-
native transplant strategies such as 3D bioprinting may pro-
vide new strategies. Modifications of the bioinks with local
immunosuppression and bioactive factors to support the cells
are new directions for the field. The recent 3D bioprinting
technology, especially with the development of the co-axial
bioprinter, thus has potential to change the current pancreatic
islet transplantation paradigm. The possibility of co-printing
islets with supporting cells and bioactive factors potentiates
direct improvement of engraftment condition, and thus surviv-
al and function of transplanted islets. Incorporation of EPCs
may accelerate revascularization of islets to support their func-
tion, and the incorporation of Tregs could provide localized
immune protection to islets. Bioactive factors such IGF-II,
VEGF, and IL-2 could enhance the survival and function of
printed cells to maximize the efficacy of the graft. Together,
extra-hepatic islet transplantation without the use of immuno-
suppression might be clinically achieved by utilizing 3D
bioprinting technology.
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Encapsulation of Human Natural and Induced Regulatory 
T-Cells in IL-2 and CCL1 Supplemented Alginate-GelMA 
Hydrogel for 3D Bioprinting
Juewan Kim, Christopher M. Hope, Narangerel Gantumur, Griffith B. Perkins, 
Sebastian O. Stead, Zhilian Yue, Xiao Liu, Ane U. Asua, Francis D. Kette,  
Daniella Penko, Christopher J. Drogemuller, Robert P. Carroll, Simon C. Barry,  
Gordon G. Wallace,* and Patrick Toby Coates*
Regulatory T-cells (Tregs) are important modulators of the immune system 
through their intrinsic suppressive functions. Systemic adoptive transfer 
of ex vivo expanded Tregs has been extensively investigated for allogeneic 
transplantation. Due to the time-consuming and costly expansion protocols 
of Tregs, more targeted approaches could be beneficial. The encapsulation 
of human natural and induced Tregs for localized immunosuppression is 
described for the first time. Tregs encapsulated in alginate-gelatin methacryloyl 
hydrogel remain viable, phenotypically stable, functional, and confined in the 
structure. Supplementation of the hydrogel with the Treg-specific bioactive 
factors interleukin-2 and chemokine ligand 1 improves Treg viability, sup-
pressive phenotype, and function, and attracts to the structure CCR8+ T-cells 
enriched with anti-inflammatory subpopulations, including Tregs, from human 
peripheral blood. Furthermore, these findings are applicable to 3D bioprinting. 
Co-axial printing of murine pancreatic islets with human natural and induced 
Tregs protects the islets from xenoresponse upon co-culture with human 
peripheral blood mononuclear cells. This establishes the co-encapsulation of 
Tregs by co-axial 3D bioprinting as a valid option for providing local immune 
protection to allogeneic cellular transplants such as pancreatic islets.
DOI: 10.1002/adfm.202000544
1. Introduction
Regulatory T-cells (Tregs) constitute a vital 
CD4+ T-cell subpopulation specialized in 
immune suppression and regulation.[1] 
Tregs were initially reported in 1970 as 
suppressor T-cells, a subset of T-cells with 
the ability to abrogate the proinflamma-
tory immune responses.[2] Since then, 
intensive investigations led to the discov-
eries of Treg-defining surface markers, 
CD4+, CD25hi, and CD127−, and the 
master transcriptional regulator of Treg-
lineage, FOXP3.[3–8] To date, two main sub-
groups of natural Tregs (nTregs) exhibit 
the CD4+ CD25hi CD127− FOXP3+ pro-
file: thymic-derived natural Tregs (tTregs), 
which stably express FOXP3, and CD4+ 
T cells that acquire FOXP3 expression in 
the periphery, called pTregs. pTregs gener-
ated in vitro are known as induced Tregs 
(iTregs).[9,10]
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Tregs are a crucial component of immunological tolerance 
and homeostasis, playing many roles in the immune system, 
including establishing tolerance to self and selected foreign 
antigens, and regulating the duration of immune responses 
to minimize self-damage.[1] Tregs mediate suppression via the 
secretion of anti-inflammatory cytokines, cytolysis of target 
cells, metabolic disruption, and modulation of dendritic 
cells.[11] Treg-mediated suppression, thus, targets a broad range 
of immune cells including other T-cell subsets, B cells, antigen 
presenting cells, and natural killer cells.[12] With such versa-
tility in modes and targets of action, immunotherapies utilizing 
Tregs have been extensively investigated for the treatment of 
autoimmunity and allogeneic transplantation.[13]
In particular, Treg-therapy could establish allograft tolerance 
in transplant recipients, overcoming challenges associated with 
the requirement for life-long systemic immunosuppression to 
prevent allograft rejection, such as an increased risk of infec-
tion, malignancy, and organ toxicity.[14] Furthermore, spon-
taneous allogeneic organ tolerance, a phenomenon in which 
transplant recipients accept the allografts without the use of 
immunosuppressive regimen, has been observed in liver trans-
plant recipients with elevated Treg levels.[15] Currently, most 
clinical trials of Treg-therapies utilize systemic adoptive transfer 
of ex vivo expanded Tregs.[16] While this method has shown 
promising results in clinical trials,[17,18] ex vivo expansion of 
Tregs requires extremely time-consuming and costly protocols 
to generate appropriate numbers of cells for clinically signifi-
cant results, due to the low frequency of Tregs in human periph-
eral blood.[13,19] Thus, it would be advantageous to employ more 
targeted approaches requiring less Tregs, such as hydrogel 
encapsulation to provide localized immunosuppression.
Pancreatic islet transplantation is currently the only curative 
cell therapy for type 1 diabetes mellitus. Islet transplantation is 
unique, compared to solid organ transplantation, as it involves the 
isolation and purification of islets from a donor pancreas, which 
are then infused into the recipient liver via the hepatic portal 
vein.[20] Due to such characteristics, it is possible to co-transplant 
islets with other cell types beneficial to their survival.[21,22] As 
rejection by the immune system remains a major hurdle, co-
encapsulation of islets with Tregs could be of great benefit. This 
could be achieved via 3D bioprinting using a recently developed 
customized co-axial bioprinter, equipped with dual bioink cham-
bers, to generate a scaffold containing a core of islets surrounded 
by a shell of Tregs, providing localized immune protection.[23–25]
Here, we encapsulated human nTregs and iTregs in an alg-
inate-gelatin methacryloyl (GelMA) hydrogel, a bioink that we 
recently developed for co-axial bioprinting of islets with sup-
porting cells.[24] While islets have been routinely encapsulated 
since 1980,[26] Tregs have never previously been encapsulated. 
Therefore, this study investigated the impact of encapsulation 
on human nTregs and iTregs. Furthermore, the hydrogel was 
supplemented with Treg-specific bioactive factors, interleukin-2 
(IL-2) and chemokine ligand 1 (CCL1), to enhance the encap-
sulation of Tregs. IL-2 is a T-cell stimulatory cytokine that is 
crucial for Treg survival and function.[27] The effect of IL-2 on 
the encapsulated Tregs was evaluated. CCL1 is a ligand for 
chemokine receptor 8 (CCR8) that is preferentially expressed 
on Tregs.[28] The capability of CCL1 to recruit additional 
Tregs to the hydrogel structure was examined, as well as the 
composition of the lymphocyte population that would actively 
be recruited from human peripheral blood. Lastly, utilizing 
an alginate-GelMA based bioink, murine islets were co-axially 
printed with human nTregs and iTregs, and then co-cultured 
with human peripheral blood mononuclear cells (PBMCs) to 
investigate the immune-protective ability of printed Tregs.
2. Results
2.1. Preparation of Alginate-GelMA Hydrogel Precursor 
and Treg Encapsulation
Alginate-GelMA hydrogel precursor was generated by the addi-
tion of GelMA to an alginate solution. GelMA was prepared 
from porcine gelatin by the addition of methacrylic anhydride 
(Figure 1a). The degree of functionalization (DoF) was meas-
ured by a ninhydrin assay quantifying absorbance at 570 nm. 
The concentration of unfunctionalized gelatin remaining in the 
GelMA was interpolated from gelatin standards ranging from 
0 to 100 mg mL−1, confirming successful methacryloyl func-
tionalization with a DoF of 82 ± 5%. The hydrogel precursor 
was then used to encapsulate Tregs via photo and chemical 
crosslinking (Figure 1b). Successful encapsulation was demon-
strated by transmission electron microscopy (TEM) (Figure 1c). 
In some experiments, Tregs were recovered via enzymatic dis-
solution of the hydrogel discs using TrypLE, which targets pep-
tide bonds on the C-termini of lysine and arginine of GelMA.
2.2. Viability of Encapsulated Tregs
The viability of encapsulated or control nonencapsulated Tregs at 
days 1 and 3 was evaluated by measuring dye exclusion, expressed 
as % propidium iodide+ (Figure 2a). On day 1, encapsulated Treg 
viability was significantly reduced in both nTregs and iTregs (8% 
and 10%; P = 0.0034 and P = 0.0038, respectively) in the absence 
of IL-2, while there was no significant decrease in viability upon 
encapsulation in the presence of IL-2. Nonencapsulated and 
encapsulated Tregs without IL-2 displayed significantly lower via-
bility than those with IL-2, a 9% (P = 0.0012) and 12% (P < 0.0001) 
decrease in nTregs and 16% (P < 0.0001) and 23% (P < 0.0001) 
decrease in iTregs, respectively. At day 3, viability of nonencapsu-
lated and encapsulated Tregs without IL-2 decreased by 23% and 
41% in nTregs and 29% and 40% in iTregs (P < 0.0001), com-
pared with those IL-2. The viability of encapsulated Tregs with 
IL-2 was significantly lower than nonencapsulated Tregs with IL-2 
(18% decreases in both nTregs and iTregs, P = 0.0001 and 0.0042, 
respectively; Figure 2b). These decreases were reversed by supple-
menting the media with IL-2 (“encapsulated with IL-2 in media”) 
instead of the hydrogel. The viability of encapsulated Tregs with 
IL-2 in the media displayed no significant differences from non-
encapsulated Tregs with IL-2 (Figure 2c).
2.3. Phenotype of Encapsulated Tregs
Tregs are classically defined as CD4+ CD25+ FOXP3+ cells. 
Expression of CD25 and FOXP3 was measured as mean 
Adv. Funct. Mater. 2020, 2000544
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fluorescence intensity (MFI) in viable CD4+ populations 
(Figure 3a). Analysis showed no significant differences in 
the MFI of CD25 expression between nonencapsulated and 
encapsulated Tregs. CD25 MFI of nonencapsulated and Tregs 
encapsulated with IL-2 were higher than Tregs without IL-2 for 
nTregs (nonencapsulated: P = 0.0305) and iTregs (P < 0.0001). 
Tregs encapsulated with IL-2 showed significantly lower FOXP3 
MFI than nonencapsulated Tregs cultured with IL-2 (P = 0.0006 
for nTregs and P < 0.0001 for iTregs). This was in contrast to 
Tregs encapsulated without IL-2, which showed no signifi-
cant decrease in FOXP3 MFI compared with nonencapsulated 
Tregs cultured without IL-2. Moreover, FOXP3 MFI of nonen-
capsulated and encapsulated Tregs without IL-2 was signifi-
cantly reduced compared with those with IL-2 in both nTregs 
(P < 0.0001 and P = 0.0069) and iTregs (P < 0.0001 and P = 
0.0001; Figure 3b). Treg functional markers CD69 (activation 
marker), transforming growth factor beta (TGF-β; inhibitory 
cytokine), CD39 (metabolic disruption), and cytotoxic T-lym-
phocyte-associated protein 4 (CTLA-4; dendritic cell modula-
tion), which are surrogates for activation status and suppressive 
functionality,[11,29] were also assessed (Figure 4a). There were 
no significant differences in CD69, CD39, and CLTA-4 MFI 
between nonencapsulated and encapsulated Tregs. Nonen-
capsulated Tregs without IL-2 showed significantly lower 
CD69 (P = 0.0472) and CD39 (P = 0.0062) MFI in iTregs and 
CTLA-4 (P = 0.0062) MFI in nTregs while there were significant 
differences between encapsulated Tregs with and without IL-2. 
TGF-β expression mimicked that of FOXP3, showing sig-
nificant differences between nonencapsulated and encapsu-
lated Tregs with IL-2 (P = 0.0001 in nTregs and P = 0.0011 in 
iTregs) and between nonencapsulated and encapsulated Tregs 
with and without IL-2 (P < 0.0001 and P = 0.0023 in nTregs 
and P < 0.0001 in iTregs; encapsulated Tregs showed n.s in 
iTregs; Figure 4b). Again, upon supplementation of the media 
with IL-2, FOXP3, and TGF-β MFI expression was equivalent 
to nonencapsulated Tregs, showing significantly higher MFI 
(FOXP3: P < 0.0001 in both nTregs and iTregs. TGF-β: P = 
0.0044 in nTregs and P = 0.0003 in iTregs) than encapsulated 
Tregs with IL-2 (Figure 4c).
2.4. Suppressor Function of Encapsulated Treg
Suppressive activities of nonencapsulated and encapsulated 
Tregs were assessed using CD154 suppression assays. CD154 
is an activation marker transiently expressed during T-cell acti-
vation and can be measured in naïve CD4+ T-cells (Teffectors) 
in the presence of Tregs to assess the suppressor function of 
Tregs.[30] Tregs to Teffectors ratios of 1:1 to 1:8 were utilized. 
DiOC18(3) (3,30-dioctadecyloxacarbocyanine perchlorate) was 
used to differentiate Teffectors from Tregs in the flow cyto-
metric analysis. Negative control (DiOC18(3) labeled and CD154 
Adv. Funct. Mater. 2020, 2000544
Figure 1. a) Schematics for preparation of alginate-GelMA hydrogel precursor and b) Treg encapsulation. c) Transmission electron microscope images 
of nonencapsulated and encapsulated nTregs and iTregs. Best represented images from n = 3. Scale bar represents 2 µm at 11 500 × magnification.
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stained) Teffectors provided baseline unstimulated % CD154+ to 
gate CD154+ cells. Positive control (DiOC18(3) labeled, CD154 
stained Teffectors stimulated with anti-CD3/CD28 beads) 
served as baseline stimulated %CD154+ to calculate % suppres-
sion (Figure 5a). No significant differences in % suppression 
were shown between nonencapsulated and encapsulated Tregs 
at all ratios. In the absence of IL-2, Tregs displayed significant 
losses in their suppressor function compared with those in 
the presence of IL-2. At 1:1 ratio, both nonencapsulated and 
encapsulated groups displayed 10% (P = 0.0115 and 0.0132) 
decreases in nTregs and 13% (P = 0.0048 and 0.0038) decreases 
in iTregs. At 1:2 ratio, 8% (n.s; P = 0.0771) and 10% (P = 0.0324) 
decreases were shown in nTregs and 13% (P < 0.0001) and 18% 
(P = 0.0034) decreases were observed in iTregs (Figure 5b).
Adv. Funct. Mater. 2020, 2000544
Figure 2. Viability of Tregs encapsulated in alginate-GelMA hydrogel at days 1 and 3. a) Gating strategy to determine the percentage of dead cells. 
Propidium iodide (PI) was used to stain dead cells (black line: unstained control; Indigo line: positive dead control). b) Viability at days 1 and 3 for 
both nTregs and iTregs. Nonencapsulated Tregs were cultured in either IL-2-supplemented media “nonencapsulated (+IL-2)” or IL-2-free media “non-
encapsulated (-IL-2)”. Encapsulated Tregs were made with either IL-2-supplemented hydrogel “encapsulated (+IL-2)” or IL-2-free hydrogel “encapsu-
lated (-IL-2)” and then cultured in IL-2-free media. c) Day 3 viability of encapsulated Tregs upon supplementation of the media with IL-2 instead of the 
hydrogel “encapsulated (+IL2 in media)”. Data represented as mean ± SEM, n = 3, statistical significance identified by One-Way ANOVA with Tukey’s 
multiple comparisons test: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
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2.5. Migration Capacity of Encapsulated Tregs and CCL 
Supplementation of the Hydrogel
For successful localized immunosuppression, it is important 
that Tregs stay confined within the hydrogel structure, which 
can be facilitated by strong chemotactic signals. The chemot-
actic response profile of nTregs and iTregs to CCL1 was meas-
ured from 100 ng mL−1 to 10 µg mL−1 with threefold increment, 
to determine concentration dose response. Spontaneous migra-
tion with no chemokine was utilized to calculate migration 
index (MI). Maximal responses were observed at 10 µg mL−1 
with migration index of 30 and 9 in nTregs and iTregs, respec-
tively (Figure 6a). 10 µg mL−1 of CCL1 was used to assess the 
migration capacity of nonencapsulated and encapsulated Tregs. 
Migration capacity of encapsulated Tregs was significantly 
reduced compared with nonencapsulated Tregs with 400-fold 
reduction (P = 0.0003) for nTregs and 220-fold (P < 0.0001) 
reduction for iTregs (Figure 6b). In parallel, the Treg-recruit-
ment capability of hydrogel discs supplemented with CCL1 was 
evaluated. CCL1-supplemented hydrogel demonstrated recruit-
ment of Tregs with an MI of 5 in nTregs and that of 3 in iTregs. 
This was significantly lower than the 10 µg mL−1 of CCL1 in 
chemotaxis buffer, which showed an MI of 43 with nTregs 
(P < 0.0001) and that of 19 with iTregs (P < 0.0001) (Figure 6c). 
Moreover, CCL1 has been shown to enhance Treg function.[31] 
Therefore, CCL1-supplimented hydrogel was used to encapsu-
late Tregs and suppressive activities of encapsulated Tregs with 
and without CCL1 were measured. Interestingly, nTregs and 
iTregs showed completely opposite results. Suppressive activity 
of encapsulated nTregs was significantly higher in the presence 
of CCL1 with 12% (P = 0.0211), 13% (P = 0.0125), and 15% 
(P = 0.0365) differences at 1:1, 1:2, and 1:8 ratios (1:4 ratio n.s 
with 12% difference; P = 0.1129) while suppressive activity of 
iTregs was significantly lower in the presence of CCL1 with 
8% (P = 0.0355), 12% (P = 0.0385), 16% (P = 0.0277), and 18% 
(P = 0.0057) differences at all ratios (Figure 6d).
To investigate which types of lymphocytes would be recruited 
from the human peripheral blood through CCL1-mediated chem-
otaxis, PBMCs were isolated from whole blood for immunophe-
notyping. Particular interests were in CD4+ T-cell subsets as most 
of the CCR8+ cells in the peripheral blood are CD4+ memory 
T-cells.[28] PBMCs were stained for CD3, CD4, CD45RA, CD25, 
and CD127 and CXCR3, CCR4, CCR6, CCR8, and CCR10 to 
compare proportions of CD4+ T-cell subsets in the whole memory 
(inclusive of CCR8+ and CCR8−) CD4+ T-cells with CCR8+ 
memory CD4+ T-cells. Within these two populations, memory 
Tregs (mTregs) and memory conventional T-cells (mTconvs) were 
gated based on their CD25 and CD127 expression. mTconvs 
Adv. Funct. Mater. 2020, 2000544
Figure 3. Expression of Treg phenotype markers upon encapsulation in alginate-GelMA hydrogel. a) Gating strategy for CD4+ cells using an unstained 
population. Mean fluorescence intensity (MFI) for CD25 and FOXP3 was measured from this CD4+ population. MFI was normalized to the maximum 
raw value in each marker and experiment. b) CD25 and FOXP3 MFI in nonencapsulated and encapsulated nTregs and iTregs (±IL-2). Data represented 
as mean ± SEM, n = 3, statistical significance identified by One-Way ANOVA with Tukey’s multiple comparisons test: *P < 0.05, **P < 0.01, ***P < 
0.001, and ****P < 0.0001.
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were then further divided into T-helper subsets using chemokine 
receptors (Figure 7a). CCR8+ memory CD4+ T-cells showed sig-
nificant enrichments of mTregs (P = 0.0006), Th2 (P = 0.0036), 
and Th22 cells (P = 0.0001) compared to whole memory CD4+ 
T-cells. Proportions of mTconvs (P = 0.0004), Th1 (P = 0.0126), 
Th1/17 (P = 0.0097), Th17 (P = 0.0035), and Th9 (P < 0.0001) 
Adv. Funct. Mater. 2020, 2000544
Figure 4. Expression of Treg functionality markers upon encapsulation in alginate-GelMA hydrogel. a) Gating strategy for CD4+ CD25+ Foxp3+ cells using 
an unstained population. Mean fluorescence intensity (MFI) for CD69, TGF-β, CD39, and CTLA-4 was then measured from this CD4+ CD25+ Foxp3+ popu-
lation. MFI was normalized to the maximum raw value in each marker and experiment. b) CD69, TGF-β, CD39, and CTLA-4 MFI in nonencapsulated and 
encapsulated nTregs and iTregs (±IL-2). c) FOXP3 and TGF-β MFI of encapsulated nTregs and iTregs (+IL-2 in media). Data represented as mean ± SEM, 
n = 3, statistical significance identified by One-Way ANOVA with Tukey’s multiple comparisons test: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
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cells showed significant reduction (Figure 7b). PBMCs were then 
utilized for the chemotaxis assay with CCL1. The proportions of 
mTregs and mTconvs migrated in response to CCL1 were com-
parable to CCR8+ memory CD4+ T-cells, with significant enrich-
ment of mTregs (P < 0.0001) and reduction of mTconvs (P < 
0.0001) compared to the whole memory CD4+ T-cells (Figure 7c). 
Percentages of CCR8+ cells in each memory CD4+ T-cell subsets 
were also measured (Figure S1, Supporting Information). Th22 
cells had the highest expression of CCR8 followed by mTregs 
and Th2 cells at (53%, 28%, and 28%, respectively). Other sub-
sets exhibited %CCR8+ below 10% (mTconvs at 10% and Th1, 
Th1/17, and Th17 at 7%) with Th9 cells being the least positive 
(2%) (Figure 7d). Moreover, FOXP3 MFI of CCR8+ mTregs and 
CCR8− mTregs was assessed (Figure S2, Supporting Informa-
tion). CCR8+ mTregs showed 1.5-fold higher FOXP3 MFI (P = 
0.0062) than CCR8− mTregs (Figure 7e).
2.6. Co-Axial Bioprinting of Pancreatic Islets with Tregs
The alginate-GelMA hydrogel precursor (bioink) is not print-
able at temperatures higher than 15 °C as it loses its gel-like 
characteristics.[24] An increase in gelatin concentration has been 
shown to enhance the storage moduli of hydrogels,[32] and the 
addition of unmodified gelatin can act as a thickening agent 
to increase printability at room temperature.[33] Thus, gelatin 
was added to alginate-GelMA bioink at 2.5%–5% w/v. The 
preliminary printability was assessed by evaluating the ability 
to form continuous filament and by observing filament mor-
phology.[34] Upon extrusion, alginate-GelMA bioink formed 
liquid droplets while alginate-GelMA-gelatin bioinks formed 
filaments. The 2|7.5|5% w/v alginate-GelMA-gelatin showed 
the longest continuous filament (≈3.5 cm; Figure 8a). In addi-
tion, upon multilayer printing ranging from two to ten layers, 
alginate-GelMA-gelatin bioinks retained scaffold structures. As 
gelatin concentration increased, the filaments in the scaffolds 
displayed over-gelation (Figure 8b). Over-“gelled” bioink is not 
optimal in extrusion-based bioprinting due to nonuniformity in 
fiber deposition leading to undesirable scaffold morphology and 
stability.[35] High cell density has been shown to decrease the 
viscosity of the bioink;[36] thus, 2|7.5|3.5% w/v alginate-GelMA-
gelatin bioink with slight over-gelation was further character-
ized by rheology measurements. Upon oscillation temperature 
Adv. Funct. Mater. 2020, 2000544
Figure 5. Function of Tregs encapsulated in alginate-GelMA hydrogel. a) Gating strategy to determine %CD154+ from DiOC18(3)+ cells. DiOC18(3) 
was used to differentiate naïve T-cells (Teffectors) from Tregs. Unstained control was used to gate for DiOC18(3)+. Negative control (black; DiOC18(3) 
labeled and CD154 stained with no anti-CD3/CD28 beads) set baseline nonactivated %CD154+. Positive control (indigo; DiOC18(3) and CD154 stained 
with anti-CD3/CD28 beads) provided baseline activated %CD154+ to calculate %suppression. Control wells contained no Tregs. b) %suppression of 
nonencapsulated and encapsulated nTregs and iTregs (±IL-2) at various Treg:Teffector ratios (1:1 to 1:8). Data represented as mean ± SEM, n = 3, 
statistical significance identified by Two-Way ANOVA with Tukey’s multiple comparisons test: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
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sweep, alginate-GelMA-gelatin bioink showed higher storage 
moduli (G′) than alginate-GelMA bioink across the temperature 
range. The storage moduli of alginate-GelMA-gelatin bioink 
reached ≈4 kPa at 5 °C while alginate-GelMA bioink reached 
≈0.4 kPa. Furthermore, gelation point (G′ and G″ intersects) 
of alginate-GelMA-gelatin bioink occurred at ≈21 °C while it 
occurred at ≈14 °C for alginate-GelMA bioink (Figure 8c). Upon 
rotational viscosity test at 22.5 °C, both alginate-GelMA and alg-
inate-GelMA-gelatin bioinks displayed decreases in viscosity as 
shear rate increased (Figure 8d). Furthermore, at shear rate of 
1 s−1 alginate-GelMA-gelatin bioink showed significantly higher 
viscosity of ≈134 Pa s compared with alginate-GelMa bioink 
with viscosity of ≈1.5 Pa s (P = 0.0005; Figure S3, Supporting 
Information).
To demonstrate the applicability of Treg encapsulation 
to a 3D bioprinting setting and the immune-protective effi-
cacy of Treg co-axial printing, murine islets were co-axially 
printed alone or with human nTregs or iTregs using further 
refined alginate-GelMA-gelatin bioink and then co-cultured 
with human PBMCs. The viability of printed murine islets 
was assessed up to 5 d post-printing through live/dead 
staining using fluorescein diacetate (FDA; live cell dye) 
and propidium iodide (PI; dead cell dye). On days 1, 3 and 
5, without human PBMCs in the culture, most of the islets 
printed alone were FDA+ indicating high viability. In con-
trast, with human PBMCs in the culture, islets printed alone 
were PI+ indicating extremely low viability and substantial 
cell death, while islets printed with nTregs or iTregs were 
FDA+ indicating high viability (Figure 9). The viability of the 
nTregs and iTregs in the hydrogel was also evaluated. On day 
1, most nTregs and iTregs were viable when printed alone 
(Figure S4, Supporting Information; calcein AM and DAPI 
staining) or with islets (Figure S5, Supporting Information). 
On day 5, nTregs remained largely viable with mostly FDA+ 
cells, while iTregs showed considerable cell death with many 
PI+ cells.
Adv. Funct. Mater. 2020, 2000544
Figure 6. Migration capacity of encapsulated Tregs and assessment of CCL-1-supplemented alginate-GelMA hydrogel. a) Chemotactic response profile 
of nTregs and iTregs to CCL1 (100 ng mL−1 to 10 µg mL−1). 10 µg mL−1 of CCL1 was used for subsequent experiments, either supplementing chemo-
taxis buffer or the hydrogel. b) Migration capacity of nonencapsulated and encapsulated Tregs. c) Treg recruitment capability of CCL-1-supplemented 
hydrogel and CCL-1-supplemeted buffer. d) %suppression of encapsulated nTregs and iTregs (±CCL1). Data represented as mean ± SEM, n = 3, 
statistical significance identified by paired two-tailed T-test: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
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2000544 (9 of 17) © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, WeinheimAdv. Funct. Mater. 2020, 2000544
Figure 7. Immunophenotyping of human peripheral blood CD4+ memory T-cells. a) Gating strategy for proportions of various CD4+ T-cell subsets 
within whole memory (CD3+ CD4+ CD45RA−) inclusive of both CCR8+ and CCR8− and CCR8+ memory T-cells from human whole blood PBMCs. CCR8+ 
was gated using naïve CD4+ T-cells (CD45RA+) as a negative control. Memory Tregs (mTregs) and memory conventional T-cells (mTconvs) were defined 
www.afm-journal.dewww.advancedsciencenews.com
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3. Discussion
This is the first study to investigate encapsulation of human 
Tregs for applications in 3D bioprinting. Tregs are a crucial 
part of the human immune system, with their key role in the 
maintenance of immune tolerance and homeostasis. Through 
encapsulation, these intrinsic properties could be co-opted in a 
localized manner. In this study, we used 2%|7.5% w/v alginate-
GelMA hydrogel to successfully encapsulate human nTregs 
and iTregs. The primary aim of this study was to demonstrate 
that Treg encapsulation caused no detrimental effects and thus 
has the capacity to provide local immune protection to co-
encapsulated cells. Indeed, encapsulated Tregs were shown to 
be viable, phenotypically stable and functional. Addition of IL-2 
directly into the hydrogel protected Tregs from the damage 
during the encapsulation process, sustained viability during 
incubation, increased expression of CD25, and enhanced sup-
pressive activity. The hydrogel was designed with high porosity 
to facilitate adequate nutrient and oxygen diffusion into the 
discs. Therefore, bioactive factors have the potential to diffuse 
out of the structure. As a result of this, Tregs encapsulated 
in IL-2-supplemented hydrogel displayed decreased viability 
at day 3 and reduced expression of FOXP3 and TGF-β com-
pared with nonencapsulated Tregs cultured with IL-2, which 
was reversible upon addition of IL-2 directly to the media, 
instead of the hydrogel (Figures 2–5). Given that the hydrogel 
discs (≈50 µL in volume) are cultured in 1 mL of IL-2-free 
media, the final concentration of IL-2, once equilibrium had 
been reached, would be 25 U mL−1, which is much lower than 
the desired concentration of 500 U mL−1. Moreover, as inter-
action of IL-2 with its receptor leads to internalization of the 
complex,[37] 25 U mL−1 of IL-2 may be rapidly sequestered by 
Tregs, as IL-2 induces high expression of CD25, the α chain of 
the high affinity IL-2 receptor.[38] IL-2 signaling also supports 
strong expression of FOXP3, reinforcing the Treg phenotype 
and lineage commitment.[39,40] This is important because Tregs 
are not able to produce IL-2 for autocrine signaling.[1,41] Thus, 
incorporation of an IL-2-eluting sustained-release system will 
be required to maintain high concentration of IL-2 within the 
hydrogel.
The primary goal of Treg encapsulation is to serve as a 
localized cellular immunosuppression for co-encapsulated 
cell types such as islets. To achieve this, Tregs need to be able 
to remain in the vicinity of the co-encapsulated cells. To this 
end, encapsulation was shown to halt migration of Tregs out 
of the hydrogel structure in the presence of a potent chemot-
actic signal (Figure 6b). Acute rejection episodes could be pre-
vented by these Tregs, yet, they may not provide a long-term 
solution as ex vivo expanded Tregs are short-lived.[42,43] Utili-
zation of a chemokine to recruit recipient Tregs could aid in 
the establishment of long-lasting recipient-driven tolerance. 
This is a common strategy employed by tumor cells. It has 
been shown that CCL1 is expressed in certain tumor cells, 
locally recruiting Tregs to generate an immunosuppressive 
milieu that abrogates the anti-tumor response mediated by 
effector CD4+ and CD8+ T-cells.[44–46] Therefore, we mimicked 
this strategy, and CCL1-supplmented hydrogel demonstrated 
recruitment of Tregs. Treg-recruitment capability of CCL1-
supplemented hydrogel was significantly lower than CCL1 in 
the chemotaxis buffer, again, due to the porous nature of the 
hydrogel. The final concentration of CCL-1 in the chemotaxis 
buffer (600 µL) would have been ≈800 ng mL−1 once equili-
brated, instead of 10 mg mL−1. The migration indices shown 
in CCL-1-suplimented hydrogel discs were comparable with the 
1 mg mL−1 of CCL1 in the buffer (Figure 6a,c). In the case of 
CCL1, the high porosity of the hydrogel facilitates the forma-
tion of chemokine gradients, and maintenance of this gradient 
through utilization of a CCL1-eluting sustained release system 
will maximize the recruitment capability. Furthermore, Tregs 
preferentially expressed CCR8 and were enriched in CCR8+ and 
CCL1-recruited peripheral blood T-cells. Taken together, this 
suggests that the use of CCL1-supplemented hydrogel could 
provide a microenvironment enriched with recipient Tregs in 
vivo. Although, it is possible that the same chemokines may 
actively recruit other T helper cells to the site. Th2 and Th22 
cells showed preferential expression of CCR8 and enrichment 
in CCR8+ peripheral blood T-cells (Figure 7b–d). Despite pre-
vious studies regarding expression of CCR8 on Th2 cells,[47] 
the use of CCL1 was justified as Th2 cells could assist with 
tolerization given their ability to inhibit rejection-causing Th1 
responses.[48] Expression of CCR8 on Th22 cells had not been 
described to date. Moreover, the role of Th22 cells in transplan-
tation is currently unknown.[49] It has been shown that CCR8+ 
conventional skin T-cells are less effector-like, with decreased 
functionality compared with their CCR8− counterparts.[50] Thus, 
recruitment of CCR8+ Th22 cells may not equate to a proinflam-
matory response, especially in an environment enriched with 
CCR8+ Tregs that have greater FOXP3 expression than CCR8- 
Tregs (Figure 7e), hence a greater suppressive capacity.[31,51] In 
addition, similar approaches have been demonstrated using 
CCL22[52] and CXCL12[53] with promising results, illustrating 
the potential of chemokine incorporation.
For translation of these findings into the clinic it is cru-
cial to demonstrate that Tregs can be bioprinted and protect 
co-printed cells from proinflammatory responses that would 
normally mediate rejection in vivo. The alginate-GelMA 
hydrogel was formulated as a bioink for 3D bioprinting of 
islets with supporting cells for its optimal macroscopic prop-
erties and its capacity to support cell survival; however, it only 
showed ideal rheological properties below 15 ˚C.[24] Given the 
lack of temperature control module in the customized co-
axial bioprinter, the bioink formulation needed to be further 
refined to increase the printability at room temperate. Indeed, 
addition of 3.5% w/v gelatin to 2%|7.5% w/v alginate-GelMA 
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as CD25+ CD127− and CD25− CD127+, respectively. mTconvs were divided into T-helper subsets using chemokine receptors: CXCR3+ CCR6− Th1, 
CXCR3+ CCR6+ Th1/17, CXCR3−, CXCR3− CCR6+ CCR4+ CCR10- Th17, CXCR3− CCR6+ CCR4− CCR10- Th9, CCR6− CCR4+ CCR10− Th2, and CXCR3− CCR6+ 
CCR4+ CCR10+ Th22. b) Proportions of T-cell subsets in whole memory and CCR8+ memory populations. c) Proportions of mTregs and Tconvs in 
PBMCs migrated in response to CCL1. d) %CCR8+ of T-cell subsets. e) FOXP3 MFI of CCR8+ and CCR8− mTregs. Data represented as mean ± SEM, n = 6 
for (b) and (d) and n = 5 for (e), statistical significance identified by paired two-tailed T-test: *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001.
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bioink enabled the bioink to form continuous filaments and 
retain structure upon multilayer printing at room tempera-
ture, with higher gelation point and higher viscosity at any 
given shear rate than alginate-GelMA bioink (Figure 8). Using 
further refined alginate-GelMA-gelatin bioink, we success-
fully bioprinted murine islets in a co-axial manner with an 
empty shell, nTregs or iTregs. To simulate infiltration of leu-
kocytes into the site of engraftment in vivo, we developed a 
Figure 8. Addition of gelatin to alginate-GelMA hydrogel precursor (bioink). Gelatin was added to 2%|7.5% alginate-GelMA bioink at 2.5%, 3.5%, and 
5% w/v. Printability of these bioinks at room temperature was assessed macroscopically and rheologically. a) Extrusion of bioinks with no gelatin, 
2.5%, 3.5%, and 5% w/v gelatin were recorded and the frames with the longest continuous filaments were utilized. b) Images of multilayered scaffolds 
printed using bioinks with 2.5%, 3.5%, and 5% w/v gelatin. Scale bars represent 2 mm at 11 × magnification. c) Oscillatory temperature sweep of 
bioinks with no gelatin and 3.5% w/v gelatin between 5 and 37 °C. The blue dotted line indicates gelation point. d) Rotational viscosity test of bioinks 
with no gelatin and 3.5% w/v gelatin as a function of shear rate between 0.1 and 1000 s−1. Best represented images from n = 3 for (a) and (b). Data 
represented as mean ± SD, n = 3 for (c) and (d).
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co-culture system using murine islets, human Tregs, and 
human PBMCs. In this co-culture system, without Tregs, 
murine islets were destroyed by day 1, with substantial cell 
death and disturbed morphology compared with murine 
islets cultured without human PBMCs. Given that we uti-
lized murine islets with human PBMCs, this was expected as 
the xenoresponse is characterized as hyperacute and aggres-
sive with substantial infiltration of leukocytes within the first 
24 h.[54–56] On the other hand, when printed with either 
human nTregs or iTregs, murine islets remained highly viable 
up to day 5 (Figure 9). This proof of principle demonstrated 
that co-printing of murine islets with human Tregs can protect 
the islets from xenorejection. While the encapsulation experi-
ment was confined to suppression of CD4+ T-cells by encapsu-
lated Tregs, this also showcased the ability of Treg to suppress 
various types of leukocyte in PBMCs including CD4+ T-cells, 
CD8+ T-cells, B cells, natural killer cells, monocytes, and den-
dritic cells.[57] Moreover, some of the printed nTregs and iTregs 
survived up to day 5 in this co-culture system without the addi-
tion of exogenous IL-2 to the bioink or the media (Figures S4 
and S5, Supporting Information). This contrasts with previous 
data which showed that, in the absence of IL-2, encapsulated 
nTregs and iTregs undergo a significant reduction in viability 
by day 3. This may be due to the presence of IL-2 produced by 
CD4+ T-cells, CD8+ T-cells, and dendritic cells upon activation 
by murine islet antigen,[58] and sequestered by printed Tregs. 
Although this does not negate the requirement of IL-2-eluting 
sustained release system, potentially lower concentrations of 
IL-2 may be required.
Two types of human Tregs, nTregs and iTregs, were com-
pared in this study to determine which would be more suitable 
for encapsulation. While both types are defined as CD4+ CD25+ 
FOXP+ T-cells, there are fundamental differences between 
them. Natural Tregs consists of tTregs generated during 
thymic development and pTregs generated in the periphery in 
vivo while iTregs are differentiated in vitro from conventional 
T-cells. Encapsulated iTregs were shown to be more sensitive 
to IL-2 than nTregs in terms of viability, CD25 expression and 
suppressive activity, which could be disadvantageous in an IL-
2-limited environment. Aligning with this, more cell death 
Figure 9. Viability of murine islets co-axially printed with human Tregs. Murine islets were printed alone or with nTregs or with iTregs using alginate-
GelMA-gelatin bioink and then co-cultured with human PBMCs up to 5 d. No PBMC control was utilized for baseline islet viability. Viability was assessed 
on days 1, 3, and 5 through fluorescent microscopy using fluorescein diacetate (FDA; green) and propidium iodide (PI; red) to stain live cells and dead 
cells, respectively. Best represented images from n = 3. Scale bars represent 200 µm at 10 × magnification.
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was observed with printed iTregs than nTregs in the xenoge-
neic co-culture system. iTregs displayed greater suppressive 
activity than nTregs, indicating that iTregs could suppress the 
recipient immune system more effectively.[59] Moreover, migra-
tion indices of nTregs in response to CCL1 was higher than 
iTregs. The migration index of nTregs in response to CXCL12, 
a ligand for pan-leukocyte chemokine receptor CXCR4,[60] 
was also higher and there were no significant differences in 
CCR8 expression between nTregs and iTregs. This indicates 
that the differences in CCL1 migration index are due to iTregs 
being more motile in nature, rather than nTregs being more 
responsive to CCL1 (Figure S6, Supporting Information). CCL1 
also had different effects on encapsulated nTregs and iTregs, 
enhancing nTreg suppressive activity while dampening iTreg 
suppressive activity. This may be due to CCR8 signaling causing 
iTregs to be less suppressive due to their origin of being dif-
ferentiated from the conventional T-cell lineage.[50] Ultimately, 
while iTregs were found to be more suppressive than nTregs 
and possess a more relevant repertoire of antigen specificities 
for allogeneic transplantation,[61] nTregs may be more suitable 
than iTregs due to their phenotypic stability. The methylation 
status of the FOXP3 promotor region and Treg-specific dem-
ethylation region determine the stability of the Treg pheno-
type. These regions in iTregs are not demethylated, allowing 
iTregs to convert to a proinflammatory Th17 phenotype in a 
proinflammatory setting.[62] Thus, the utilization of iTregs for 
co-encapsulation with other cells may act as an immunological 
Trojan horse.
4. Conclusion
In this study, we demonstrated the potential of encapsulating 
human Tregs in alginate-GelMA hydrogel to provide localized 
cellular immunosuppression to transplanted islets. IL-2 and 
CCL1, as Treg-specific bioactive factors, were investigated as 
supplements to the hydrogel. Encapsulated Tregs were viable, 
and phenotypically and functionally stable. Furthermore, 
encapsulation prevented migration of Tregs out of hydrogel 
structure. Addition of IL-2 and CCL1 to the hydrogel showed 
several benefits including 1) improvement of Treg viability, 
2) enhanced suppressive phenotype and function, and 3) 
capacity to recruit additional Tregs. Due to the highly porous 
nature of the hydrogel, adding these factors directly into the 
hydrogel produced sup-optimal concentrations once the fac-
tors diffused into the surrounding media. Therefore, incor-
poration of a sustained-release system via recently developed 
polylactic-co-glycolic acid-based microspheres will be imple-
mented for additional improvement.[63] To further enhance 
Treg numbers, low-dose rapamycin could be added as an addi-
tional bioactive factor,[64] utilizing recently developed rapa-
mycin-loaded porous silicon nanoparticles.[65,66] Moreover, 
peripheral blood CCR8+ T-cells were highly enriched with 
Tregs, and CCL1-supplemented hydrogel was shown to spe-
cifically induce chemotaxis of these cells, providing an insight 
into the cellular microenvironment in humans upon utiliza-
tion of CCL-1-supplemented hydrogel. Lastly, the findings 
from Treg encapsulation translated into the 3D bioprinting 
system as bioprinted Tregs were viable and functional, and 
protected co-printed murine islets from xenoresponse medi-
ated by human PBMCs. While this study focused on the 
encapsulation and 3D bioprinting of Tregs for applications 
in islet transplantation, the findings could be applied to other 
types of cell therapies such as adrenocortical, thyroid, and 
parathyroid cell transplantation.[67–69]
5. Experimental Section
Preparation of Alginate-GelMA Hydrogel Precursor: Gelatin (porcine 
skin, type A, gel strength ≈175 g Bloom, Sigma-Aldrich) was dissolved in 
phosphate buffered saline (PBS; 10% w/v) for 1 h at 50 °C. Methacrylic 
anhydride (Sigma-Aldrich) was added to the 10% w/v gelatin solution in 
a drop-wise manner with stirring (final concentration of 7.4% v/v). The 
reaction continued for 3 h and then terminated by diluting the solution 
four times with PBS. 1% v/v of chloroform was added, and the mixture 
was dialyzed against distilled water for 7 d at 40 °C (cellulose membrane, 
molecular weight cutoff: ≈12 kDa). The dialyzed GelMA solution was 
lyophilized to white porous foam (stored at −20 °C until further use). 
The above process was undertaken under sterile conditions. The DoF 
of GelMA was measured by a ninhydrin assay as described by Loessner 
et al.[70] Alginate (medium viscosity, Sigma-Aldrich) was sterilized 
by UV for 20 min and then dissolved in PBS (2% w/v) for 2 d at 
37 °C. GelMA was added to the alginate solution at a concentration of 
7.5% w/v, resulting in 2%|7.5% w/v alginate-GelMA. The alginate-GelMA 
hydrogel precursor was incubated at 37 °C with occasional shaking until 
a homogenous formulation was formed.
Cell Isolation and In Vitro Expansion: Human buffy coat (Australian Red 
Cross) was treated with a RosetteSep Human CD4+ T cell enrichment 
cocktail (STEMCELL Technologies) for 20 min on a platform mixer at 
80 rpm. Treated buffy coat was diluted with PBS (+2% fetal calf serum 
(FCS), Bovogen) prior to isolation of CD4+ T cells by density-gradient 
centrifugation over Lymphoprep (STEMCELL Technologies). Enriched 
CD4+ T cells were surface-stained for CD4, CD25, CD127, and CD45RA. 
CD4+ CD25+ CD127− T cells (natural regulatory T cells or nTregs) and 
CD4+ CD25− CD127+ CD45RA+ T cells (naïve CD4+ T-cells) were sorted 
by fluorescence-activated cell sorting (FACS; BD FACSAria Fusion, BD 
Biosciences). Sorted nTregs and naïve CD4+ T-cells were rested overnight 
in a complete X-vivo 15 medium (cX-vivo: serum-free with gentamycin 
and phenol red, Lonza, supplemented with 2% HEPES, 1% L-glutamine 
and 5% human serum (Gibco, HyClone, and Sigma-Aldrich, respectively)) 
with 500 U mL−1 of IL-2 (Novartis Vaccines and Diagnostics). nTregs 
were cultured in an expansion medium consisting of cX-vivo and a 1:1 
ratio of Human T-expander CD3/CD28 Dynabeads (Thermo Fisher 
Scientific). Naïve CD4+ T-cells were cultured in an induction medium 
composed of the expansion medium supplemented with 5 ng mL−1 of 
human TGF-β (eBioscience), 10 1 × 10−9 m mL−1 of all-trans retinoic acid 
(Sigma-Aldrich), and 2 1 × 10−9 m mL−1 rapamycin (LC Laboratories) for 
the generation of induced regulatory T cells (iTregs). nTreg expansion and 
iTreg generation were verified by expression of CD4, CD25, and FOXP3 
(Foxp3/transcription factor staining buffer set, eBioscience). Following 
expansion, the expander beads were removed and Tregs were rested in 
cX-vivo (+500 U mL−1 of IL-2) for 2 d prior to use.
Encapsulation of Tregs: Rested Tregs were mixed well with 2%|7.5% w/v 
alginate-GelMA hydrogel precursor at 2 × 106 cells mL−1, and then 
lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP, Tocris 
Bioscience; a final concentration of 0.06% w/v) was added. For some 
experiments, IL-2 (500 U mL−1) or CCL1 (10 µg mL−1) was directly added 
to the above cell suspension. The hydrogel precursor-cell suspension 
was injected into a disc-mold (8 mm diameter with 1 mm height; ≈50 µL 
in volume per disc) using a drawing-up needle (BD Biosciences), which 
was then photo crosslinked at 400 nm (Omnicure LX505, Excelitas) for 
1 min and then further crosslinked in 2% w/v CaCl2 (BDH) solution 
for 10 min. The cell-laden discs were cultured in cX-vivo medium 
(no IL-2) for 24 or 72 h at 37 °C with 5% CO2 prior to downstream 
assays. Nonencapsulated Tregs were prepared by suspending Tregs at 
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2 × 106 cells mL−1 in cX-vivo medium (+ 500 U mL−1 of IL-2). Some discs 
made with IL-2-free 2%|7.5% w/v alginate-GelMa were cultured in cX-vivo 
medium (+ 500U mL−1 of IL-2); these were dubbed “Encapsulated 
(+IL-2 in media)”. For viability, phenotype, functionality, and CD154 
suppression assay, the encapsulated Tregs were recovered by digesting 
the hydrogel constructs in TrypLE Express (Thermo Fisher Scientific) for 
10 min at 37 ˚C and then washed twice with PBS (nonencapsulated Tregs 
were treated the same way).
Transmission Electron Microscopy: Encapsulated Tregs and 
nonencapsulated controls were fixed overnight in electron microscopy 
fixative (4% paraformaldehyde/1.25% glutaraldehyde in PBS, + 4% 
sucrose, pH 7.2). Fixed samples were washed in washing buffer (PBS 
+ 4% sucrose) for 5 min and then stained with 2% OsO4 solution for 
1 h. Stained samples were dehydrated through a series of washes (two 
washes in 70% ethanol for 15 min each, two washes in 90% ethanol 
for 15 min each, three washes in 100% ethanol for 15 min each and 
then one wash in propylene oxide for 15 min). Dehydrated samples 
underwent resin infiltration (50% propylene oxide 50% epoxy resin 
for 1 h, two washes in 100% resin for 1 h each and then 100% resin 
overnight). After overnight incubation, samples were embedded in fresh 
100% resin and then polymerized at 70 °C for at least 24 h. Sections 
were cut from the polymerized samples and analyzed by FEI Tecnai G2 
Spirit Biotwin TEM at 100 kV after appropriate staining.
Viability, Treg Phenotype, and Treg Functionality Assay: Unstained 
control and compensation controls were used when required. For 
assessment of viability, a positive dead control was prepared by three 
cycles of rapid freeze-thaw (at −80 °C and 37 °C, respectively). For 
viability, PI (50 µg mL−1; Thermo Fisher Scientific) was added to the 
samples to a final concentration of 2.5 µg mL−1. For Treg phenotype 
and functionality, recovered cells were stained for viability and then 
surface-stained for CD4 and CD25 before being fixed, permeabilized, 
and intracellularly stained for FOXP3. Stained cells were divided into 
four groups: the first group was stained for CD69, the second for TGF-β, 
the third for CD39, and the fourth for CTLA-4. All samples were analyzed 
on a BD FACS Canto II flow cytometer (BD Biosciences), and the data 
analyzed with FCS Express 6 (De Novo Software).
CD154 Suppression Assay: Human PBMCs cells were isolated from a 
fresh buffy coat by density gradient centrifugation as described above. 
Naïve CD4+ T-cells were isolated using EasySep Human Naïve CD4+ 
T Cell Isolation kit (STEMCELL Technologies). Naïve CD4+ T-cells were 
labeled with DiOC18(3) (Thermo Fisher Scientific; a final concentration 
of 2 µg mL−1) by incubation at 37 ˚C with 5% CO2 for 45 min. 96-well 
round bottom plates were seeded with DiOC18(3)-labeled naïve CD4+ 
T-cells (5 × 104 cells per well; “Teffector”) and Tregs were added to the 
wells at various ratios of Treg:Teffector (1:1, 1:2, 1:4, and 1:8). Human 
T-expander CD3/CD28 Dynabeads (bead:Teffector ratio of 1:4) and 
anti-CD154 antibody were added to each well. DiOC18(3)-labeled naïve 
CD4+ T-cells with and without Tregs were used as positive and negative 
controls, respectively. The plate was incubated at 37 ˚C with 5% CO2 for 
7 h and then analyzed for expression of CD154 by flow cytometry (FACS 
Canto II). Percentage suppression was calculated as follows: 100 × [1 – 
(%CD154+ in the experiment sample divided by %CD154+ in the positive 
control)].
Whole Blood Chemokine Receptor Phenotyping: Human PBMCs were 
isolated from a fresh whole blood by density gradient centrifugation, 
as above. PBMCs were stained for CD3, CD4, CD45RA, CD25, CD127, 
CXCR3, CCR4, CCR6, CCR8, and CCR10 and then analyzed on BD 
FACSymphony (BD Biosciences). Additionally, PBMCs were stained 
for CD4, CD45RA, CD25, CD127, CCR8, and FOXP3 for assessment of 
FOXP3 expression by CCR8+ and CCR8− Tregs.
Chemotaxis Assay: Chemotaxis assays were performed with either 
96-well or 24-well transwell plates with 5 µm polycarbonate membranes 
(Corning). All chemokines and cells were resuspended in a chemotaxis 
buffer composed of RPMI 1640 medium (Gibco) with 0.5% w/v bovine 
serum albumin (Sigma-Aldrich) and 2.5% HEPES. 96-well plates 
employed 150 µL in the lower chamber and 50 µL in the upper chamber. 
24-well plates employed 600 µL in the lower chamber and 100 µL in 
the upper chamber. To generate a migration response profile for CCL1 
(96-well), various concentrations of CCL1 ranging from 100 ng mL−1 to 
10 µg mL−1 (threefold increments) were placed in the lower chambers, 
and Tregs (2 × 106 cells mL−1) were placed in the upper chambers. 
CXCL12 (30 ng mL−1) was utilized as a positive control. For assessment 
of encapsulated Treg migration (24-well), 10 µg mL−1 of CCL1 was 
placed in the lower chamber and encapsulated (2 × 106 cells mL−1) and 
nonencapsulated (1 × 106 cells mL−1) Tregs were placed in the upper 
chamber. For assessment of CCL1 addition to the hydrogel (24-well), 
CCL-1-added hydrogel disc (no cells) and 10 µg mL−1 of CCL1 were 
placed in the lower chamber and Tregs (2 × 106 cells mL−1) were placed 
in the upper chamber. For all transwell migration assays, a spontaneous 
migration control with no chemokine in the lower chamber was included. 
The plates were incubated for 3 h at 37 °C with 5% CO2, and then 
migrated cells in the lower chamber were analyzed by flow cytometry 
(BD LSRFortessa for the 96-well setup and BD FACS Canto II for the 
24-well setup; BD Biosciences) using counting beads (CountBright 
Absolute Counting Beads; Thermo Fisher Scientific). Migration index was 
calculated as follows: the number of cells in the experimental sample per 
1000 beads divided by the number of cells in the spontaneous migration 
control per 1000 beads. For immune phenotyping post-chemotaxis with 
CCL1, human PBMCs (2 × 106 cells mL−1) were placed in the upper 
chambers with 10 µg mL−1 of CCL1 in the lower chamber (24-well). After 
3 h incubation, cells in the lower chamber were stained as described in 
whole blood chemokine receptor phenotyping.
Preparation of Alginate-GelMA-Gelatin Bioink: Gelatin was sterilized 
by UV for 20 min and then added to 2%|7.5% w/v alginate-GelMA 
hydrogel precursor (bioink) at 2.5%, 3.5%, and 5% w/v. Resulting bioink 
formulations were incubated at 37 °C with occasional shaking until 
homogenous formulations were formed.
Printability Test: Alginate-GelMA bioink and alginate-GelMA-gelatin 
bioinks with 2.5%, 3.5%, and 5% gelatin concentrations were incubated 
at room temperature and then extruded using a customized co-axial 
printer.[24] Extrusion of each bioink was recorded to measure length of 
extruded filament from the nozzle, prior to the break point. Additionally, 
multilayered scaffolds ranging from two to ten layers were printed using 
the co-axial printer for each bioink to observe filament morphology. 
Images of the scaffolds were taken using Leica M205 C microscope 
(Leica Microsystems).
Rheology Measurement: Oscillation temperature sweeps and viscosity 
tests were performed with TA instruments AR-G2 controlled-stress 
rheometer equipped with 2° 20 mm stainless steel geometry (New 
Castle, DE) for 2%|7.5% w/v alginate-GelMA bioink and 2%|7.5%|3.5% 
w/v alginate-GelMA-gelatin bioink. The temperature sweep was 
performed within the range of 5–37 °C with a ramp of 1.5 °C min−1. The 
storage moduli (G′) and loss moduli (G″) were recorded. The viscosity 
was tested as a function of shear rate ranging from 0.1 to 1000 s−1 at 
22.5 °C. All the measurements were performed at oscillation frequency 
of 1 Hz and 0.1% strain. Prior to rheological tests, bioinks were 
incubated at 37 °C for 30 min and then loaded into prewarmed plates. 
The hydrogel precursor and bioink were equilibrated for 5 min to remove 
their thermos-history at given temperature. A trap was also equipped on 
each test to reduce dehydration. The gap between the geometry plates 
was set at 52 µm and ≈750 µL sample was loaded each time.
Murine Islet Isolation: This procedure was approved by the Animal 
Ethics Committee of the University of Adelaide (Ethics number 
M-2018-123) and conformed to the guidelines established by the 
Australian Code of Practice for the Care and Use of Animals for Scientific 
Purposes. Murine islets were isolated from 7 to 8 week old male 
C57BL/6 mice (University of Adelaide Laboratory Animal Services). 3 mL 
cold M199 medium (Sigma-Aldrich) containing Liberase T-Flex Research 
Grade (collagenase I/II blend at 0.227 mg mL−1 and thermolysin at 
0.0136 mg mL−1; Roche) was injected into the pancreatic duct in situ to 
inflate the pancreas. Upon full inflation, the pancreas was harvested and 
then digested at 37 °C for 11 min. Digested pancreatic acinar tissue was 
homogenized through 425 µm test sieve (Endecotts). Islets were purified 
from homogenized pancreatic tissue by density-gradient centrifugation 
over Lymphoprep. Purified islets were counted and then rested overnight 
in complete RPMI 1640 medium (Gibco), supplemented with 10% 
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FCS, 1% L-glutamine, and 1% penicillin-streptomycin (Gibco), on 
nonadherent 6-well plates.
Co-Axial Printing of Murine Islets with Human Tregs: The customized 
co-axial printer was placed into a PC2 biosafety cabinet and then 
sterilized with 70% ethanol followed by UV for 20 min. Co-axial 
nozzle and tweezers were sterilized as well. Murine islets and human 
nTregs and iTregs were washed with printing culture medium (X-vivo 
15 supplemented with 5% FCS, 1% L-glutamine, and 2% HEPES) three 
times and then resuspended in 2%|7.5%|3.5% alginate-GelMA-gelatin 
bioink (prewarmed at 37 °C at 300 islets mL−1 and 2 × 106 cells mL−1). 
LAP was added to islet-containing, nTreg-containing, iTreg-containing, 
and empty bioinks at 0.06% w/v. Each bioink was loaded into 3 mL 
Luer-Lock syringe (Hapool) and then locked with Luer-Lock caps 
to maintain sterility. Bioink loaded syringes were cooled on ice for 
10 min and then incubated at room temperature for 10 min. Islet-
containing bioink was placed into the core compartment and other 
bioinks were placed into the shell compartment nonsimultaneously. 
Islet-laden structures, islet-nTreg-laden structures, and islet-iTreg-laden 
structures were printed as two layers of 10 mm × 10 mm × 6 mm 
with 2.5 mm fiber spacing at core:shell ratio of 0.5:0.5. Each structure 
consisted of ≈100 µL of core bioink and 100 µL of shell bioink. Printed 
structures were crosslinked as described above. After washing twice 
in PBS, printed structures were placed in 1 mL of printing culture 
medium on 24-well plates. Human PBMCs were isolated as above and 
2 × 105 human PBMCs (Treg:PBMC ratio of 1:1) were added to each 
well, except for no PBMC controls (islet-laden structures with no 
PBMCs). Printed structures and PBMCs were co-cultured up to 5 d at 
37 °C with 5% CO2.
Fluorescence Microscopy: Printed structures were washed three times 
with PBS to remove human PBMCs. Printed structures were placed in 
400 µL of PBS. Printed structures were stained with FDA (Thermo Fisher 
Scientific) and PI at final concentrations of 500 × 10−6 m and 5 µg mL−1, 
respectively, for 10 min at room temperature in the dark. Printed 
structures were washed in PBS and imaged with Olympus IX73 inverted 
fluorescence microscope (Olympus).
Confocal Microscopy: Human nTregs and iTregs were 3D bioprinted 
as described as above with an empty core at 2 × 106 cells mL−1. nTreg-
laden and iTreg-laden structures were cultured in cX-vivo medium 
(+500 U mL−1 of IL-2) overnight at 37 °C with 5% CO2. Printed structures 
were stained with calcein AM (final concentration 1 × 10−6 m; Thermo 
Fisher Scientific) and DAPI (300 ng mL−1; Thermo Fisher Scientific) 
for 30 min at 37 °C with 5% CO2 in the dark. 3D-bioprinted Tregs were 
washed in PBS and then imaged with Olympus FV3000 confocal laser 
scanning microscope (Olympus).
Statistics: Statistical significance (P < 0.05) was analyzed using the 
GraphPad Prism 7. One-Way ANOVA with Tukey’s multiple comparisons 
test, Two-Way ANOVA with Tukey’s multiple comparisons test, and 
paired two-tailed T-test were used to identify statistical significance. All 
replicates are biological replicates. All experiments utilized triplicates 
as technical replicates except for whole blood chemokine receptor 
phenotyping that used no technical replicates.
Antibodies: Antibody details are listed in Table S1 (Supporting 
Information).
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